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Disruption of RNA homeostasis is a shared feature across multiple neurodegenerative 
diseases that are associated with mutations in RNA binding proteins or factors involved in RNA 
processing. One prime example is the neurodegenerative disease spinal muscular atrophy (SMA), 
which is characterized by the degeneration of spinal motor neurons and atrophy of skeletal muscle 
through poorly defined mechanisms. SMA is the consequence of ubiquitous deficiency in the 
survival motor neuron (SMN) protein, which has a well-characterized role in the assembly of small 
nuclear ribonucleoproteins (snRNPs). SMN-dependent dysfunction of major (U2) and minor (U12) 
spliceosomal snRNPs as well as U7 snRNP – which functions in histone mRNA processing – 
along with consequent RNA misprocessing events have been characterized in SMA. Additionally, 
SMN has been implicated in additional RNA pathways that may also be involved in SMA etiology. 
With the broad implications of multifaced roles of SMN in RNA regulation, an outstanding 
challenge in the SMA field has been the identification of key downstream RNA-dependent events 
and their contributions to pathogenesis. 
While the selective loss of spinal motor neurons is a key hallmark of SMA pathology, the 
molecular mechanisms remain incompletely understood. Through my dissertation work, I aimed 
to characterize the RNA mediated pathways that underlie neurodegeneration in SMA. We 
previously demonstrated that SMA motor neuron death is driven by converging mechanisms of 
p53 activation that include upregulation and phosphorylation – the latter of which establishes the 
vulnerability of specific motor neuron pools – however, the upstream triggers remained unknown. 
Here, I show that the function of SMN in the assembly of Sm-class snRNPs of the splicing 
machinery regulates alternative splicing of Mdm2 and Mdm4 – two non-redundant repressors of 
p53 – and increased skipping of critical exons in these genes is associated with p53 stabilization. 
 
 
Further investigation uncovered that dysfunction of Stasimon – a U12 intron-containing gene 
regulated by SMN – converges on p53 upregulation to induce phosphorylation of p53 through the 
activation of p38α MAPK and contributes to the demise of SMA motor neurons. Thus, this work 
elucidated the upstream RNA mediated mechanisms underlying multiple modes of p53 activation, 
implicating impairments in both the U2 and U12 snRNP pathways in SMA motor neuron death. It 
further established Mdm2, Mdm4, and Stasimon as effector genes that are regulated by SMN’s 
role in snRNP assembly and play key roles in the degeneration of SMA motor neurons. 
Studies in mouse models of SMA have revealed broader deficits in the motor circuit beyond 
motor neuron death, which include reduced excitatory drive on motor neurons brought on by a 
loss of proprioceptive synapses. Restoration in SMA mice revealed that Stasimon dysfunction 
also contributes to the deafferentation of motor neurons – a cellular defect originating in 
proprioceptive neurons – revealing Stasimon’s dual contribution to motor circuit pathology in SMA. 
However, the Stasimon-dependent molecular mechanisms that mediate synaptic loss in 
proprioceptive neurons, along with the pathway through which Stasimon impairment induces 
p38α MAPK activation in motor neurons are not well established. Stasimon was initially identified 
as a novel contributor to motor circuit dysfunction in Drosophila and motor axon outgrowth deficits 
in zebrafish models of SMN deficiency. However its cellular roles remain poorly understood. In an 
effort to address this, I identify Stasimon as an endoplasmic reticulum (ER) resident protein that 
localizes at mitochondria-associated ER membranes (MAM) – specialized contact sites between 
ER and mitochondria membranes. Additionally, through characterization of novel knockout mice, 
I show that Stasimon is an essential gene for mouse embryonic development. These findings 
provide key insight into Stasimon function and set the stage for further investigation of the p53-
dependent mechanisms of motor neuron degeneration as well as cellular pathways driving 
proprioceptive synaptic loss in SMA. 
This dissertation also expands beyond RNA mediated mechanisms of SMA – which occur 
as a consequence of SMN-deficiency – to translational efforts aimed to treat the disease by 
 
 
describing an unexpected gain of toxic function associated with SMN overexpression that is 
accompanied by RNA dysregulation and sensory-motor circuit pathology. I further explore these 
surprising findings of neuronal toxicity induced by AAV9-mediated SMN overexpression that 
paradoxically affects sensory-motor function and reveal that they parallel features of SMA 
pathogenesis. Accordingly, I find that the functional basis of long-term motor toxicity of AAV9-
SMN involves motor neuron deafferentation and proprioceptive neurodegeneration. At the cellular 
level, toxicity is associated with the accumulation of large cytoplasmic aggregates of SMN in 
motor circuit neurons that sequester Sm proteins, disrupt snRNP biogenesis, and induce 
widespread transcriptome alterations and splicing deficits. These findings identify a novel 
deleterious role for SMN when expressed at supraphysiological levels that acts through inhibition 
of SMN’s normal function in snRNP biogenesis, akin to disease mechanisms of SMA. These 
observations have important implications regarding the approved use of AAV9-SMN for gene 
therapy in humans and suggest a need for further, careful consideration of potential detrimental 
effects when SMN is expressed at supraphysiological levels. 
Collectively, this dissertation identifies the direct involvement of key SMN-dependent 
splicing events in select aspects of SMA pathology in a mouse model, in particular those 
converging on the p53-mediated mechanisms of motor neuron death and the loss of 
proprioceptive synapses. This work also establishes causal links between impairments in snRNP 
biology and neuronal dysfunction in SMA, providing mechanistic insight into the process of motor 
neuron death. Lastly, it uncovers a new, clinically relevant aspect of SMN biology associated with 
its long-term overexpression which has shared features with the RNA mediated mechanisms of 
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1.1 Spinal muscular atrophy (SMA)1 
Clinical characteristics of SMA 
Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative disorder and 
the leading hereditary cause of infant mortality. SMA affects approximately 1 in every 10,000 
newborns and has a carrier frequency of about 1 in 50 (Muralidharan et al., 2011). The clinical 
features of SMA were first described in the 1890’s by Werdnig and Hoffman (Hoffmann, 1893, 
1897, 1900; Werdnig, 1891), characterized by the progressive weakness and atrophy of proximal 
muscles. Subsequent reports further described the intermediate form of SMA (Byers and Banker, 
1961; Dubowitz, 1964; Thomson and Bruce, 1893) as well as additional clinical subtypes of both 
more severe (Beevor, 1902; Sylvestre, 1899) and milder (Kugelberg and Welander, 1956; 
Wohlfart et al., 1955) patients with the common clinical presentation of progressive proximal 
muscle weakness and post-mortem histological analysis displaying a loss of anterior horn cells 
and muscle atrophy. This wide spectrum of phenotypes encompassed by SMA are broadly 
classified into clinical types – though additional sub-types are now being outlined – spanning from 
the most frequent and severe type I SMA to the milder type IV form of the disease based on the 
highest level of motor function achieved and age of disease onset (Munsat and Davies, 1992). 
SMA Type I patients typically present symptoms in the first six months of life, are not able to sit 
unassisted and have a lifespan of around two years (Zerres and Rudnik-Schöneborn, 1995). 
Additionally, babies with a rare, most severe form of the disease with prenatal onset are either 
classified as Type IA or Type 0 present with respiratory insufficiency at birth and die within weeks 
(Dubowitz, 1999; MacLeod et al., 1999). SMA Type II patients are characterized by an age of 
                                               
1 Parts of this section were adapted from a review I co-authored entitled “Advances in modeling and treating 




onset at 6 to 18 months old, are able to sit unassisted – though some patients may lose this ability 
over disease course – and are never able to walk independently (Zerres and Rudnik-Schöneborn, 
1995). At the mild end of the spectrum, Types III and IV SMA patients are ambulatory with an age 
of onset at 3 years or older for Type III and in adulthood for Type IV (Zerres and Rudnik-
Schöneborn, 1995).  
In Type I SMA patients, proximal muscles are preferentially affected while eye and facial 
muscles are generally spared. Upper limbs are not as affected as lower extremities, and the 
development of severe weakness in the lower limbs results in a “frog-leg” posture. Furthermore, 
intercostal muscles are severely affected while the diaphragm is largely spared resulting in a bell-
shaped deformity of the chest and paradoxical breathing characterized by contraction of the chest 
during inspiration (Schroth, 2009). Progressive muscle weakness leads to feeding difficulties and 
the severely affected intercostal muscles leads to respiratory complications such as impaired 
expiratory power, diminished airway clearance, pneumonia, and poor oxygen exchange resulting 
in a requirement for ventilatory support and underlying the primary cause of death which is 
respiratory failure (Schroth, 2009). SMA Type II patients also display similar features of proximal 
weakness most particularly in the lower limbs. In addition, they develop scoliosis which results in 
restrictive lung disease requiring respiratory support and some of the more severely affected also 
require nutritional support as with Type I patients (Oskoui et al., 2017). Unlike the more severe 
subtypes, Type III and IV SMA patients do not develop respiratory complications and life 
expectancy is normal, but common features of proximal weakness are shared though the 
progression is slower and more mild (Oskoui et al., 2017). 
The key histopathological features of SMA are the selective and progressive loss of spinal 
motor neurons and skeletal muscle atrophy. Assessment of SMA pathology in the spinal cord of 
patients has mainly focused on SMA Type I and several studies have reported severe reductions 
of motor neuron number in autopsy tissue (Robertson et al., 1978; Simic et al., 2000; Soler-Botija 




identified pronounced reductions in motor neurons which appear to correlate with disease severity 
(Araki et al., 2003; Hayashi, 2004; Ito et al., 2011; Kuru et al., 2009). Interestingly, the patterning 
of affected or spared muscles is believed to reflect the selective degeneration of innervating motor 
neuron pools which has been carefully studied in mouse models (Mentis et al., 2011). However, 
a detailed profiling of differential vulnerabilities of motor neuron populations in patients is missing. 
In addition to motor neuron degeneration, abnormalities at the neuromuscular junction (NMJ) and 
muscle fibers are characteristic of SMA pathology across subtypes (Goulet et al., 2013; Wadman 
et al., 2012). Morphological analysis of the NMJ in SMA patients has led to identification of 
impairments in acetylcholine receptor clustering, abnormal pre-synaptic vesicle accumulation, 
structural changes associated with reduced maturation and denervation (Harding et al., 2015; 
Martínez-Hernández et al., 2013). Muscle biopsy shows differences between patient subtypes 
with Types I and II displaying mostly small atrophic fibers distributed around a low frequency of 
normal and hypertrophic fibers, while Type III patients show neurogenic groupings of both atrophic 
as well as hypertrophic muscle fibers with the proportion of hypotrophic fibers correlating with 
disease severity (Buchthal and Olsen, 1970; Dubowitz et al., 2013; Mastaglia and Walton, 1971; 
Zalneraitis et al., 1991).  
 
 
Genetic basis of SMA 
The homozygous deletion or mutation of the survival motor neuron 1 (SMN1) gene is the 
genetic cause of SMA (Lefebvre et al., 1995). Due to an evolutionarily recent duplication, two 
SMN genes (the telomeric SMN1 and the centromeric SMN2) exist on human chromosome 5q 
that only differ by five non-polymorphic nucleotide changes. One of these differences – a C to T 
transition located in exon 7 – is of particular functional relevance as it converts an exonic splicing 
enhancer which can be bound by ASF/SF2 to an exonic splicing silencer which is recognized by 
hnRNP A1/A2 causing the majority of transcripts produced from SMN2 to skip exon 7 (Figure 1.1)  




Additionally, the C to T transition in SMN2 establishes a binding site for SAM68, which can recruit 
hnRNPA1 and interfere with binding of the general splicing factor U2AF65 to promote exon 7 
skipping (Pagliarini et al., 2015; Pedrotti et al., 2010). Isoforms of SMN2 transcripts which lack 
exon 7 produce a truncated, rapidly degraded form of the protein (Burnett et al., 2009; Cho and 
Dreyfuss, 2010; Lorson and Androphy, 2000). Complete ablation of SMN is incompatible with life 
(Schrank et al., 1997), and while SMN2 produces sufficient protein to prevent embryonic lethality 
it cannot fully compensate for the loss of SMN1, resulting in a setting of SMN protein deficiency 
which causes SMA (Hsieh-Li et al., 2000; Le et al., 2005; Monani, 2000).  
Importantly, protein levels of SMN correlate with disease severity (Coovert et al., 1997; 
Lefebvre et al., 1997) and SMN2 copy number can vary among patients serving as a critical 
modifier of pathology (McAndrew et al., 1997; Wirth et al., 2006). Most frequently, SMA Type I 
patients have 2 copies of SMN2, SMA Type II patients have 3 copies of SMN2 and SMA Type III 
patients have 3 or 4 copies of SMN2. Carriers with only one SMN1 gene copy are phenotypically 
healthy indicating that 50% of SMN protein levels are sufficient (Oskoui et al., 2017). Along these 
lines, individuals with no SMN1 copies but five gene copies of SMN2 are able to produce sufficient 
SMN protein to suppress pathology and remain asymptomatic (Prior et al., 2004).  
 
 
SMN requirement in mouse models of SMA 
SMN is a ubiquitously expressed protein and both invertebrate and vertebrate model 
organisms possess a single SMN gene, ablation of which is non-viable (Burghes and Beattie, 
2009; Tisdale and Pellizzoni, 2015). The development and characterization of animal models has 
fundamentally advanced our knowledge of SMA pathogenesis (Schmid and DiDonato, 2007). One 
key feature of the human disease is the expression of low steady levels of SMN from 
the SMN2 gene. To date, this has only been accomplished in mice, which therefore represent the 
most accurate model currently available (Burghes and Beattie, 2009; Schmid and DiDonato, 2007; 




(for a detailed description of which see (Edens et al., 2015; Schmid and DiDonato, 2007), the 
general design principle used to generate severe mouse models of SMA was to combine 
homozygous ablation of murine Smn alleles, which alone results in early embryonic lethality 
(Schrank et al., 1997), with the introduction of one or two copies of the human SMN2 gene (Hsieh-
Li et al., 2000; Monani, 2000). One of the most widely studied mouse models of SMA, the SMNΔ7 
mouse model, additionally contains multiple transgenic copies of the SMNΔ7 cDNA which slightly 
ameliorates the severe phenotype (Le et al., 2005). 
Severe SMA mice are phenotypically indistinguishable from wild type littermates at birth, 
but soon display severe motor deficits and reduced body weight, and do not survive past the 
second postnatal week (Burghes and Beattie, 2009; Schmid and DiDonato, 2007; Tisdale and 
Pellizzoni, 2015). Importantly, the development of Smn alleles for either conditional depletion or 
restoration of SMN in SMA mice allowed delineation of the temporal requirement of SMN during 
development and the capacity of SMN restoration to rescue phenotypic deficits before and after 
disease onset (Kariya et al., 2014; Lutz et al., 2011). Through the use of an inducible Smn allele 
in the SMNΔ7 background, post-symptomatic restoration of SMN at postnatal day 4 corrected 
motor function and survival, while SMN induction at later time points resulted in limited rescue 
(Lutz et al., 2011), indicating the existence of an early window for maximum therapeutic efficacy 
of SMN induction. Similar conclusions were reached using either a drug-inducible SMN transgene 
(Le et al., 2011), adeno-associated virus serotype 9 (AAV9)-mediated SMN gene delivery (Foust 
et al., 2010; Robbins et al., 2014), and antisense oligonucleotides which correct SMN2 exon 7 
skipping (Arnold et al., 2016). The converse experiment using a conditional Smn knockout allele 
to induce ubiquitous SMN depletion in mice demonstrated that early postnatal SMN reduction 
rapidly elicits an SMA-like phenotype, while reduction after the second postnatal week fails to 
generate an overt phenotype (Kariya et al., 2014). Thus, following maturation of the 
neuromuscular system, the threshold requirement for SMN decreases to a lower level that is 




As in the human disease, the phenotypic characterization of mouse models of SMA has 
indicated that motor neurons are at the most vulnerable end of the spectrum of cell types affected 
and that the predominant effect of SMN deficiency is pathology of the motor system (Burghes and 
Beattie, 2009; Tisdale and Pellizzoni, 2015). However, increasing evidence also points to 
functional deficits outside the central nervous system (CNS) (Hamilton and Gillingwater, 2013). 
Recent insights into the spatial requirement of SMN from studies of central and peripheral deficits 
associated with its deficiency in mouse models are discussed below. 
 
Motor system dysfunction in SMA 
Severe SMA mice demonstrate a pronounced loss of motor neurons, a hallmark of the 
human disease (Burghes and Beattie, 2009; Tisdale and Pellizzoni, 2015), the features and 
mechanisms of which are discussed further in Chapter 1.4. In addition to motor neuron 
degeneration, SMN deficiency induces several pathological changes in the motor circuit (Figure 
1.2). Morphological and functional alterations at the NMJ include reduced synaptic vesicle density 
and neurotransmission as well as denervation, which occur at early stages of disease and are 
more prominent in vulnerable than resistant muscles, correlating with impaired muscle growth 
(Arnold et al., 2016; Kariya et al., 2008; Kong et al., 2009; Ling et al., 2012; Murray et al., 2008). 
In addition to distal deficits, several central defects have been documented in SMA mice, including 
selective and progressive loss of excitatory but not inhibitory synapses on both the somata and 
dendrites of vulnerable motor neurons (Figure 1.2), which represent one of the earliest 
pathological manifestations of the disease (Ling et al., 2010; Mentis et al., 2011). Loss of these 
synapses and the associated reduction in the excitatory drive from proprioceptive neurons and 
glutamatergic interneurons underlies a homeostatic response within motor neurons leading to 
their increased membrane excitability (Fletcher et al., 2017; Simon et al., 2016).  
A key aspect for understanding SMA pathology and designing appropriate therapeutic 




effects on the motor system. Fundamental advances to this regard came from studies employing 
conditional Smn alleles that could be turned on or off in a spatially restricted manner. The 
combination of both approaches, i.e. the analysis of both depletion and restoration of SMN in 
specific cell types, is required to reach solid conclusions as to the cell type-specific requirement 
of SMN in vivo. Interestingly, while muscle atrophy is an ultimate outcome in SMA, depletion of 
SMN restricted to muscle had no effect on the size, strength and function of skeletal muscle (Iyer 
et al., 2015). Moreover, selective restoration of SMN in muscle of SMA mice failed to induce major 
phenotypic improvement beyond a modest increase in weight (Gavrilina et al., 2008; Iyer et al., 
2015; Martinez et al., 2012), although one study also reported enhanced myofiber growth 
(Martinez et al., 2012). Together these studies indicate that intrinsic, SMN-dependent deficits in 
skeletal muscle do not significantly contribute to SMA pathology. Conversely, two prominent 
hallmarks of the disease—death of motor neurons and dysfunction and loss of NMJs—originate 
cell autonomously within the motor neuron. The targeted depletion of SMN in motor neurons 
elicited specific pathological features of the disease such as impaired motor behavior, decreased 
functional output at the NMJ, loss of motor neurons and reduced myofiber size (McGovern et al., 
2015; Park et al., 2010). Furthermore, selective restoration of SMN in motor neurons of SMA mice 
rescued motor neuron survival and corrected both innervation and neurotransmission deficits at 
the NMJ (Fletcher et al., 2017; Gogliotti et al., 2012; Martinez et al., 2012; McGovern et al., 2015). 
However, motor neuron-specific depletion of SMN failed to elicit a severe SMA phenotype and 
selective restoration in motor neurons did not have a robust impact on the survival of SMA mice, 
despite a measurable improvement of motor unit function, (Fletcher et al., 2017; Gogliotti et al., 
2012; Martinez et al., 2012; McGovern et al., 2015; Park et al., 2010), clearly pointing to a role for 
cells beyond motor neurons in SMA pathogenesis.  
Motor neurons function in the context of neural circuits that include local interneurons, 
proprioceptive afferents and descending pathways from the brain (Garcia-Campmany et al., 2010; 




depletion of SMN was more effective in inducing an SMA-like phenotype in mice (McGovern et 
al., 2015), and pan-neuronal SMN restoration in SMA mice led to a more robust phenotypic 
correction than in motor neurons alone including strong extension of survival (Gavrilina et al., 
2008). Together with studies in a Drosophila model of the disease (Imlach et al., 2012; Lotti et al., 
2012), these findings indicate that neuronal restoration of SMN is critical for ameliorating SMA-
related deficits in the motor system and point to SMA as a disease of motor circuits, not just motor 
neurons alone. However, elucidating the role of specific neural circuit components in the 
dysfunction of the SMA motor system requires direct testing through selective depletion and 
restoration approaches in mouse models. To date, in addition to motor neurons, this has only 
been performed in proprioceptive neurons. Selective genetic restoration of SMN in proprioceptive 
neurons has shown that deafferentation of motor neurons in SMA is results from dysfunction 
originating in proprioceptive neurons (Fletcher et al., 2017). Additionally, multiple aspects of SMA 
motor neuron dysfunction – increased input resistance and reduced firing – are a consequence 
of a decrease in excitatory drive from proprioceptive neurons (Fletcher et al., 2017). Impairment 
in neurotransmission associated with reduced glutamate release at proprioceptive inputs results 
in a reduction of Kv2.1 channels on motor neurons negatively affecting their firing frequency, 
which is a key determinant for normal muscle contraction (Fletcher et al., 2017). These findings 
highlight the contribution of proprioceptive neurons to motor circuit pathology in SMA and provide 
mechanistic insight into non-cell autonomous aspects of motor neuron dysfunction in SMA. 
Despite clear involvement of neurons in the disease process, genetic restoration of SMN in 
all neurons was unable to fully rescue the SMA phenotype in mice nor was neuronal depletion 
able to mimic the disease to the extent accomplished using ubiquitous drivers (Iyer et al., 2015; 
Kariya et al., 2014; Lutz et al., 2011; McGovern et al., 2015), arguing for the functional contribution 
of additional cell types to SMA pathology. Indeed, recent studies have documented a variety of 
additional deficits in the CNS that may influence the severity of SMA. Astrocytes have critical roles 




expression of SMN driven by the Glial Fibrillary Acidic Protein promoter in the astrocytes of SMA 
mice enhanced motor function and body weight as well as extended survival (Rindt et al., 2015). 
Interestingly, the phenotypic benefit was associated with reduced loss of central synapses and 
partial restoration of NMJ innervation, but no improvement of motor neuron survival. An increased 
number of unmyelinated motor axons in vulnerable intercostal nerves, but not dorsal corticospinal 
tract neurons, has also been observed in severe SMA mice at symptomatic stages (Hunter et al., 
2014), which is proposed to reflect intrinsic SMN-dependent deficits in Schwann cells (Hunter et 
al., 2016). Lastly, SMN deficiency is also associated with reduced capillary density and abnormal 
development of the vascular architecture in the spinal cord and skeletal muscle as well as 
evidence of hypoxia at mid- to late-symptomatic stages in SMA mouse models (Somers et al., 
2016), indicating vascular deficits as potential exacerbating factors. However, conclusive 
evidence that intrinsic SMN-dependent deficits in these cell types contribute to SMA pathology 
awaits in vivo analysis after selective depletion and restoration of SMN with genetic approaches. 
 
Peripheral tissue defects in SMA 
SMN-deficiency has been shown to induce defects in tissues beyond the motor system. 
Altered cardiac function (bradycardia and dilated cardiomyopathy) was among the first deficits 
outside of the CNS to be documented in SMA mice (Hamilton and Gillingwater, 2013). More 
recently, additional deficits identified in peripheral organs include alterations in the normal 
development of the pancreas, testis, spleen and gastrointestinal system. Studies in an 
intermediate SMA mouse model uncovered progressive loss of insulin-producing β cells and an 
increase in glucagon-producing α cells in the pancreatic islets, as well as defects in glucose 
metabolism upon fasting (Bowerman et al., 2012), which appear to occur independent of 
neuromuscular pathology (Bowerman et al., 2014). A reduction in testis size and spermatogenesis 
associated with decreased fertility has also been documented in a mild mouse model (Ottesen et 




organ. Defects in spleen size and morphology have also been identified in both mild and severe 
models of SMA (Deguise et al., 2017; Khairallah et al., 2017). Lastly, the enteric nervous system 
controlling smooth muscle of the colon also exhibits vulnerability to SMN deficiency resulting in 
gastrointestinal symptoms (Gombash et al., 2015). Collectively, these findings indicate that 
restoration of SMN in the periphery may be important for complete correction of the SMA 
phenotype. The potential contribution of peripheral deficits to SMA pathology is supported by the 
observation that peripheral SMN restoration in the absence of a measurable SMN increase in the 
CNS robustly rescues SMA mice (Bowerman et al., 2012; Hua et al., 2011). 
To date, however, two main issues remain to be addressed: i) the precise cellular origin of 
the peripheral organ deficits, and ii) the clinical relevance of these defects for the human disease, 
as evidence of peripheral organ dysfunction has often been anecdotal and limited to small cohorts 
of SMA patients at the most extreme spectrum of disease severity. Future studies geared towards 
answering these questions are required to define tissues that need to be directly targeted for SMA 
therapy and to exclude the possibility that peripheral defects represent confounding elements 
inherent to modeling disease in mice rather than clinically relevant features in humans. 
 
 Progress in the development of SMA therapeutics 
Basic research in the field of SMA has led to critical findings enabling translation into clinical 
approaches. Studies in mice have indicated that early restoration of SMN levels is an effective 
therapeutic approach and that widespread expression of SMN is preferable for robust rescue. 
Among several different strategies tested to date, two main approaches have successfully 
emerged from pre-clinical studies, moved to clinical trials and been granted FDA approval: SMN 






SMN2 splicing modulation by antisense oligonucleotides 
One targeted approach to increase SMN levels is modulating SMN2 splicing through 
chemically modified antisense oligonucleotides (ASOs) designed to base pair to specific splicing 
regulatory sequences to prevent binding by trans-acting factors without triggering degradation 
(Schoch and Miller, 2017). Detailed tiling approaches evaluated both the exonic regions of SMN2 
exon 7 as well as the flanking intronic regions for oligonucleotides that targeted key regulatory 
elements and could effectively modulate splicing to promote inclusion (Hua et al., 2007, 2008). 
While the efficacy of targeting other regulatory regions is also being explored (Osman et al., 2014), 
one optimal target for an ASO-based approach in SMA is an intronic splicing silencer element 
ISS-N1 located in intron 7 of SMN2 (Singh et al., 2006), which has two tandem hnRNP A1/A2 
motifs (Hua et al., 2008) and exerts a potent inhibitory role on exon 7 inclusion. Masking of ISS-
N1 was shown to effectively promote exon 7 inclusion and restore SMN expression both in 
vitro and in vivo (Hua et al., 2008, 2011; Porensky et al., 2012). Accordingly, delivery of 2′-O-
methoxyethyl-modified or morpholino ASOs targeting ISS-N1 either systemically or by ICV 
injection led to remarkable improvement of both motor function and survival in severe SMA mice 
(Hua et al., 2011; Passini et al., 2011; Porensky et al., 2012). Intrathecal and ICV delivery in non-
human primates was well-tolerated and provided further support to move this candidate approach 
into the clinic (Rigo et al., 2014).      
An open label Phase 1 trial using intrathecal delivery of Nusinersen — the ISS-N1 specific 
ASO developed by Ionis Pharmaceuticals in collaboration with Biogen — in Type II and Type III 
SMA patients demonstrated safety and increased motor function at the highest dosage (Chiriboga 
et al., 2016). An open label Phase 2 trial showed no safety concerns in type I SMA infants who 
lived longer and achieved more motor milestones than expected based on the natural history of 
the disease (Finkel et al., 2016). A Phase 3 randomized double-blind study to assess efficacy and 
safety of intrathecal injection of Nusinersen in infants with early onset SMA (NCT02193074) was 




relative to control group at an interim analysis (Finkel et al., 2017). A double-blinded, placebo 
controlled study in later-onset SMA patients also demonstrated safety and measurable motor 
improvements (Mercuri et al., 2018) and an additional Phase 2 trial in pre-symptomatic SMA 
infants (NCT02386553) is ongoing to examine the potential for increased efficacy due to early 
intervention. As a consequence of these landmark studies, anti-sense oligonucleotide therapy 
(Spinraza) for all SMA patients was granted FDA approval in December 2016, the first approved 
therapy for SMA. As antisense oligonucleotides do not cross the blood brain barrier (Schoch and 
Miller, 2017), Spinraza is administered directly to the CNS by an intrathecal bolus injection 
following lumbar puncture (Biogen, 2016), which has been shown to be effective for efficient 
targeting of motor neurons and widespread delivery across the CNS (Rigo et al., 2014). At the 
onset of treatment patients receive four loading doses over the first two months (Biogen, 2016), 
followed by subsequent maintenance doses every four months, a protocol established 
considering the long half-life of the ASO in the CNS (Rigo et al., 2014). 
 
SMN2 splicing modulation by small molecules 
In addition to ASO-mediated approaches, there has been tremendous recent progress in 
the development of small chemical compounds as a means to modulate SMN2 exon 7 splicing 
pharmacologically. A series of orally bioavailable, blood-brain barrier-penetrant small molecules 
(SMN-C class compounds) capable of promoting exon 7 splicing with high efficiency and 
selectivity have been developed through the concerted efforts of the SMA Foundation, PTC 
Therapeutics and Roche (Naryshkin et al., 2014). Treatment of SMA mice with these compounds 
demonstrated remarkably robust phenotypic benefit, including enhanced motor function, weight 
gain, and survival. This was associated with increased SMN expression, correction of SMN-
dependent RNA processing deficits, and suppression of morphological defects in the motor 




additional chemical modifiers of SMN2 splicing (NVS compounds) with strong efficacy in SMA 
mice (Palacino et al., 2015).  
Strikingly, these compounds corrected SMN2 splicing while globally altering the expression 
of only a handful of genes in human SMA fibroblasts (Naryshkin et al., 2014; Palacino et al., 2015; 
Sivaramakrishnan et al., 2017), reflecting an unprecedented selectivity for chemical modifiers of 
splicing. Genome wide analysis of the limited set of exons whose inclusion was promoted by the 
NVS compound revealed enrichment for an nGA motif at the 3’end (Palacino et al., 2015). Initial 
mechanistic studies suggest both classes of compounds recognize the intron-exon junction and 
can modulate splicing by stabilizing the binding of the U1 small nuclear ribonucleoprotein to the 
weak 5′ splice site of SMN2 exon 7 (Palacino et al., 2015; Sivaramakrishnan et al., 2017). In 
addition to SMN2, inclusion of exon 8 in STRN3 is similarly affected by the SMN-C class 
compounds, which has an identical 5’ splice site (5’ss), and introduction of the SMN2 5’ss to a 
non-responsive exon renders it sensitive (Sivaramakrishnan et al., 2017). In addition, a purine-
rich ESE region in SMN2 exon 7 (ESE2) is shared with STRN3, and recognition of this sequence 
by U1 snRNP by SMN-C class compounds has been proposed to mediate their positive effects 
on splicing (Sivaramakrishnan et al., 2017). Recent NMR analysis of SMN-C5 (an evolution of 
SMN-C class compounds) has revealed that the molecule sits across the major groove at the 
exon-intron junction and the positively charged piperazine group interacts with the phosphate 
group of C9 of U1 snRNA while the central aromatic ring of the compound hydrogen bonds with 
the amino group of the unpaired adenine base at position -1 of the 5’ss, providing a structural 
framework for selectivity of the 5’ss sequence of SMN2 exon 7 (Campagne et al., 2019). 
Furthermore, the unpaired adenine residue can sterically block U1-C zinc finger interactions, 
which instead become optimized in the presence of the compound supporting a mechanism for 
cooperation with the splicing machinery and detailing the key interactions which serve to bridge 




Following the encouraging results of pre-clinical studies, both Roche and Novartis are now 
investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of 
the SMN2 splicing modifiers in human trials. An initial phase 1 clinical trial evaluating dosing in 
healthy subjects showed the Roche compound (RG7800, RO6885247) was well tolerated and 
increased SMN levels (MOONFISH; NCT02240355). However, a parallel study in cynomolgus 
monkeys revealed long-term retinal toxicity and the study was terminated. Further compound 
optimization led to the development of Risdiplam (RG7916, RO7034067), which showed 
increased potency in preclinical studies and safety and tolerability in healthy volunteers 
(NCT02633709). Risdiplam is currently being evaluated in clinical trials for several patient groups 
including phase 2/3 trials in Type I SMA infants (FIREFISH; NCT02913482) and Type II and III 
patients from ages 2 through 25 (SUNFISH; NCT02908685), as well as a phase 2 study in 
previously treated SMA patients (JEWELFISH; NCT03032172). Additionally, an open-label phase 
1/2 study is being conducted by Novartis for their splicing modulator Branaplam (LMI070) in Type 
I SMA infants (NCT02268552). 
 
SMN gene therapy 
Another therapeutic approach for restoration of SMN levels is gene delivery with AAV9, 
which has been shown to efficiently transduce motor neurons and lead to phenotypic correction 
when delivered systemically or by ICV injection in neonatal SMA mice (Dominguez et al., 2011; 
Foust et al., 2010; Passini et al., 2010; Robbins et al., 2014; Valori et al., 2010). Viral-mediated 
delivery of human SMN was also able to correct SMA-like pathology in a swine model induced by 
injection of an AAV vector driving RNAi-mediated knockdown of endogenous pig SMN (Duque et 
al., 2015). Additional pre-clinical studies demonstrated short-term safety and tolerability of AAV9-
GFP gene delivery as well as proper targeting of motor neurons following intrathecal injection in 




Based on results of the preclinical studies, AveXis conducted a Phase 1 clinical trial 
(NCT02122952) to determine the safety, tolerability and efficacy of AAV9-mediated gene therapy 
(AVXS-101) in Type I SMA patients following systemic administration, which showed very 
encouraging results at doses of 2x1014vg/kg in the two-year period following treatment in which 
patients were monitored (Mendell et al., 2017). FDA approval was granted for the systemic 
treatment of SMA patients less than 2 years old with AVXS-101 (Zolgensma) in May 2019, the 
second approved therapy for the disease. A phase 3 extension of the pilot trial is ongoing in SMA 
Type I patients (STRIVE; NCT03461289), and a phase 1 trial is also underway to test the safety 
and efficacy of CNS delivery of AVXS-101 by intrathecal injection in clinically milder SMA Type II 
patients (STRONG; NCT03381729). 
In contrast to Spinraza, gene therapy can be administered in a single treatment, 
circumventing the requirement for repeated ASO injections in the particularly fragile population of 
SMA patients. However, despite favorable outcomes in preclinical and early clinical studies, 
potential side effects associated with AAV gene therapy and the long-term safety profile of AAV9-
mediated SMN overexpression has not been fully evaluated as only a handful of years have 
passed since the first patients were treated. In this respect, unlike other SMA therapeutics aimed 
at correcting splicing of endogenous SMN2 transcripts, the potential for SMN expression at 
supraphysiological levels is a unique feature associated with AAV9-SMN gene therapy, and the 
biology of SMN overexpression is largely unknown. Importantly, a recent study reported severe 
liver toxicity and sensory pathology in non-human primates and piglets injected with therapeutic 
doses of AAVhu68-SMN (2x1014vg/kg) analogous to those given to SMA patients (Hinderer et al., 
2018), although the small number of animals analyzed and the lack of dose-response studies 
limited the breadth of the conclusions. The implications and potential complications associated 





Therapeutic complements to SMN upregulation 
Despite the remarkable progress described above, SMN upregulating approaches alone do 
not lead to a complete cure for SMA and some patients do not respond to treatment (Sumner and 
Crawford, 2018). In particular, SMN upregulation after disease onset might fall short of providing 
sufficient correction in SMA patients. Thus, it is conceivable that SMN-independent approaches 
designed to correct cellular deficits downstream of SMN deficiency within and outside the CNS 
might be particularly valuable for SMA treatment.  
Therapeutic application of any SMN-independent strategy focused on ameliorating a 
specific disease-relevant deficit would be most logically used in combination with SMN 
upregulating drugs as alone they may not have a strong clinical impact. To this end, recent studies 
have set the stage for evaluation of combinatorial therapies by exploiting severe SMA mice 
treated with suboptimal doses of either ASO (Hosseinibarkooie et al., 2016; Janzen et al., 2018; 
Riessland et al., 2017; Torres-Benito et al., 2019; Zhou et al., 2015) or SMN upregulating 
compounds (Feng et al., 2016). The resulting animals displayed incremental improvement with 
moderately extended survival and partially ameliorated motor system pathology, resembling 
pathological features of milder SMA forms. Interestingly, myostatin inhibition through AAV1-
mediated Follistatin gene delivery into skeletal muscle of SMA mice treated with suboptimal doses 
of an SMN-inducing compound improved muscle atrophy pointing to the potential benefit of 
muscle enhancing therapies in SMA (Feng et al., 2016). Accordingly, Cytokinetics has conducted 
a double-blind Phase 2 trial which showed effects of oral treatment with a troponin activator (CK-
2127107) on fatigability in types II-IV SMA patients (NCT02644668). A similar experimental 
paradigm using low doses of ASO has also been used to evaluate the combinatorial therapeutic 
potential of the modulation of genetic modifiers of SMA such as Plastin 3 (Hosseinibarkooie et al., 
2016), Neurocalcin delta (Torres-Benito et al., 2019), and Calcineurin-like EF-hand protein 1 




approaches to establish the therapeutic value of combinatorial treatments aimed to act 
synergistically with SMN enhancement.  
 
1.2 The survival motor neuron (SMN) complex  
Ribonucleoprotein complexes (RNPs) – formed through the interaction of messenger RNAs 
and non-coding RNAs with RNA binding proteins (RBPs) – regulate essentially all aspects of RNA 
metabolism and gene expression (Glisovic et al., 2008). Furthermore, RNPs are often assembled 
through multi-step biosynthetic pathways that are highly regulated and the disruption of RBPs is 
a shared feature across multiple neurodegenerative disorders (Conlon and Manley, 2017). The 
study of SMN – the gene product of the SMA disease determining gene – revealed its key role in 
RNP biogenesis and post-transcriptional gene regulation, providing key insight into RNP biology 
as well as foundations to elucidate the molecular mechanisms underlying SMA pathology. 
 
The SMN complex 
SMN is a ubiquitously expressed protein that is evolutionarily conserved, and localizes to 
the cytoplasm and in nuclear Gems – a structure often associated with Cajal bodies (Liu and 
Dreyfuss, 1996). SMN is a component of large macromolecular complexes that are 
heterodisperse in nature and can range from 20S to 80S (Battle et al., 2007; Carissimi et al., 
2006a). The SMN complex consists of SMN along with eight additional proteins (Gemins2-8 and 
Unrip) which associate through multiple protein-protein interactions (Figure 1.4) (Baccon et al., 
2002; Carissimi et al., 2005, 2006b; Charroux et al., 1999, 2000; Grimmler et al., 2005; Gubitz et 
al., 2002; Liu et al., 1997; Pellizzoni et al., 2002a). SMN contains several highly conserved 
domains including a Gemin2 binding domain, a Tudor domain, a proline-rich domain, and a 
tyrosine and glycine-rich region (YG-box). The Gemin2 binding domain is highly evolutionarily 
conserved from yeast to human underlining the functional importance of the interaction between 




product of SMN’s ability to self-oligomerize (Lorson et al., 1998; Pellizzoni et al., 1999), which is 
mediated by the conserved YG-box domain and has been shown to be a key factor for SMN 
functionality. Additionally, the Tudor domain mediates binding to symmetrically dimethylated 
arginine residues, which is a feature of many SMN-interacting proteins (Brahms et al., 2000, 2001; 
Friesen et al., 2001a, 2001b; Meister and Fischer, 2002; Tripsianes et al., 2011).  
Components of the SMN complex can be found associated in distinct complexes such as 
SMN/Gemin2 (Battle et al., 2007), Gemin3/4 (with or without Gemin5) (Battle et al., 2006; 
Charroux et al., 1999, 2000) and Gemin6/7/Unrip (Carissimi et al., 2005), suggesting the SMN 
complex may be formed in a stepwise manner though precisely how it is assembled has not been 
fully described. Gemin2 was the first interactor of SMN to be identified and shown to colocalize 
with SMN (Liu et al., 1997). An ancestral version of the SMN complex in Schizosaccharomyces 
pombe consists only of SMN and Gemin2 – lacking homologs for the other complex components 
– suggesting that these two components are the foundation of the complex and increased 
evolutionary complexity has led to the addition of multiple Gemins to this core (Hannus et al., 
2000; Kroiss et al., 2008). Gemin3 is a DEAD-box RNA helicase which directly interacts with SMN 
through the YG box domain and recruits Gemin4 to the SMN complex (Charroux et al., 1999, 
2000). Gemin5 recognizes key structural features of snRNAs, allowing them to be distinguished 
from other RNAs to establish selectivity in snRNP assembly (Battle et al., 2006; Gubitz et al., 
2002; Lau et al., 2009; Yong et al., 2010). Gemin8 is critical for function of the SMN complex and 
can directly interact with SMN as well as serve as an adaptor for Gemin6/7/Unrip association with 
the SMN complex (Carissimi et al., 2006b, 2006a). Unrip is recruited to the SMN complex through 
binding with Gemin6/7 in a spatially specific manner as it does not colocalize with the rest of the 





Role of the SMN complex in snRNP biogenesis 
Studies investigating the cellular functions of SMN have uncovered a central role in the 
regulation of several RNA-processing pathways, including the assembly of small nuclear RNPs 
(snRNPs) responsible for carrying out pre-mRNA splicing and histone mRNA 3’-end processing 
(Li et al., 2014).  
 
The biogenesis of spliceosomal snRNPs 
Splicing is a key processing step in the maturation of messenger RNAs and is mediated by 
the spliceosome – a molecular machine composed of multiple snRNP complexes (Wahl et al., 
2009). Most introns are removed by the major (U2-dependent) spliceosomal snRNPs which 
include U1, U2, U4, U6 and U5 snRNPs, while a small subset is processed by the minor (U12-
dependent) spliceosomal machinery which consists of U11, U12, U4atac, U6atac and U5 snRNPs 
(Patel and Steitz, 2003; Wahl et al., 2009; Will and Lührmann, 2011). Each of these spliceosomal 
snRNPs contains a uridine rich small nuclear RNA (snRNA), seven Sm (or Sm-like) proteins, and 
additional snRNP-specific proteins (Will and Lührmann, 2001, 2011). With the exception of U6 
and U6atac, spliceosomal snRNAs of the Sm-class contain an Sm site – a sequence element 
around which a hetero-heptameric core of common Sm proteins B/B’, D1, D2, D3, E, F, and G is 
formed (Will and Lührmann, 2001). 
The biogenesis pathway of Sm-class snRNPs is highly complex and involves multiple 
nuclear and cytoplasmic steps (Figure 1.5) (Fischer et al., 2011; Kiss, 2004; Pellizzoni, 2007). 
Firstly, pre-snRNAs are transcribed by RNA polymerase II and a 7-methylguanosine cap is added 
co-transcriptionally (Fischer et al., 2011). This facilitates association with the cap-binding complex 
(CBC) – consisting of CBP20 and CBP80 – which recruits the phosphorylated adaptor for RNA 
export (PHAX) that in turn binds to Exportin-1/CRM1 and ras-related nuclear protein GTP 
(RanGTP) in order to mediate export from the nucleus (Fischer et al., 2011; Pellizzoni, 2007). The 




(Karijolich and Yu, 2010), and a second reversible dimethylation event can also occur at the N6 
position of the first adenine residue (m6Am) which is removed by the Fat mass and obesity-
associated protein (FTO) (Mauer et al., 2019). In the cytoplasm, Sm proteins are first recognized 
by a complex containing the chloride conductance regulatory protein (pICln), methylosome protein 
50 or WD repeat-containing protein 77 (MEP50/WDR77), and the protein arginine 
methyltransferase 5 (PRMT5) where a subset (B/B’, D1 and D3) are symmetrically dimethylated 
(Chari et al., 2008; Friesen et al., 2001b; Meister et al., 2001a). pICln acts as a chaperone for 
newly synthesized Sm proteins initiated through cooperation with the ribosome (Chari et al., 2008; 
Paknia et al., 2016) and maintains separation from snRNAs until they are brought to the SMN 
complex which mediates the specific assembly of the Sm-core on snRNAs (Meister et al., 2001b; 
Pellizzoni et al., 2002b). Recognition of precursor snRNAs by the SMN complex is enabled by 
Gemin5  (Yong et al., 2010) and in the case of U1 snRNA further specificity is conferred by the 
U1-specific protein U1-70K (So et al., 2016). Subsequently to SMN-mediated Sm core formation, 
snRNAs become hypermethylated at the 5’-end by the Trimethylguanosine synthase 1 (TGS1) 
enzyme (Mouaikel et al., 2002) and trimmed at the 3’-end. After cytoplasmic maturation, the 
assembled snRNPs are then imported into the nucleus through association of the SMN complex 
with Snurportin – an adaptor protein which recognizes the trimethylguanosine cap of snRNAs – 
and  the transport receptor importin-β (Huber et al., 1998; Massenet et al., 2002; Narayanan et 
al., 2004), where they can then function in pre-mRNA splicing. 
 
The biogenesis of U7 snRNP 
 In contrast to spliceosomal snRNPs, U7 snRNP mediates the processing of the 3’-end of 
histone mRNAs (Marzluff et al., 2008). Unlike other pre messenger RNAs, histone mRNAs do not 
undergo splicing or polyadenylation and instead require U7 snRNP-mediated endonucleolytic 
cleavage to produce the proper 3’-end (Marzluff et al., 2008). The biogenesis pathway of U7 




sequence of Sm-class snRNAs and SmD1 and SmD2 proteins in the Sm-core are replaced by 
Sm-like (LSm) proteins LSm10 and LSm11 (Pillai, 2003; Pillai et al., 2001; Schumperli and Pillai, 
2004). Similar to the assembly of spliceosomal snRNPs, the SMN complex is also required for 
the assembly of the U7-specific LSm/Sm core onto U7 snRNA and the proper 3’-end processing 
of histone mRNAs (Pillai et al., 2003; Tisdale et al., 2013). 
 
SMN as a molecular chaperone for the specificity of snRNP assembly 
 Initial studies of purified Sm proteins showed that Sm cores could undergo self-assembly 
onto snRNAs (Raker et al., 1999). Thus, it was seemingly discordant that a large macromolecular 
machine such as the SMN complex was needed to mediate a spontaneous process. However, 
RNP assembly in vivo is increasingly complex due to the potential for numerous non-specific 
interactions, and studies of the role of the SMN complex in snRNP biogenesis revealed its 
requirement for a molecular chaperone to facilitate the process (Figure 1.6). Sm proteins 
minimally require a short, single stranded uracil-rich RNA to spontaneously assemble Sm cores 
(Raker et al., 1999). However, the SMN complex is critically required for the specificity and 
efficiency of the interaction of Sm proteins and snRNAs in vivo (Pellizzoni et al., 2002b). 
Specifically, Gemin5 serves as the RNA binding protein for the recognition of snRNAs by the SMN 
complex, ensuring the fidelity of snRNP assembly (Battle et al., 2006; Pellizzoni et al., 2002b; 
Yong et al., 2010). Additionally, interactions of pICln and the PRMT5 complex with Sm core 
intermediates are believed to prevent illicit interactions with other RNAs and association with the 
SMN complex facilitates transfer of Sm proteins for assembly on the appropriate snRNAs (Paknia 
et al., 2016; Pellizzoni, 2007). The SMN complex has also been implicated in surveillance systems 
to target mutant U snRNAs that cannot be incorporated into snRNPs to cytoplasmic P-bodies 
where they can be degraded by the exosome (Ishikawa et al., 2014; Shukla and Parker, 2014). 




decrease expression of Sm proteins to prevent unwanted accumulation and aggregation (Prusty 
et al., 2017). 
 
Broader roles of the SMN complex in RNA regulation 
 In addition to the role of the SMN complex in the biogenesis of Sm-class spliceosomal and 
U7 snRNPs discussed above, several lines of evidence have suggested further roles of SMN in 
RNA regulation.  LSm2-8 proteins – which share significant homology with Sm proteins – form a 
heteroheptameric ring which binds to the 3’ end of U6 and U6atac snRNAs influencing stability 
and formation of the U4/U6 and U4atac/U6atac di-snRNPs involved in pre-mRNA splicing (Achsel 
et al., 1999; Cooper et al., 1995; Salgado-Garrido et al., 1999). Early studies showed that SMN 
directly binds to Lsm4 and LSm6 in vitro (Brahms et al., 2001; Friesen and Dreyfuss, 2000). 
LSm1-7 proteins form another heteroheptameric complex involved in cytoplasmic mRNA decay 
(Bouveret et al., 2000; Tharun et al., 2000). Taken together with the molecularly defined role of 
SMN in the assembly of both Sm-class spliceosomal snRNPs and U7 snRNP, this data suggests 
that the SMN complex may have a more general role in the biogenesis of RNPs containing 
Sm/LSm proteins that has yet to be fully described. In support of this, the SMN complex has also 
been shown to mediate the assembly of Sm cores on Herpesvirus saimiri small U-rich RNAs 
(HSURs) to form viral snRNPs (Golembe et al., 2005).  
SMN can associate with several mRNA binding proteins that play key roles in gene 
regulation through mRNA stability, transport and local translation in neurons (Li et al., 2014). Early 
studies showed evidence for localization of SMN in the axons of motor neurons in vivo (Béchade 
et al., 1999; Pagliardini et al., 2000). Moreover, SMN colocalizes with RBPs hnRNP R, HuD, 
KSRP, FMRP and IMP1 in RNA granules of cultured neuronsthat can be mobilized along the 
axons (Fallini et al., 2011, 2014; Piazzon et al., 2008; Rossoll et al., 2002, 2003; Tadesse et al., 
2008). These SMN-containing granules can undergo bidirectional transport along axons and 




in this context is independent from its role in snRNP biogenesis (Fallini et al., 2011; Hao et al., 
2015; Zhang et al., 2006). In accordance with a function in mRNP trafficking, SMN deficiency 
leads to a reduction in the axonal localization of RNA binding proteins such as HuD and IMP1 in 
motor neurons as well as a general impairment in the transport of poly(A)-containing mRNAs 
(Akten et al., 2011; Fallini et al., 2011, 2014). In particular, SMN deficiency leads to a reduction 
in b-actin and Gap43 mRNAs in the distal axons and growth cones of cultured motor neurons, 
which is associated with impairments in axonal growth (Donnelly et al., 2013; Fallini et al., 2016; 
Rossoll et al., 2003). Further studies have shown SMN-dependent association of IMP1 and b-
actin mRNA, supporting a role for SMN in mRNP complex assembly by facilitating the interaction 
between mRNA binding proteins and their mRNA targets (Donlin-Asp et al., 2016, 2017). 
 SMN has also been implicated in the formation of several other classes of RNPs. Small 
nucleolar RNPs (snoRNPs) are critical in the processing and modification of ribosomal RNAs in 
the nucleolus and are classified as box C/D or box H/ACA snoRNPs (Watkins and Bohnsack, 
2012). SMN has been shown to interact and colocalize with snoRNP associated proteins of both 
classes such as GAR1 and Fibrillarin (Jones et al., 2001; Pellizzoni et al., 2001a; Wehner et al., 
2002; Whitehead et al., 2002). Expression of a dominant negative mutant form of SMN leads to 
redistribution of snoRNPs from the nucleolus to SMN-containing aggregates (Pellizzoni et al., 
2001a). Furthermore, SMA fibroblasts show a reduction of the snoRNP chaperone Nopp140 in 
Cajal bodies which correlates with disease severity (Renvoisé et al., 2009). Telomerase is an 
RNP that contains two critical catalytic subunits: the telomerase RNA (TR) and the telomerase 
reverse transcriptase (TERT) protein (Egan and Collins, 2012). SMN has been shown to directly 
interact with TERT in vitro and a dominant-negative mutant of SMN led to the sequestration and 
mislocalization of TERT suggesting a role for the SMN complex in its biogenesis (Bachand et al., 
2002). The signal recognition particle (SRP) is an RNP that contains six protein components 




nascent secretory and membrane proteins to the endoplasmic reticulum (Keenan et al., 2001). 
The SMN complex has been shown to bind 7S RNA in vitro, associate with SRP proteins in 
mammalian cell extracts and play a functional role in the association of SRP components in 
Xenopus oocytes, suggesting an expanded function in this RNP biogenesis pathway (Piazzon et 
al., 2013).  
 Roles for SMN in transcription have also been reported. Evidence for this includes the 
interaction of SMN with the C-terminal domain (CTD) of RNA polymerase II (Pellizzoni et al., 
2001b) – a domain important for the coupling of transcription and processing of nascent RNAs 
(Hsin and Manley, 2012) – mediated by RNA helicase A. Additional experiments utilizing a 
dominant negative mutant of SMN provided evidence for a functional role of SMN in transcription 
(Pellizzoni et al., 2001b).   More recently, a study proposed that SMN association with RNA pol II 
is regulated by the symmetric dimethylation of an arginine residue in the CTD (Zhao et al., 2016a). 
This interaction with SMN in turn leads to the recruitment of Senataxin – a DNA-RNA helicase 
which resolves R-loops created near the termination region of genes during RNA pol II 
transcription – suggesting a role for SMN in transcription termination (Zhao et al., 2016a). 
 Collectively, these studies provide additional lines of evidence that situate the SMN complex 
as a general mediator of RNA-protein interactions that can have widespread effects on RNA 
regulation (Figure 1.7). 
 
1.3 Role of RNA dysfunction in SMA pathology 
 In order to establish causality of how SMN deficiency leads to SMA, a particular function of 
SMN must first be molecularly defined (ie. snRNP biogenesis) and its contribution to the 
pathogenesis of SMA must also be validated in animal models. Since initial characterization of 
SMN as the disease-determining gene, several advancements have been made in understanding 





snRNP dysfunction in SMA 
 Several lines of evidence support the contribution of impaired snRNP biogenesis to SMA 
pathogenesis. Analysis of SMA patient-derived cell lines has shown deficiencies in snRNP 
assembly that correlate with the degree of reduction in SMN (Wan et al., 2005). Furthermore, 
deficits in snRNP assembly are proportional to disease severity when compared across several 
mouse models of SMA (Gabanella et al., 2007). However, this impaired capacity for snRNP 
assembly observed in vitro is not accompanied by a reduction in the steady-state levels of 
snRNPs in patient-derived cell lines, indicating that a degree of reduction in SMN can be tolerated 
at least in certain cellular contexts (Boulisfane et al., 2011; Gabanella et al., 2007). This finding 
also suggests that the in vivo capacity for snRNP biogenesis is in excess of its functional 
requirement and in order to have functional consequences on snRNP levels the deficiency in SMN 
has to reach a certain threshold – a degree which is likely dependent on both cell type and 
developmental stage (Gabanella et al., 2005). Importantly, multiple studies utilizing SMA mouse 
models have identified reductions in spliceosomal and U7 snRNPs at the whole tissue level 
(Gabanella et al., 2007; Tisdale et al., 2013; Workman et al., 2009; Zhang et al., 2008). 
Additionally, higher snRNP assembly activity of disease-linked SMN alleles has been shown to 
correlate with their increased ability to rescue SMA mice (Workman et al., 2009). Remarkably, 
when analyzed by immunohistochemistry, a much more severe reduction in snRNP levels is 
observed in disease-relevant SMA motor neurons when compared to other cells in the spinal cord 
(Ruggiu et al., 2012; Tisdale and Pellizzoni, 2015), consistent with their preferential vulnerability 
to SMN deficiency. The proposed explanation for this is an intrinsically low efficiency of SMN2 
exon 7 inclusion in motor neurons relative to other spinal cells resulting in lower levels of SMN 
derived from the SMN2 gene (Ruggiu et al., 2012). Moreover, within the setting of SMA, this deficit 
in the spliceosomal machinery of motor neurons creates a negative feedback loop that further 
exacerbates the already inefficient inclusion of SMN2 exon 7 (Jodelka et al., 2010; Ruggiu et al., 




correction of motor neuron deficits (Winkler et al., 2005). Collectively, these results support a role 
for impaired snRNP biogenesis in SMA pathology, while also accounting for how ubiquitous 
deficiency in SMN can lead to context-dependent effects on snRNP pathways. These findings 
potentially explain the cell-type specific susceptibilities observed in SMA and why downstream 
effects of SMN deficiency could be particularly exacerbated in motor neurons. 
 
RNA processing dysfunction in SMA 
 In an effort to identify downstream molecular changes resulting from SMN deficiency, 
several groups have performed transcriptome-wide analysis in multiple models of SMA. Firstly, 
whole tissue analysis showed widespread alterations in transcript levels and splicing at late 
disease stages in the SMNΔ7 SMA mice (Zhang et al., 2008). Another study performed profiling 
of gene expression and mRNA processing changes over disease course in the same mouse 
model and showed a progressive increase in the number and degree of differentially expressed 
exons from pre- to post-symptomatic stages, suggesting that widespread alterations observed at 
late timepoints may be a secondary consequence of pathology (Bäumer et al., 2009). In 
agreement with this possibility, only minimal changes have been observed at pre-symptomatic 
stages in the spinal cord and other tissues of multiple severe mouse models of SMA (Bäumer et 
al., 2009; Doktor et al., 2017; Murray et al., 2010). Thus, conclusions that can be drawn from 
transcriptome analysis at the whole tissue level are limited due to the lack of cell-type specificity 
and the added confounding effects of disease pathology at late symptomatic stages. In order to 
obtain greater resolution, several subsequent studies focused on the specific profiling of motor 
neurons (Huo et al., 2014; Murray et al., 2015; Ng et al., 2015; Simon et al., 2017; Zhang et al., 
2013). In contrast to analysis at the whole tissue level, transcriptome alterations were observed 
in motor neurons at pre-symptomatic stages of disease, consistent with more prominent disruption 
of RNA regulation in this particularly vulnerable neuronal population and the importance of cell 




 Identification of a preferential reduction in the levels of minor spliceosomal snRNPs induced 
by SMN deficiency in tissues of SMA mice suggested that dysregulation of U12-dependent 
splicing may be particularly relevant for SMA pathology (Gabanella et al., 2007). The minor 
spliceosome is responsible for removing less than 1% of total introns and U12 containing genes 
are enriched for those with neuronal functions potentially accounting for the primarily motor 
system pathology observed in SMA (Verma et al., 2018). SMN-dependent effects on the removal 
of U12-introns have been identified in SMA patient derived cell lines (Boulisfane et al., 2011) and 
mammalian cell models of SMN-deficiency as well as animal models of SMA (Lotti et al., 2012). 
Additionally, the stabilization of minor snRNAs leads to a partial restoration of U12-dependent 
splicing deficits in the context of SMN deficiency (Shukla and Parker, 2014). SMN deficiency in 
Drosophila results in lower levels of minor snRNAs and genome-wide analysis showed intron 
retention and a reduction in the mRNA levels of several U12 intron-containing genes, which 
partially phenocopies the effects of a U6atac mutant (Lotti et al., 2012). Importantly, this study 
also identified the U12-intron containing gene Stasimon as  the first splicing target regulated by 
SMN that contributes to motor circuit dysfunction in animal models of SMA (Lotti et al., 2012). 
These findings were further confirmed and expanded by tissue-wide analysis of both severe SMA 
mice and postnatally induced SMN-deficient mice which showed prominent U12 intron retention 
(Doktor et al., 2017; Jangi et al., 2017). Taken together, these studies provide evidence for U12-
dependent splicing being a prominent RNA pathway dysregulated in SMA. 
 In addition to intron-containing mRNAs, changes in the U7-dependent 3’end processing of 
histone mRNAs have also been identified in tissues from an SMA mouse model as well as in 
patient samples (Tisdale et al., 2013). SMA motor neurons show increased levels of 
misprocessed histone mRNAs, demonstrating a clear disruption of this RNA pathway in a 
disease-relevant cell type (Tisdale et al., 2013). However, a potential contribution of U7-





Axonal mRNA transport deficits in SMA  
 Considering the potential for expanded roles of SMN in RNA regulation beyond snRNP 
biogenesis, SMN-dependent effects on axonal mRNA transport for local translation is appealing 
as a potential disease mechanism in SMA since it would be a relevant function during neuronal 
development (McGovern et al., 2008). Evidence to support this hypothesis initially derived from 
studies showing a reduction in both the mRNA and protein level of b-actin in distal axons and 
growth cones of cultured SMA motor neurons, which correlated with impaired axonal growth 
(Rossoll et al., 2003). Further, the knockdown of Smn in zebrafish leads to motor axon outgrowth 
and pathfinding deficits (Carrel et al., 2006; McWhorter et al., 2003). This has been accredited to 
SMN chaperoning mRNP assembly through interaction with several RNA binding proteins such 
as hnRNP R, HuD, IMP1, and KSRP (Akten et al., 2011; Donlin-Asp et al., 2017; Fallini et al., 
2011, 2014; Glinka et al., 2010; Gu et al., 2002; Rossoll et al., 2003; Tadesse et al., 2008). 
Additional SMN-dependent reductions in the axonal levels of specific mRNA targets such as 
Gap43 and neuritin/cpg15 as well as a general reduction in polyA+ mRNAs and associated RBPs 
have been shown in cultured neurons (Akten et al., 2011; Fallini et al., 2011, 2014, 2016; Rage 
et al., 2013). However, it is interesting to note that the knockout of b-actin mRNA in mouse motor 
neurons does not phenocopy motor circuit pathology characteristic of SMA (Cheever et al., 2011) 
and the knockout of SMN-associated RNA-binding proteins such as FMRP (Consorthium et al., 
1994), HuD (Akamatsu et al., 2005; DeBoer et al., 2014), KSRP (Lin et al., 2011), and IMP1 
(Hansen et al., 2004) also fail to elicit SMA-like phenotypes. Furthermore, while axonal mRNA 
transport would be particularly important for axon outgrowth and pathfinding during 
embryogenesis, motor axon development occurs normally in SMA mice (McGovern et al., 2008). 
Thus, additional investigation is required to establish a contribution of SMN-dependent effects on 





Contributions of SMN-dependent RNA dysregulation events to SMA pathology  
An outstanding challenge in SMA biology has been the identification of key downstream 
effectors that are dysregulated as a consequence of SMN deficiency, and causally implicated in 
motor circuit dysfunction. The relatively mild effects on snRNP levels that are observed in SMA 
models are not necessarily consistent with a global functional collapse of spliceosomes. 
Nevertheless, hundreds of splicing/mRNA changes have been documented in SMA models 
(Bäumer et al., 2009; Doktor et al., 2017; Huo et al., 2014; Murray et al., 2010, 2015; Ng et al., 
2015; Simon et al., 2017; Zhang et al., 2008, 2013) and the identification of uniquely critical genes 
affected by SMN-dependent RNA pathways that play fundamental roles in SMA pathology is 
critical for elucidating disease mechanisms. In order to assign causality, these downstream events 
must be identified and selectively restored in SMA models, to validate potential contributions to 
given pathological characteristics of SMA.  
To date, several mRNA targets – in addition to SMN2 itself (Lorson et al., 1999; Monani, 
2000) – have been evaluated in animal models of SMA for their contribution to pathogenesis. 
Stasimon was initially characterized as a U12-intron containing gene and a downstream target 
affected by splicing dysfunction induced by SMN deficiency in Drosophila (Lotti et al., 2012). The 
knockdown of Stasimon induces motor circuit dysfunction in Drosophila larvae and zebrafish 
embryos (Lotti et al., 2012), phenocopying deficits induced by SMN knockdown (Imlach et al., 
2012). Importantly, restoration of Stasimon is sufficient to rescue specific aspects of motor circuit 
dysfunction induced by SMN deficiency in these model organisms providing the first proof-of-
concept of an SMN-dependent splicing target that functions in the motor circuit and is a direct 
effector of SMA-related phenotypes in vivo (Imlach et al., 2012; Lotti et al., 2012). Intron retention, 
aberrant splicing, and a reduction in mRNA levels of Stasimon was also observed in severe SMA 
mice, especially prominent in vulnerable motor neurons and proprioceptive neurons (Lotti et al., 




animal models, but the cellular functions of Stasimon and its contribution to pathogenesis in SMA 
mouse models are yet to be characterized. 
Transcriptome-wide profiling of splicing changes in SMA motor neurons uncovered RNA 
processing deficits in genes that could be particularly relevant to SMA pathology such as Agrin 
(Zhang et al., 2013). Agrin is a critical regulator of NMJ structure and function – the most active 
form of which derives from inclusion of neuron specific Z exons – which is  expressed in motor 
neurons and secreted at the motor endplate where it is a key organizer in the clustering of post-
synaptic acetylcholine receptors (AChR) during synaptic differentiation (Nitkin et al., 1987, 
Gautam et al., 1996) and is also required for post-natal NMJ maintenance (Samuel et al., 2012). 
Profiling of SMA motor neurons has shown reduced inclusion of Z exons (Kim et al., 2017; Zhang 
et al., 2013) – a change in isoform which dramatically reduces the activity in AChR clustering 
(Burgess et al., 1999; Ferns et al., 1993). Importantly, studies restoring Agrin in SMA mice, either 
systemically through delivery of an Agrin biologic (Boido et al. 2018), or genetically by selective 
expression in motor neurons (Kim et al., 2017), have been shown to ameliorate NMJ denervation. 
Dysregulation of ubiquitin homeostasis has also been implicated in neurodegenerative 
processes in SMA. Ubiquitin-like modifier activating enzyme 1 (Uba1) is involved in the ubiquitin-
mediated targeting of proteins for proteasomal degradation and impaired splicing of Uba1 mRNA 
was detected in the spinal cord of SMA mice (Wishart et al., 2014). Disruptions in the ubiquitin 
pathway and reductions in Uba1 expression have also been identified in patient-derived iPSC 
motor neurons and multiple mouse models (Fuller et al., 2016; Powis et al., 2016; Wishart et al., 
2014). Additionally, a rare form of X-linked SMA is caused by mutations in the UBA1 gene 
(Ramser et al., 2008). In agreement with this, suppression of UBA1 either through 
pharmacological or genetic approaches induced SMA-like phenotypes in zebrafish and delivery 
of full-length UBA1 mRNA was able to rescue motor circuit pathology following SMN knockdown 
(Powis et al., 2016; Wishart et al., 2014). AAV9-mediated delivery of UBA1 in an SMA mouse 




denervation, and proprioceptive synaptic loss (Powis et al., 2016; Shorrock et al., 2018). However, 
an increase in SMN levels was also detected and likely contributed to this phenotypic rescue, 
complicating evaluation of a direct contribution of UBA1 to neuromuscular pathology independent 
of SMN induction (Powis et al., 2016; Shorrock et al., 2018). 
 Additional downstream targets of RNA-misprocessing induced by SMN deficiency have 
been investigated which have neuronal-specific functions. Chondrolectin (Chodl) is a gene that 
encodes for a C-type lectin which is highly expressed in motor neurons though its precise function 
remains unknown. Chodl expression levels are reduced in SMA models and initial evidence 
pointed to alterations in alternative splicing while additional investigation uncovered SMN-
dependent regulation of expression levels through miR-431 (Bäumer et al., 2009; Wertz et al., 
2016; Zhang et al., 2008). Knockdown of Chodl in zebrafish leads to defects in motor axon 
outgrowth and its overexpression rescues SMN-deficiency induced motor axon defects (Sleigh et 
al., 2014; Zhong et al., 2012). However, genetic ablation of the functional C-type lectin domain in 
Chodl mutant mice only led to mild synaptic deficits at the NMJ and did not phenocopy features 
of SMA such as denervation and motor neuron death (Oprişoreanu et al., 2019). Neurexin2a 
(Nrxn2a) – a presynaptic membrane protein involved in neurotransmitter release – is 
downregulated and alternatively spliced in SMN-deficient zebrafish and motor neurons from a 
severe mouse model of SMA and loss-of-function of Nrxn2a phenocopies SMN-deficiency in 
zebrafish (See et al., 2014). As discussed previously, Neuritin (also known as cpg15) – a factor 
highly expressed in the developing spinal cord that serves neurotrophic functions (Zhou and Zhou, 
2014)– colocalizes with SMN and HuD in axons (Akten et al., 2011). mRNA levels of cpg15 are 
reduced in neurites of SMN-deficient cultured neurons and overexpression in zebrafish partially 
restores SMN-deficiency associated phenotypes in motor axon outgrowth (Akten et al., 2011).  
Collectively these studies have provided initial evidence of disease contribution of several 




accurately reflect features of the human disease (Van Alstyne and Pellizzoni, 2016) will allow 
precise identification of their potential role in SMA pathology.  
 
1.4 Mechanisms of motor neuron death in SMA mouse models 
SMA is a result of ubiquitous SMN deficiency, yet the key hallmark of SMA is the selective 
degeneration of spinal motor neurons. Therefore, the molecular mechanisms that underlie motor 
neuron degeneration have been actively studied in SMA mouse models – which most faithfully 
recapitulate aspects of the human disease (Van Alstyne and Pellizzoni, 2016) in order to gain 
insight into the pathogenesis of SMA and their selective vulnerability. Furthermore, elucidating 
the death pathway underlying degeneration can uncover new therapeutic strategies to spare SMA 
motor neurons.  
 
Characteristics of motor neuron death in SMA 
Severe SMA mice demonstrate a pronounced and selective loss of alpha motor neurons, a 
hallmark of the human disease (Burghes and Beattie, 2009; Tisdale and Pellizzoni, 2015), while 
spindle-innervating gamma motor neurons and cholinergic spinal interneurons are largely spared 
(Powis and Gillingwater, 2016). Importantly, there are differential susceptibilities of individual 
motor neuron pools along the rostro-caudal and medio-lateral axis of the spinal cord correlating 
with the vulnerability of distinct muscle groups (Mentis et al., 2011). For example, loss of motor 
neurons innervating vulnerable axial muscles can be detected by postnatal day 4 in the L1 
segment of the lumbar spinal cord. However, in the L5 segment, loss of medial motor neurons 
innervating proximal muscles begins at postnatal day 9, while lateral motor neurons innervating 
resistant distal muscles are spared (Mentis et al., 2011). 
 Neuronal health is maintained by support from surrounding glial cells which provide 




occur as a consequence of cellular deficits within the neuron itself as well as in supporting cells. 
Numerous studies have investigated the cell autonomy of motor neuron degeneration in SMA 
through the selective genetic restoration of SMN. As discussed in Chapter 1.1, motor neuron 
specific restoration of SMN utilizing ChAT-Cre or Hb9-Cre drivers has shown that an increase in 
SMN levels in SMA motor neurons prevents degeneration in a cell-autonomous manner (Fletcher 
et al., 2017; Gogliotti et al., 2012; Martinez et al., 2012; McGovern et al., 2015). The degree of 
rescue is not fully complete in these models, which could be explained by the efficiency of 
recombination as well as an added contribution of other cell types. While non-cell autonomous 
mechanisms may exacerbate motor neuron degeneration (Hua et al., 2015), strong genetic 
evidence argues for the cell-autonomous nature of motor neuron degeneration in SMA. 
Investigation of the molecular mechanisms of selective neurodegeneration in SMA should 
recapitulate both this finding and provide an explanation for the differing vulnerabilities of specific 
motor neuron pools to SMN deficiency. 
 
Cellular pathways implicated in SMA motor neuron death 
Several pathways of cellular stress and dysfunction have been linked to motor neuron 
degeneration in SMA. The c-Jun NH(2)-terminal kinase (JNK) signaling pathway is activated in 
response to cellular stress and can regulate apoptotic cell death as well as developmental 
processes in neurons (Coffey, 2014; Nishina et al., 2004). Recent studies have proposed that 
activation of JNK underlies motor neuron death in SMA mice. More specifically, a CNS specific 
isoform – JNK3 – was shown to be activated in SMN-deficient cultured neurons and genetic 
knockout as well as pharmacological inhibition in SMA mice led to a rescue of motor neuron 
number and NMJ innervation (Genabai et al., 2015; Schellino et al., 2018).  
ER stress leads to compensatory activation of the unfolded protein response (UPR) which 
can either mediate recovery or trigger apoptosis (Hetz, 2012; Schröder and Kaufman, 2005). 




motor neurons which was associated with increased apoptosis (Ng et al., 2015). Further, elevated 
levels of UPR markers were present in spinal cord from SMA mice and pharmacological inhibition 
of the UPR was reported to preserve motor neuron survival and NMJ innervation in the SMNΔ7 
mouse model (Ng et al., 2015).  
Hyperphosphorylation of microtubule associated protein Tau is associated with the 
formation of neurofibrillary tangles – a characteristic feature of Alzheimer’s disease (Grundke-
Iqbal et al., 1986). An increase in Tau phosphorylation has been observed in the spinal cord and 
motor neurons of multiple SMA models and human patient tissue – though there was no evidence 
of aggregation (Miller et al., 2015). This hyperphosphorylation – mediated by CDK5 – contributes 
to motor axon growth defects in zebrafish and the genetic knockout of Tau in SMA mice rescues 
motor neuron loss and deafferentation along with NMJ denervation (Miller et al., 2015).  
Other proposed mechanisms underlying SMA motor neuron degeneration are related to 
DNA damage. SMN deficiency has been linked to impaired R-loop resolution due to reduced 
Senataxin recruitment to RNA polymerase II inducing double strand breaks (Kannan et al., 2018; 
Zhao et al., 2016a). Another study in a model of SMN-deficiency in adult mice attributed the 
induction of a DNA damage response to global intron-retention (Jangi et al., 2017). Low levels of 
SMN are associated with reduced DNA-activated protein kinase catalytic subunit (DNA-PKcs) 
activity – leading to impaired DNA repair pathways (Kannan et al., 2018). Overexpression of 
Senataxin is able to suppress DNA damage accumulation in cultured SMA neurons (Kannan et 
al., 2018). However, investigation of DNA damage and its potential role on the degenerative 
pathway of SMA motor neurons in vivo is yet to be performed.  
 Taken together, these studies have implicated numerous cellular pathways in mediating 
SMA motor neuron degeneration. However, a mechanistic understanding of how SMN deficiency 
may lead to the specific activation of these cellular pathways in motor neurons, whether they can 
be unified into a single death cascade, and the precise downstream mechanisms mediating 




able to account for the selective vulnerabilities of specific motor neuron pools in SMA – a key 
characteristic that should be integrated into a model for the mechanism(s) of motor neuron 
degeneration in SMA. 
 
p53-dependent mechanisms of SMA motor neuron death 
 In order to determine molecular pathways associated with selective motor neuron 
degeneration, multiple groups have performed transcriptional profiling of vulnerable and resistant 
SMA motor neurons from mouse models. Analysis of transcriptional differences in motor neuron 
populations of the Smn2B/- and SMNΔ7 mouse models identified upregulation of known p53 
transcriptional targets in vulnerable SMA motor neurons (Murray et al., 2015; Simon et al., 2017). 
Interestingly, transcriptome analysis from a postnatally induced model of Smn-deficiency also 
uncovered activation of the p53 pathway (Jangi et al., 2017), supporting conservation across 
models. A time-dependent nuclear accumulation of p53 can be observed in both vulnerable and 
resistant motor neurons of SMNΔ7 SMA mice, however, it occurs earlier and to a larger extent in 
the vulnerable population (Simon et al., 2017). Importantly, both pharmacological and genetic 
inhibition of p53 rescues motor neuron survival, highlighting the importance of p53 as a driver of 
motor neuron degeneration in SMA mice (Simon et al., 2017). Interestingly, at late stages of the 
disease, nuclear accumulation of p53 extends beyond motor neurons and is present throughout 
the spinal cord as well as in the cerebellum, however p53 upregulation remains restricted to the 
CNS and is not associated with death of these neurons (Simon et al., 2017). Additionally, 
overexpression of p53 in wild-type motor neurons does not cause neurodegeneration (Simon et 
al., 2017). Thus, while p53 drives death of vulnerable SMA motor neurons, the upregulation of 
p53 alone is neither sufficient to induce the degeneration of motor neurons nor explain the differing 
vulnerabilities of distinct SMA motor neuron pools to SMN deficiency. 
 Importantly, post-translational modification of p53 by phosphorylation at serine 18 was 




neurons concomitant with the timing of degeneration (Simon et al., 2017), serving as a marker for 
SMA motor neuron death. Further, AAV9-mediated replacement studies demonstrated that N-
terminal phosphorylation at multiple residues in the transactivation domain of p53 – including 
serine 18 – is required to mediate SMA motor neuron death (Simon et al., 2017). This study 
established p53 as a key driver of motor neuron loss in SMNΔ7 SMA mice and indicated that 
distinct converging modes of p53 activation underlie the selectivity of SMA motor neuron 
degeneration (Figure 1.8).  
 Several cellular pathways implicated in SMA motor neuron death can act through p53 as a 
downstream effector. p53 is well-established to be activated in response to DNA-damage, 
however there was no evidence of gH2AX phosphorylation in SMNΔ7 SMA motor neurons (Simon 
et al., 2017). While activation of Cdk5 in SMA has been characterized in the context of Tau 
hyperphosphorylation (Miller et al., 2015), it can also post-translationally modify p53 and may be 
involved in the N-terminal phosphorylation associated with SMA motor neuron death (Lee et al., 
2007). Similarly, JNK signaling leads to p53 stabilization and activation (Fuchs et al., 1998), and 
JNK has been implicated in the neurodegenerative cascade induced by SMN deficiency (Genabai 
et al., 2015). However, immunohistochemical analysis of SMA motor neurons showed no 
evidence for phosphorylated JNK or correlation between activation of c-Jun – a downstream 
substrate of JNK – and motor neuron degeneration (Pilato et al., 2019; Simon et al., 2017). 
Interestingly, while in vitro studies of SMA motor neurons identified ER-stress induced apoptosis 
(Ng et al., 2015), no evidence for caspase activation or DNA fragmentation were observed in vivo 
indicating that p53-mediated SMA motor neuron death might occur through caspase-independent, 
non-apoptotic mechanisms (Simon et al., 2017). Thus, p53-mediated SMA motor neuron death 
does not appear to be activated by previously described pathways. These findings set the stage 
for my studies to elucidate the SMN-dependent upstream mechanisms responsible for the 
upregulation and phosphorylation of p53 in vulnerable motor neurons that converge to trigger their 





1.5 Modes of p53 regulation 
 p53 is an extensively studied gene due to its key role as a “guardian of the genome”. The 
most well-defined function for p53 is in the integration of stress signals to program a cellular 
response – such as cell-cycle arrest or cell death – through the transcriptional activation of 
downstream target genes (Vousden and Lane, 2007). As p53 serves as a critical crux for 
determining cell fate, it requires intricate and complex regulation. In this section, the cellular roles 
of p53 as well as key regulatory mechanisms will be discussed.  
 
The tumor suppressor p53 
 p53 is one of the hallmark tumor suppressor genes as highlighted by its inactivation in over 
50% of cancers (Hollstein et al., 1991; Levine, 1997). Ablation of p53 in a mouse model leads to 
increased tumor susceptibility with homozygous knockout mice developing tumors by 4.5 months 
or heterozygous mice by 10 months on average (Donehower et al., 1992). On the opposite hand, 
when p53 levels are uncontrolled they lead to embryonic lethality in mouse models (Johnson et 
al., 2005; Jones et al., 1995; de Oca Luna et al., 1995; Parant et al., 2001). Thus, the regulation 
of p53 is critical to maintain protective effects and prevent illicit activation. 
 
p53 domains and functions 
p53 contains two N-terminal transactivation domains (Candau et al., 1997; Fields and Jang, 
1990; Raycroft et al., 1990), a proline-rich domain (Walker and Levine, 1996), a DNA binding 
domain (Pavletich et al., 1993), an oligomerization or tetramerization domain (Shaulian et al., 
1992), and a C-terminal domain (Figure 1.9). The two tandem transactivation domains are highly 
post-translationally modified and are required for tumor suppressor activity and induction of a p53 




copies of the sequence PXXP and while dispensable for DNA binding and transcriptional 
activation, does play a role in p53-mediated apoptosis and tumor suppression (Sakamuro et al., 
1997; Venot et al., 1998; Walker and Levine, 1996; Zhu et al., 1999). Through the DNA binding 
domain (DBD), p53 binds in a sequence-specific manner to consensus elements which are 
present proximal to the promoters of target genes (El-Deiry et al., 1992; Funk et al., 1992; 
Pavletich et al., 1993). The binding motif for p53 contains two 10 base pair half-site sequences 
which can each be recognized by two dimers of p53, which binds in a cooperative manner as a 
tetramer (Wang et al., 1995; Weinberg et al., 2004). The oligomerization domain stabilizes 
tetramer formation and mutants with impaired oligomerization show reduced transcriptional 
activity (Davison et al., 1998; Kawaguchi et al., 2005). The C-terminal domain (CTD) of p53 is 
highly unstructured (Bell et al., 2002) and is also subject to numerous post-translational 
modifications (Toledo and Wahl, 2006), which likely contribute to the diverse functionalities that 
have been attributed to this region. Initial studies presented much contradictory evidence for the 
role of the CTD as both a positive and negative regulator of p53 activity (Sullivan et al., 2018); 
however, current functions for the CTD include the non-specific binding to DNA which permits 
scanning prior to recognition of a conserved sequence and binding by the DBD (Khazanov and 
Levy, 2011; McKinney et al., 2004; Tafvizi et al., 2008, 2011) as well as stabilization of the DNA 
and DBD interaction through conformational changes (Laptenko et al., 2015).  
 
Activation of p53 by stressors 
 Under physiological conditions, p53 is maintained at low levels mainly through protein 
degradation; however, upon an activating trigger it can become rapidly stabilized (Lavin and 
Gueven, 2006). Many stressors have been identified which lead to the accumulation of p53 – the 
first documented and most pronounced of which is DNA damage by exposure to UV or ionizing 
radiation (Kastan et al., 1991; Maltzman and Czyzyk, 1984). p53 is a general protectant against 




(Saretzki et al., 1999). In the absence of DNA damage, p53 can also be stabilized in response to 
disruptions in cellular homeostasis such as hypoxia (Hammond et al., 2002), oncogenic activation 
(Pomerantz et al., 1998; Zhang et al., 1998), and impaired ribosomal biogenesis (Golomb et al., 
2014; Pestov et al., 2001). Upon activation, p53 serves a protective role by activating pathways 
governing repair and arrest, or those executing senescence and apoptosis depending on the 
upstream triggers (Figure 1.10). 
 
Roles of Mdm2 and Mdm4 in p53 suppression 
 Murine double minute 2 (Mdm2) was first identified as a product of an amplified gene on 
extrachromosomal bodies (named “double minutes”) in a spontaneously transformed mouse cell 
line and was shown to have tumorigenic potential when overexpressed (Cahilly-Snyder et al., 
1987; Fakharzadeh et al., 1991). Later studies found that Mdm2 was able to bind p53 and serve 
as a potent negative regulator (Momand et al., 1992). Murine double minute X (Mdmx or Mdm4) 
was first identified as a homologue of Mdm2 (Shvarts et al., 1996) and later shown to possess 
oncogenic properties and play a distinct role in the inhibition of p53 in concert with Mdm2 (Sharp 
et al., 1999; Stad et al., 2000). Several modes of action through which Mdm2 and Mdm4 serve 
as the two key negative regulators of p53 activity are described below. 
 
Mdm2 domains and function 
Mdm2 contains an N-terminal p53-interacting domain which binds to the transactivation 
domain of p53 (Chen et al., 1993) occluding interactions with co-activators, and serving as the 
first mechanism through which Mdm2 keeps p53 activity in check (Lin et al., 1994; Momand et al., 
1992). The second primary means by which Mdm2 inhibits p53 is mediated by the Really 
Interesting New Gene (RING) domain – a common feature of ubiquitin-ligase enzymes. 




nuclear export (Boyd et al., 2000; Carter et al., 2007; Li et al., 2003) or polyubiquitinate p53 an 
target it for proteasomal degradation, keeping levels extremely low or even undetectable at 
physiological conditions (Honda and Yasuda, 2000). Investigation of deletion mutants has shown 
that the RING domain of Mdm2 is required for ubiquitination of its targets, which beyond p53 
includes Mdm2 itself and Mdm4 (Honda and Yasuda, 2000; Pan and Chen, 2003). Under normal 
conditions Mdm2 primarily localizes to the nucleus, however it is able to shuttle between the 
nucleus and cytoplasm due to the presence of both nuclear localization and nuclear export 
sequences, and is thus able to play an active role in the export of p53 and prevention of 
transcriptional activity (Roth et al., 1998). Mdm2 also possesses an internal acidic domain and 
while the potential functions have not yet been fully defined, studies have suggested a breadth of 
roles in mediating p53-binding (Kulikov et al., 2006), E3-ubiquitin ligase activity (Kawai et al., 2003; 
Meulmeester et al., 2003), or facilitating protein-protein interactions which modulate p53 
degradation (Grossman et al., 2003). Mdm2 also contains a central zinc-finger domain, though 
the function remains unknown. 
  
Mdm4 domains and function 
Mdm4 shares homology with Mdm2, however, it is functionally non-redundant and mediates 
repressive activity over p53 through unique mechanisms. Similar to Mdm2, Mdm4 also contains 
an N-terminal p53-binding domain which recognizes the transactivation domain of p53 and can 
mask p53-mediated transactivation of target genes (Shvarts et al., 1996, 1997). Mdm4 also 
contains a RING domain, which facilitates interaction with the same conserved domain of Mdm2 
to form heterodimers, which have been found to be more stable than either homodimer (Sharp et 
al., 1999; Tanimura et al., 1999). Importantly, the RING domain of Mdm4 has little or no E3 
ubiquitin ligase activity, despite significant homology with Mdm2 and instead has been shown to 
promote Mdm2 activity (Linares et al., 2003; Uldrijan et al., 2007). Again in contrast to Mdm2, 




the cytoplasm (Migliorini et al., 2002a). However, Mdm2 can shuttle Mdm4 into the nucleus via 
interaction between RING domains, allowing Mdm4 to inhibit p53 transcriptional activity (Migliorini 
et al., 2002a). 
 
Cellular requirement for Mdm2 and Mdm4  
 Genetic studies have revealed an essential requirement for both Mdm2 and Mdm4 as 
ubiquitous ablation is embryonic lethal at the pre-implantation and mid-gestational stages due to 
increased apoptosis and cell proliferation arrest, respectively (Finch et al., 2002; Jones et al., 
1995; Migliorini et al., 2002b; de Oca Luna et al., 1995; Parant et al., 2001). Importantly, these 
studies underline a non-redundant role for Mdm2 and Mdm4 despite the high degree of sequence 
similarity as one is unable to compensate for the other. Furthermore, concomitant knockout of 
p53 was able to rescue phenotypes associated with Mdm2-null or Mdm4-null mice, emphasizing 
that uncontrolled p53 induction underlies embryonic lethality and negative regulation of p53 is the 
key cellular function for Mdm2 and Mdm4 (Finch et al., 2002; Jones et al., 1995; Migliorini et al., 
2002b; de Oca Luna et al., 1995; Parant et al., 2001).  
Selective genetic deletion of Mdm2 and Mdm4 in mouse models has provided further insight 
into their spatial requirement (Wade et al., 2010). Knockout of either Mdm2 or Mdm4 in the CNS 
resulted in neonatal lethality associated with apoptosis or apoptosis and cell cycle arrest, 
respectively (Francoz et al., 2006; Xiong et al., 2006). Additionally, knockout of both genes 
resulted in a more severe phenotype, suggesting that there is a critical requirement for both Mdm2 
and Mdm4 in neural progenitors and the two proteins act cooperatively to suppress p53 in this 
context. The conditional inactivation of Mdm2 in quiescent smooth muscle cells of the 
gastrointestinal tract leads to fatality associated with p53 activation, while Mdm4 appeared to be 
dispensable in these terminally differentiated cells (Boesten et al., 2006). In contrast, Mdm4 – 
along with Mdm2 – is required for suppression of p53 in proliferative intestinal epithelial cells 




phenotypes due to the loss of Mdm2 than Mdm4, though both showed cellular defects associated 
with p53 induction and the knockout of Mdm2 has also been linked to apoptotic phenotypes in the 
spleen, testis and thymus (Maetens et al., 2007). In support of a mechanistic model for 
cooperation between Mdm2 and Mdm4, knock-in mouse models with mutations in the RING 
domain of Mdm4 – which interfere with heterodimerization but not p53 binding – led to embryonic 
lethality (Huang et al., 2011; Pant et al., 2011).  
In summary, in vivo data supports a degree of cell-type specificity regarding p53 regulation 
with a primary role for Mdm2 in modulating p53 levels, while Mdm4 inhibits p53 activity. These 
studies also demonstrate a requirement for Mdm2 and Mdm4 in both proliferative and quiescent 
cells, however, Mdm2 appears to have a general and pronounced role in all tissues, while the 
loss of Mdm4 results in milder phenotypes and can even be tolerated depending on the cellular 
context. Proposed models to explain the necessity of both regulators are that either Mdm2 and 
Mdm4 play distinct and critical roles or a cooperative model where they act concurrently in a 
complex. While the precise nature of this regulation is complex and likely context-dependent, 
there is clear interplay between Mdm2 and Mdm4, and both factors should be considered when 
investigating regulatory mechanisms of p53. 
 
Mechanisms of Mdm2 and Mdm4 inactivation 
 In response to cellular stresses, Mdm2 and Mdm4 are inactivated to enable a p53 response 
(Figure 1.11). DNA damage triggers a cellular response that activates ataxia telangiectasia 
mutated (ATM) kinase and DNA-activated protein kinase (DNA-PK), which can phosphorylate 
Mdm2 at sites within the RING domain (Maya et al., 2001) and the p53-binding domain (Maya et 
al., 2001), respectively. These post translational modifications can impair the E3 ligase and p53 
binding activity of Mdm2 permitting accumulation of p53. Additionally, modifications of Mdm2 
triggered by DNA damage alter its binding selectivity so it targets itself and Mdm4 for degradation 




response to DNA damage, ATM also directly phosphorylates Mdm4 which facilitates ubiquitination 
and degradation by Mdm2 (Pereg et al., 2005). In response to ribosomal stress, several ribosomal 
proteins including L5, L11, L23 and S7 can be released from the nucleolus and interact with Mdm2 
to abrogate p53 suppression (Dai and Lu, 2004; Jin et al., 2004; Lohrum et al., 2003; Zhang et 
al., 2003; Zhu et al., 2009). Further, studies have shown that Mdm2 inhibition by S7 is dependent 
on the presence of Mdm4 and overexpression of Mdm4 is able to suppress induction of p53 in 
response to ribosomal stress (Gilkes et al., 2006; Zhu et al., 2009). Alternate Reading Frame of 
locus INK4a (p14ARF in human and p19ARF in mouse) which acts as a sensor of proliferative signals 
– such as myc activation and increased E2F1 expression – inhibits Mdm2 through multiple 
mechanisms (Bates et al., 1998; Zindy et al., 1998). ARF can inhibit Mdm2 ubiquitination of p53 
(Honda and Yasuda, 1999; Kamijo et al., 1998; Tao and Levine, 1999), increase affinity for 
ubiquitination of Mdm4 (Pan and Chen, 2003), and sequester Mdm2 in the nucleolus to prevent 
p53-binding (Tao and Levine, 1999; Weber et al., 1999; Zhang and Xiong, 1999). Importantly, 
Mdm2 itself is a transcriptional target of p53 establishing an negative feedback loop in which p53 
activation results in increased levels of Mdm2 (Wu et al., 1993). Once Mdm2 levels are sufficiently 
increased, this autoregulatory mechanism once again restricts the p53 response allowing a return 
to homeostasis. 
 
Post-translational modifications of p53 
 Studies have found numerous post-translational modifications for p53 at approximately 50 
different sites which can include phosphorylation, acetylation, ubiquitination, neddylation, 
sumoylation, and beyond (Meek and Anderson, 2009) (Figure 1.9). Such modifications can play 





Ubiquitination of p53 
 As addressed previously, p53 is subject to mono and polyubiquitination which can lead to 
its nuclear export or proteasomal degradation. p53 can be ubiquitinated at six lysine residues in 
the C-terminus as well as a few sites in the DNA binding domain (Bruins et al., 2004). In addition 
to Mdm2, p53 can be ubiquitinated by Pirh2, an E3 ligase which is also a p53 target gene and 
involved in an autoregulatory feedback loop on p53 (Leng et al., 2003). Additional studies have 
identified further ubiquitin ligases such as constitutively photomorphogenic 1 (COP1) (Dornan et 
al., 2004) and ARF-BP1 (Chen et al., 2005) which can target p53 for degradation; however, 
evidence suggests these are subsidiary to Mdm2 (Lee and Gu, 2010). 
 Surprisingly, knock-in mutant mice with all six (6KR) or seven (7KR) C-terminal lysines 
mutated to arginines were phenotypically normal and did not show alterations in p53 stability 
(Feng et al., 2005; Krummel et al., 2005). However, one group found that mutant p53 (7KR) was 
more efficiently activated in irradiated thymocytes (Krummel et al., 2005). These studies suggest 
that C-terminal post-translational modifications of lysine residues are not critical for the efficient 
degradation of p53 in vivo and perhaps ubiquitination at additional sites can be utilized by Mdm2 
to modulate p53 levels. 
 
Phosphorylation of p53 
 p53 contains 23 potential serine and threonine sites throughout the polypeptide that can be 
modified by phosphorylation, most of which are clustered in the N-terminus. Initial in vitro studies 
showed that stress such as DNA damage induces phosphorylation of human p53 at several 
residues in the transactivation domain such as serine 15 (S15), threonine 18 (T18), S20 and S37 
which are present in the binding region of Mdm2 (Craig et al., 1999; Lees-Miller et al., 1992). 
Phosphorylation has been proposed to reduce p53 affinity for Mdm2 and in turn promote 
interaction with co-activators such as histone acetyl transferases (HATs) p300 and CREB-binding 




S33 and S46 has been linked to p53 stabilization and pro-apoptotic functions (Bulavin et al., 1999). 
p53 can also be phosphorylated at C-terminal residues such as S392 in response to UV radiation, 
which has been suggested to modulate DNA-binding (Hupp et al., 1992; Kapoor and Lozano, 
1998; Lu et al., 1998).  
 The generation of targeted point mutations of several phosphorylated residues of p53 
provided insight into the in vivo relevance of these post-translational modifications. Mutation of 
S18 (equivalent to human S15) to alanine (S18A) in mouse only led to mild apoptotic and 
transactivation defects but no changes in p53 stability or cell proliferation (Chao et al., 2003; Sluss 
et al., 2004). An S23A mutant (equivalent to human S20A) also resulted in similar phenotypic 
effects, though at very advanced stages did develop B-cell lymphomas (MacPherson et al., 2004; 
Wu et al., 2002). A double mutation of both phosphorylation sites led to a more pronounced 
phenotype with mild effects on p53 stability and transactivation as well as a greater impairment in 
apoptotic activity, though defects were much milder than p53-null mice (Chao et al., 2006). S389 
(equivalent to human S392) mutant mice had very mild phenotypic effects in the form of some 
impairment in a UV induced apoptotic response (Bruins et al., 2004). Collectively, these studies 
indicate physiological relevance for these post-translational modifications and support a 
mechanism where each individual modification has mild effects on p53 activation, but together 
can serve synergistic roles. 
 There are several layers of redundancy in the phosphorylation of p53 as individual kinases 
are capable of phosphorylating multiple residues, and each residue can be phosphorylated by 
numerous kinases (Toledo and Wahl, 2006). In support of this, in vitro assays show DNA-
dependent protein kinase (DNA-PK) can directly phosphorylate p53 at multiple sites including S15, 
S37, T18 and S9 (Lees-Miller et al., 1992; Soubeyrand et al., 2004). Additionally, activated p38 
mitogen activated protein kinase (MAPK) can directly phosphorylate S15, S33 and S46 (Bulavin 
et al., 1999; She et al., 2000). S15 was among the first identified sites of phosphorylation on p53, 




can be phosphorylated by adenosine monophosphate-activated protein kinase (AMPK), ataxia 
telangectasia mutated (ATM), ataxia telangectasia (ATR), extracellular signal-regulated kinase 
(ERK), CDK-activating kinase (CDK9) and more (Toledo and Wahl, 2006).  Further, 
phosphorylation at one site is able to trigger the indirect addition of other modifications 
showcasing the interdependency of these post-translational modifications. For example, 
activation of ATM can directly phosphorylate p53 at S15 (Banin et al., 1998; Canman et al., 1998) 
which can in turn trigger the indirect addition of further modifications at S9, S20 and S46 (Saito et 
al., 2002). 
 
Acetylation of p53 
Lysine residues of p53 can also be modified through acetylation by HATs such as p300 and 
CBP, which has been generally associated with increased protein stabilization and interaction 
with coactivators that promote transcriptional activity (Barlev et al., 2001; Ito et al., 2001; Li et al., 
2007; Luo et al., 2000). Acetylation modifications have also been proposed to enhance sequence-
specific DNA-binding activity (Gu and Roeder, 1997; Liu et al., 1999; Luo et al., 2004). However, 
as discussed previously, knock-in mice with six or seven mutated C-terminal lysine residues have 
no overt deficits or alterations in p53 stability and only show some mild promoter-specific 
impairment in DNA damage-induced p53 transactivation in the K6R mutants (Feng et al., 2005). 
These results suggest the role of p53 acetylation in vivo is less prominent than originally predicted 
from in vitro studies, and may serve as a mechanism for fine-tuning p53 responses (Feng et al., 
2005; Krummel et al., 2005). Interestingly, p53 with eight mutated lysine residues – including 
mutation at a new acetylation site K164 – is unable to activate downstream transcriptional targets 
and induce cell cycle arrest in vitro, while individual mutations have little effect on p53 activation 
(Tang et al., 2008). Although the effect of all eight collective mutations has yet to be evaluated in 
vivo, these studies underline a high degree of redundancy and potential for compensation with 




As ubiquitination and acetylation both occur on lysine residues and are mutually exclusive, 
there is evidence for cross-talk between these modifications to enable proper regulation of p53 
activity. Namely, acetylation of C-terminal residues blocks ubiquitination by Mdm2 and increases 
stability (Tang et al., 2008). Additionally, HATs such as p300 and CBP have been proposed to 
have dual functions in regards to p53 where they participate both in acetylation and ubiquitination 
(Grossman et al., 2003; Shi et al., 2009). Studies have also shown interdependency between C-
terminal acetylation and phosphorylation of residues in the transactivation domain (Knights et al., 
2006; Sakaguchi et al., 1998). 
 
Other modifications of p53 
In addition to the modifications described above, C-terminal lysine residues have also been 
linked to sumoylation, neddylation and methylation though these are not as well-understood. 
Sumoylation of p53 at lysine 386 (K386) appears to be regulated by Mdm2 and ARF activity, 
though there is not yet consensus on whether it activates or represses p53 activity (Chen and 
Chen, 2003; Gostissa et al., 1999; Rodriguez et al., 1999). Mdm2-dependent neddylation of p53 
was linked to inhibition of transcriptional activity (Xirodimas et al., 2004) and K372 methylation 
has been shown to increase stability (Chuikov et al., 2004). Further investigation of these other 
modifications has the potential to uncover additional layers of regulation of p53. 
 Collectively, in vitro studies of p53 post-translational modifications demonstrated key roles 
in determining selectivity for specific interactors, modulating stability and regulating activity of p53. 
However, in vivo investigation of these modifications led to much milder phenotypes than initially 
anticipated indicating a role in the fine-tuning of the p53 response. Many post-translational 
modifications of p53 are interdependent where modification at one site can serve as a nucleation 
event to spur modification of another. There also appears to be a great deal of redundancy where 
residues can compensate for one another. Taken together this data supports a model where 




rather than any singular residue serving a major role (Meek and Anderson, 2009; Toledo and 
Wahl, 2006). 
 
Cellular outcomes of p53 activation 
Following activation, the main role of p53 is as a transcription factor which can directly 
induce expression of target genes (Fischer, 2017). As p53 can modulate the levels of many 
downstream genes involved in DNA repair, cell cycle arrest and apoptotic pathways, the degree 
and time of induction is a critical determinant for cellular outcomes (Hafner et al., 2019). The two 
key functionalities through which p53 activates transcription is by direct binding to DNA and 
recruitment of transcriptional coactivators. The affinity of p53 for DNA can range depending on 
the precise features of the recognition element (Bandele et al., 2011; Tomso et al., 2005; 
Veprintsev et al., 2006; Wang et al., 2009, 1995; Weinberg et al., 2004). Studies showed target 
genes involved in cell cycle arrest have high-affinity binding sites while those involved in apoptosis 
are generally weaker and more varied (Inga et al., 2002; Qian et al., 2002). Additionally, the levels 
of p53 were shown to modulate cellular response with lower levels triggering cell cycle arrest and 
higher levels promoting apoptosis (Chen et al., 1996). This data supports a model where both 
p53 levels and the recognition elements of transcriptional targets can modulate the cellular 
response. However, additional investigation showed that the binding of p53 to promoters of 
apoptotic genes did not strictly correlate with cell death as an outcome, and p53 has high binding 
affinity for some key apoptotic target genes such as PUMA (Kaeser and Iggo, 2002). Further, 
studies have shown that p53 is bound to the promoter regions of target genes under homeostatic 
conditions (Kaeser and Iggo, 2002; Szak et al., 2001) and chromatin immunoprecipitation 
experiments demonstrate significant binding of p53 at sites without a consensus sequence 
(Cawley et al., 2004). Thus, while sequence recognition plays a role, it alone is not sufficient to 




p53 can act as a pioneer transcription factor by binding to closed chromatin and recruiting 
chromatin remodeling complexes (CRC) or HATs which alter nucleosome occupancy and 
promote accessibility for the general transcriptional machinery (Laptenko et al., 2011; Lidor Nili et 
al., 2010; Sammons et al., 2015). p53 interacts with the SWI/SNF complex – a CRC that can 
modulate nucleosome structure – which has been shown to be required for transactivation and 
proper regulation of cell growth arrest and apoptotic pathways in cellular models (Lee et al., 2002). 
Several studies have identified functional interaction of p53 with the HATs p300 and CBP which 
facilitate transcriptional activation through histone acetylation (Avantaggiati et al., 1997; Barlev et 
al., 2001; Lill et al., 1997). Interestingly, p53 preferentially binds chromatin over DNA (Espinosa 
and Emerson, 2001) and some evidence suggests that chromatin state can direct p53 binding. 
For example, activation of the target gene 14-3-3-σ is dependent on the status of DNA methylation 
(París et al., 2008), and the chromatin remodeling factor RSF1 is required for p53-mediated 
apoptosis (Min et al., 2018). However, more investigation is required to understand the interplay 
between chromatin structure and p53 target gene selection.  
Cofactors and binding partners can also serve as a regulatory mechanism to dictate target 
specific transcriptional activity of p53. For example, apoptosis stimulating protein of p53 1 (ASPP1) 
and ASPP2 are direct interactors of p53 which do not affect cell cycle arrest, but specifically 
promote the p53-mediated transactivation of apoptotic genes (Samuels-Lev et al., 2001). 
Apoptosis-antagonizing transcription factor (AATF)/Che-1 is another regulator of the p53 
response that can bind to promoter regions of pro-apoptotic genes and suppress p53-
transcriptional activity (Höpker et al., 2012). Hematopoietic Zinc Finger (Hzf) is a p53 target gene 
that can bind to the DNA binding domain and preferentially promote transactivation of cell-cycle 
arrest genes (Das et al., 2007), while human cellular apoptosis susceptibility protein (hCAS) acts 
as a co-activator of a subset of p53 target genes involved in apoptosis (Tanaka et al., 2007). Also, 
ATM and p53-associated KZNF protein (Apak) binds to p53 and suppresses activation of pro-




regions of target genes can serve to modulate the p53 response towards cell-cycle arrest or 
apoptosis. 
 Taken together, these studies show that several elements such as p53 levels, DNA-binding 
affinity, co-factor recruitment, and post-translational modification contribute to tailor a specific 
response of p53 transactivation that will elicit the appropriate cellular outcome (Figure 1.12). 
 
Role of p53 in neurodegenerative diseases 
While p53 is most renowned as a tumor suppressor, several studies have implicated 
aberrant activation of p53 in neurodegenerative disorders (Culmsee and Mattson, 2005; 
Szybińska and Leśniak, 2017). p53 activation has been observed in models of ischemic insult 
and genetic knockout or pharmacological inhibition is protective against neurodegeneration 
(Crumrine et al., 1994; Culmsee et al., 2001; Li et al., 1994). Traumatic brain injury induces a p53 
response and inhibition with pifithrin-α in multiple models has neuroprotective effects by blocking 
apoptosis (Huang et al., 2018; Napieralski et al., 1999; Plesnila et al., 2007). p53 activation has 
also been linked to amyloid beta induced neuronal apoptosis in models of Alzheimer’s disease 
(Culmsee et al., 2001; de la Monte et al., 1997; Tamagno et al., 2003) and elevated levels of p53 
have been detected in post-mortem patient brains (Cenini et al., 2008; Kitamura et al., 1997). 
Similarly, increased levels of p53 have been documented in the brains of Parkinson’s disease 
patients in association DNA fragmentation and activation of caspase 3 and Bax, suggesting 
activation of a p53-dependent apoptotic pathway (Mogi et al., 2007; Tatton, 2000). p53 has also 
been causally linked to pathogenesis in Drosophila models of Huntington’s disease as genetic 
deletion of p53 rescues degenerative phenotypes (Bae et al., 2005; Ryan et al., 2006). 
Additionally, p53 expression is increased in motor neurons in the spinal cord of amyotrophic 
lateral sclerosis (ALS) patients (Martin, 2000), which is associated with elevated levels of 
apoptotic proteins such as Bax, Fas and caspases (Ranganathan and Bowser, 2010). Taken 




neurodegenerative disorders; however, whether p53 plays a causal role in the pathogenesis or is 
activated as a secondary feature of neurodegeneration remains to be determined.  
 
1.6 Hypotheses to be addressed in the following chapters 
While key hallmarks of SMA include multiple pathogenic insults to the motor circuit such motor 
neuron loss, deafferentation and denervation, the molecular mechanisms underlying these events 
have remained elusive. Moreover, there is a lack of understanding of the discrete contribution(s) 
of specific functions of SMN in RNA regulation to SMA pathogenesis and elucidation of these 
pathways would provide critical insight into SMN biology and SMA disease mechanisms. Based 
on the current understanding of SMN’s critical role in snRNP biogenesis, this work explores the 
hypothesis that distinct SMN-dependent RNA pathways contribute to select aspects of SMA 
pathology. Additionally, I envision that, rather than global impairment in RNA regulation, specific 
downstream targets dysregulated by SMN deficiency are particularly critical for proper motor 
circuit connectivity and function. Here, I sought to identify and evaluate key SMN-regulated 
effectors of motor circuit dysfunction in SMA, which would not only strengthen direct links between 
snRNP dysfunction and disease etiology, but also potentially lead to new therapeutic strategies 
that can complement SMN upregulation approaches. 
Our recent work revealed that motor neuron death in SMA is driven by p53 activation (Simon 
et al., 2017). Furthermore, we demonstrated that the selective vulnerability of SMA motor neurons 
is a result of two distinct pathways converging on p53 activation – upregulation and 
phosphorylation – both of which are necessary for neuronal death. However, the SMN-dependent 
mechanisms that resulted in p53 activation were unknown. Here, I address the hypothesis that 
key genes responsible for control of the p53 response are regulated by SMN’s function in snRNP 
biogenesis and their dysregulation is responsible for the pathogenic activation of p53 in SMA 




Prior work in the lab identified Stasimon as a splicing target regulated by SMN which has both 
a physiological role in maintaining proper motor circuit function and a causal role contributing to 
motor circuit dysfunction in Drosophila and zebrafish models of SMA (Lotti et al., 2012). In this 
dissertation, I explore the idea that Stasimon is also a critical factor involved in the sensory-motor 
circuit pathology of an SMA mouse model that better recapitulates the human disease (Chapter 
3). Additionally, I further investigate Stasimon’s requirement in mammalian models and its cellular 
functions that appear to be particularly important for motor circuit neurons (Chapter 4).  
 Considering the critical role of SMN levels in SMA pathology, it is possible that a non-
physiological imbalance elicited by excess SMN such as that associated with AAV9-SMN gene 
therapy could have deleterious consequences – particularly on the motor system which is most 
sensitive to perturbations of SMN homeostasis in SMA. In addressing this issue, I highlight motor 
dysfunction and sensory-motor circuit connectivity defects induced by long-term, AAV9-mediated 
SMN overexpression in mouse models (Chapter 5). The identification of neuron-specific toxicity 
associated with AAV9-SMN uncovers unappreciated aspects of the biology of SMN 
overexpression at the molecular, cellular and circuit level that has important clinical relevance at 













Figure 1.1. Genetic basis for SMA. SMA is the result of homozygous deletion or mutation of 
the SMN1 gene with retention of the nearly identical SMN2 gene. Most transcripts 
from SMN2 lack exon 7 due to alternative splicing and produce an unstable truncated form of the 
protein (SMNΔ7), leading to a setting of ubiquitous SMN deficiency in SMA. Reproduced with 






Figure 1.2. Cell-autonomy of motor circuit deficits in SMA. SMA is a consequence of multiple 
insults on the motor circuit, which originate in distinct cellular types. Motor neurons are particularly 
vulnerable to reduced levels of SMN expression and degenerate over the course of the disease. 
In addition to motor neuron death, several deficits that contribute to motor system dysfunction in 
SMA mouse models have been documented which include: i) reduced density of synaptic vesicles, 
decreased neurotransmission, and increased denervation of the NMJs of vulnerable muscles; ii) 
reduced myofiber size and skeletal muscle atrophy; iii) defective excitatory neurotransmission 
and loss of glutamatergic synapses from proprioceptive neurons and local interneurons resulting 
in reduced excitatory drive; and iv) hyperexcitability of motor neurons. Genetic restoration studies 
have identified the cell-autonomous nature of several defects in motor neurons (blue) and 






Figure 1.3. SMN-dependent therapeutic approaches for SMA. Current SMN upregulating 
therapeutic approaches for SMA include SMN2 splicing modulation through small molecules or 
antisense-oligonucleotides (ASO) or replacement of SMN1 through AAV9-mediated gene therapy. 
Spinraza, an ASO which targets a key inhibitory splicing regulatory sequence ISS-N1 in intron 7 
to promote inclusion, was granted FDA approval for all SMA patients in 2016 and is delivered 
directly to the CNS through lumbar puncture. Small molecule compounds include Risdiplam and 
Branaplam which are orally bioavailable and promote exon 7 inclusion through recognition of the 
SMN2 intron-exon junction and stabilization of U1 snRNP are currently in clinical trials. Lastly, 
AAV9-mediated gene therapy with Zolgensma was granted approval for intravenous delivery in 
severe SMA Type I patients, and clinical trials in extended patient groups as well as intrathecal 















Figure 1.4. The SMN complex. Schematic representation of the core SMN complex components 










Figure 1.5. The snRNP biogenesis pathway. The biogenesis of snRNPs occurs through a multi-
step process involving both nuclear and cytoplasmic events. Pre-snRNAs transcribed in the 
nucleus are exported through interaction with the cap-binding complex (CBC), phosphorylated 
adaptor for RNA export (PHAX) and Exportin-1 (XpoI) and ras-related nuclear protein GTP 
(RanGTP). Sm proteins in the cytoplasm are recognized by the chloride conductance regulatory 
protein (pICln) which brings them to a complex containing methylosome protein 50 and the protein 
arginine methyltransferase 5 (PRMT5) where a subset are symmetrically dimethylated before 
transfer to the SMN complex. The SMN complex mediates the efficiency and specificity through 
which Sm proteins are assembled on snRNAs. Following Sm core formation, the 5’cap of snRNAs 
is hypermethylated by trimethylguanosine synthase 1 (TGS1) then imported into the nucleus 
through association of the SMN complex with snurportin and the transport receptor importin-b 













Figure 1.6. Role of the SMN complex in spliceosomal and U7 snRNP biogenesis. Molecularly 
defined roles for the SMN complex include mediating the assembly of Sm proteins on U snRNAs 
to produce spliceosomal snRNPs as well as the unique core of Sm/LSm proteins of the U7 snRNP 










Figure 1.7. SMN-dependent RNA pathways. The most well-characterized role of SMN is in the 
assembly of Sm and U7 snRNPs, however additional roles in RNA regulation have been proposed. 
These include a more generalized function in RNP assembly such as the biogenesis of LSm-
containing U6 and U6atac snRNPs as well as snoRNPs. Additionally, SMN has been implicated 
in the assembly of mRNP complexes through interactions with several RNA-binding proteins. 
Further, functions of SMN in telomere synthesis and protein translocation have been proposed to 
be mediated by interactions of SMN with RNPs such as telomerase and SRP. Lastly, recruitment 
of SMN by RNA polymerase II suggests involvement in the coupling of transcription with mRNA 











Figure 1.8. Converging mechanisms of p53 activation drive the death of vulnerable motor 
neurons in SMA. SMN deficiency leads to the upregulation of p53 in both vulnerable and resistant 
SMA motor neurons. N-terminal phosphorylation of p53 occurs selectively in vulnerable SMA 
motor neurons, and convergence of the post-translational modification of p53 along with 



















Figure 1.9. Protein domains and post-translational modifications of p53. p53 contains an 
N-terminal transactivation domain (TAD), proline-rich domain (PRD), DNA-binding domain, 
tetramerization domain (TET), and a C-terminal domain (CTD). Several serine (S), threonine 
(T), lysine (K) and arginine (R) residues of p53 (depicted here for human p53) can be post-
translationally modified by phosphorylation (P), acetylation (Ac), ubiquitination (Ub), methylation 















Figure 1.10. Stress triggers for p53 activation (blue) and cellular outcomes (purple). 
Activation of p53 can occur in response to several upstream triggers. The induction of a p53 
transcriptional response is a key determinant of cell-fate and can lead to different outcomes 




















Figure 1.11. Mdm2- and Mdm4-dependent mechanisms of p53 activation. (A) Mdm2 and 
Mdm4 act in concert as the key negative regulators of p53 at homeostasis. (B) DNA damage by 
ionizing radiation can lead to the activation of ataxia telangiectasia mutated (ATM) kinase which 
can induce post-translational modifications of Mdm2 and Mdm4 through signaling cascades that 
destabilize binding to p53 and trigger degradation, permitting induction of a p53 response. (C) 
Ribosomal stress can induce p53 activation through the direct binding of ribosomal proteins to 
Mdm2 (such as L11) which abrogate p53 suppression. (D) Oncogenic stress can activate p53 
through proliferative signals such as an increase in the tumor suppressor alternate reading frame 
(ARF) which inhibits degradative activity of Mdm2 towards p53 and promotes Mdm4 ubiquitination. 
















Figure 1.12. Regulatory mechanisms of p53 transactivation and cellular outcomes. Stress 
such as DNA damage can elicit a p53 response which is subject to additional layers of control 
through modulation of the levels, DNA-binding affinity, post-translational modifications and 
association of p53 with co-factors. When integrated, these regulatory mechanisms lead to the 
upregulation of specific target genes at the transcriptional level, which can elicit cellular outcomes 





 Chapter 2 
Dysregulation of Mdm2 and Mdm4 alternative splicing underlies motor 
neuron death in spinal muscular atrophy2 
 
2.1 Introduction 
Perturbation of RNA homeostasis is a common theme of many neurodegenerative disorders 
in which genetic mutations are associated with the direct or indirect impairment of RNA-binding 
proteins or factors controlling RNA processing at multiple levels (Conlon and Manley, 2017; 
Cooper et al., 2009; Li et al., 2014). Remarkably, while disease-linked proteins are ubiquitously 
expressed and carry out essential biological processes, pathology is characterized by selective 
degeneration of specific neuronal populations. Furthermore, these proteins are often 
multifunctional and involved in the regulation of diverse RNA pathways, making it difficult to 
discern specific disease-relevant events among many transcriptome abnormalities. These 
complexities have made it remarkably challenging in most instances to establish causal links 
between RNA dysregulation and disease etiology. Nonetheless, dissecting the RNA-mediated 
mechanisms underlying the dysfunction and death of select neurons is necessary to uncover the 
molecular basis of human disease and identify drivers of neurodegeneration, which may also 
represent key targets for therapeutic intervention. 
Spinal muscular atrophy (SMA) is one prominent example of a neurodegenerative disease 
featuring RNA dysfunction as a consequence of ubiquitous deficiency in the survival motor neuron 
(SMN) protein (Burghes and Beattie, 2009; Tisdale and Pellizzoni, 2015). Reflecting the emerging 
multifaceted role of SMN in RNP assembly and post-transcriptional gene regulation, disruption of 
several distinct SMN-dependent RNA pathways has been proposed to contribute to SMA 
                                               
2  This chapter is adapted from an article I co-authored entitled “Dysregulation of Mdm2 and Mdm4 




pathogenesis (Donlin-Asp et al., 2016; Li et al., 2014). However, proving clear mechanistic links 
between select SMN-dependent RNA pathways and specific disease-relevant features of SMA 
remains an outstanding challenge. 
Here, I sought to address this issue by focusing on the molecular mechanisms of motor 
neuron death in SMA. The classical hallmark of SMA in both patients and mouse models is the 
progressive loss of spinal motor neurons, leading to skeletal muscle atrophy (Burghes and Beattie, 
2009; Tisdale and Pellizzoni, 2015). Studies in SMA mice have shown that motor neuron death 
occurs cell-autonomously (Fletcher et al., 2017; Gogliotti et al., 2012; Martinez et al., 2012; 
McGovern et al., 2015), and distinct motor neuron pools display differential vulnerability to SMN 
deficiency (Fletcher et al., 2017; Mentis et al., 2011; Simon et al., 2017)—a feature reflected in 
the varying degree of denervation of the respective target muscles (Ling et al., 2012). This 
faithfully recapitulates clinical characteristics of the disease in which axial and proximal muscles 
are more affected than distal ones (Oskoui et al., 2017). Importantly, degeneration of vulnerable 
motor neurons in a mouse model of severe SMA is driven by a p53-dependent death pathway 
(Simon et al., 2017), and p53 induction has also been documented in motor neurons from milder 
mouse models of the disease (Jangi et al., 2017; Murray et al., 2015) as well as post-mortem 
spinal cords of SMA patients (Simic et al., 2000). However, the molecular mechanisms linking 
SMN deficiency to p53 activation and motor neuron death in SMA are unknown. 
Under normal conditions, p53 expression is maintained at low levels by Mdm2 and Mdm4 
— two nonredundant negative regulators that act in concert to prevent unwarranted induction of 
the p53 pathway, which can lead to cell cycle arrest or cell death in a context-dependent manner 
(Vousden and Prives, 2009). Mdm2 mainly serves as an E3 ubiquitin ligase that targets p53 for 
degradation, while Mdm4 inhibits p53 transcriptional activity in addition to enhancing Mdm2 
function (Marine et al., 2006; Shadfan et al., 2012). I hypothesized that p53 activation and motor 
neuron degeneration in SMA could involve dysregulation of the repressive activity of Mdm2 and 




Consistent with this possibility, previous studies implicated alternative splicing of critical exons of 
Mdm2 and Mdm4 in the regulation of p53. Mdm2 transcripts that exclude exon 3 produce a 
truncated form of the protein that induces p53 stabilization through multiple mechanisms (Giglio 
et al., 2010; Perry et al., 2000; Saucedo et al., 1999). Skipping of exon 7 in Mdm4 introduces an 
early stop codon that induces nonsense-mediated decay or production of an inactive protein, 
leading to p53 activation through loss of function (Bardot et al., 2015; Bezzi et al., 2013; Dewaele 
et al., 2016). 
In this chapter, I identified Mdm2 exon 3 and Mdm4 exon 7 as critical downstream targets 
whose coordinated alternative splicing is regulated by SMN through its function in snRNP 
biogenesis. Importantly, I show that defective splicing of these key regulatory exons induced by 
SMN deficiency, which occurs early and is most pronounced in vulnerable motor neurons, acts 
as a biological switch governing initiation of the p53 response in SMA mice. Through selective 
induction of exon skipping in wild-type mice, I demonstrate that perturbation of Mdm2 and Mdm4 
alternative splicing synergistically induces p53 anti-repression such that both splicing events, but 
neither alone, are necessary and sufficient to elicit robust activation of p53 in vivo. Conversely, 
correction of either deficit by restoration of full-length Mdm2 or Mdm4 is sufficient to suppress p53 
induction and prevent motor neuron degeneration in SMA. Thus, while SMN deficiency induces 
widespread transcriptome perturbations with the potential to contribute to SMA pathology (Li et 
al., 2014; Zhang et al., 2008), I show that it is the selective dysregulation of Mdm2 and Mdm4 
alternative splicing that underlies p53 anti-repression and motor neuron death in a mouse model 
of the disease. These findings provide a direct mechanistic link between the disruption of SMN's 
function in the assembly of the snRNP constituents of the splicing machinery and the molecular 





Mdm2 and Mdm4 alternative splicing is disrupted in cellular models of Smn deficiency 
To determine the mechanisms by which SMN deficiency induces p53 in SMA, I first 
investigated whether SMN regulates alternative splicing of Mdm2 exon 3 and Mdm4 exon 7 in 
vitro. In previously established NIH3T3-SmnRNAi fibroblasts with doxycycline (Dox) inducible RNAi 
knockdown of Smn to ~10% of normal levels (Lotti et al., 2012; Ruggiu et al., 2012; Tisdale et al., 
2013), RT-PCR analysis revealed that the inclusion of both Mdm2 exon 3 and Mdm4 exon 7 was 
significantly reduced upon Smn deficiency (Figure 2.1A-D). Moreover, these splicing changes 
were reversed by expression of RNAi-resistant human SMN in NIH3T3-SMN/SmnRNAi cells 
(Figure 2.1A-D) (Lotti et al., 2012; Ruggiu et al., 2012; Tisdale et al., 2013), highlighting the 
specificity of the effects for SMN depletion. Additionally, RT-qPCR analysis of the levels of Mdm2 
exon 3 and Mdm4 exon 7 included isoforms normalized to the total levels of their respective 
mRNAs confirmed reduced inclusion of these exons (Figure 2.1E and F). These results 
demonstrate that SMN regulates the alternative splicing of specific exons of Mdm2 and Mdm4 
mRNAs in vitro. 
I wanted to determine the specificity with which SMN regulates Mdm2 and Mdm4 
alternative splicing. To do so, I utilized Smn-deficient NIH3T3 fibroblasts in order to assess 
potential Smn-dependent changes in the alternative splicing of other exons in Mdm2 and Mdm4 
by RT-PCR (Figure 2.2). I found that Mdm2D3 and Mdm4D7 are the predominant alternatively 
spliced isoforms present in NIH3T3 fibroblasts and there were no other perturbations in the 
splicing of the remaining exons as a consequence of Smn deficiency.  
 
Mdm2 and Mdm4 alternative splicing is disrupted in SMA mice 
To assess whether SMN deficiency affects Mdm2 and Mdm4 splicing regulation in vivo, I 




mouse Smn, two copies of the human SMN2 gene and transgenic SMND7 cDNA (Le et al., 2005). 
I specifically monitored alternative splicing of Mdm2 and Mdm4 mRNAs by RT-PCR in the spinal 
cord of WT and SMA mice at pre-symptomatic (P1), early symptomatic (P6) and late symptomatic 
(P11) stages of the disease in this animal model. I found that SMN deficiency induces time-
dependent, progressive accumulation of Mdm2D3 and Mdm4D7 mRNAs in the spinal cord of SMA 
mice relative to control mice (Figure 2.3A-B and D-E), revealing SMN-dependent dysregulation 
of Mdm2 and Mdm4 alternative splicing in vivo. This reduction in the levels of normalized inclusion 
of Mdm2 exon 3 and Mdm4 exon 7 was also confirmed by RT-qPCR analysis (Figure 2.3C and 
2.3F). Furthermore, the accumulation of alternatively spliced Mdm2D3 and Mdm4D7 transcripts 
correlates with an increase in the number of cells displaying p53 activation induced by SMN 
deficiency over disease progression as revealed by immunohistochemistry analysis of spinal cord 
from WT and SMA mice with anti-p53 antibodies (Figure 2.4). 
 
SMN deficiency disrupts Mdm2 and Mdm4 alternative splicing in SMA motor neurons 
As the onset of p53 activation occurs earliest in motor neurons before extending to other 
spinal neurons that do not degenerate in SMA mice (Figure 2.4) (Simon et al., 2017), I next sought 
to determine the effects of SMN deficiency on Mdm2 and Mdm4 alternative splicing in vulnerable 
SMA motor neurons at an early stage of the disease. To do so, we retrogradely labeled vulnerable 
motor neurons that innervate the axial muscles iliopsoas (IL) and quadratus lumborum (QL) by 
intramuscular injection of fluorescently conjugated cholera toxin B subunit (CTb) in WT and SMA 
mice at P2 (Figure 2.5A). We then isolated CTb-labeled motor neurons located in the lumbar 
segments L1 through L3 by laser capture microdissection (LCM) from spinal cords of injected 
mice at P6 (Figure 2.5B) – a time point at which ~60% of these motor neurons express p53 in 
SMA mice (Simon et al., 2017) (see also Figure 2.4 and Figure 2.19A and 2.19B). Remarkably, 




in vulnerable SMA motor neurons relative to WT motor neurons (Figure 2.5C and 2.5D). Thus, 
SMN deficiency strongly affects the alternative splicing of Mdm2 and Mdm4 mRNAs in vulnerable 
SMA motor neurons. Moreover, consistent with a potential involvement in p53 activation and 
motor neuron degeneration, splicing dysregulation of these mRNAs occurs earlier and to a much 
greater extent in these disease-relevant neurons than in whole spinal cord of SMA mice.  
 
Defective snRNP biogenesis induces Mdm2 and Mdm4 splicing dysregulation and p53 
activation 
Given SMN’s essential function in the assembly of spliceosomal snRNPs (Meister et al., 
2001b; Pellizzoni et al., 2002b), I investigated whether SMN-dependent effects on Mdm2 and 
Mdm4 splicing were mediated by deficits in snRNP biogenesis. To do so, I utilized a previously 
established cellular model in which Dox-dependent RNAi knockdown of SmB – a core protein 
component of spliceosomal snRNPs (Li et al., 2014) – results in the selective impairment of 
snRNP biogenesis without altering SMN levels in NIH3T3-SmBRNAi fibroblasts (Ruggiu et al., 2012) 
(see also Figure 2.7A and B). Importantly, RT-PCR analysis (Figure 2.6A-D) and RT-qPCR 
analysis (Figure 2.6E and 2.6F)showed that SmB knockdown strongly reduced inclusion of Mdm2 
exon 3 and Mdm4 exon 7 in Dox-treated NIH3T3-SmBRNAi cells relative to untreated controls, 
mimicking effects of SMN deficiency on the splicing of these mRNAs. Therefore, a reduction in 
SmB levels disrupts the splicing of Mdm2 and Mdm4 regulatory exons. 
Further characterization of NIH3T3-SmBRNAi cells revealed that SmB deficiency also led to 
marked upregulation of p53 protein levels as monitored by Western blot (Figure 2.7A and 2.7B) 
as well as strong nuclear accumulation of p53 (Figure 2.7C). Further, SmB knockdown also led 
to robust mRNA upregulation of p53 transcriptional targets (Figure 2.7D). Thus, consistent with 
Mdm2 and Mdm4 dysregulation, defective snRNP biogenesis results in p53 activation in 




It has been shown that snRNP levels are reduced much more prominently in the nucleus 
of SMA motor neurons than other cells in the spinal cord of SMA mice (Ruggiu et al., 2012; Tisdale 
and Pellizzoni, 2015). To investigate whether SMN-dependent snRNP reduction correlated with 
p53 activation in SMA motor neurons in vivo, I performed immunostaining experiments with 
antibodies against p53 and SmB using spinal cords from WT and SMA mice throughout disease 
progression followed by quantification of the nuclear levels of SmB as a proxy for snRNP 
expression in vulnerable L2 motor neurons (Figure 2.8). I found that p53+ SMA motor neurons 
had significantly lower levels of nuclear SmB than either SMA or WT motor neurons that are p53- 
at P1, P6 and P11 (Figure 2.8A-F), indicating a correlation between snRNP reduction and p53 
activation in SMA motor neurons. This correlation is also maintained in the L5 spinal segment for 
both lateral motor column (LMC) and medial motor column (MMC) motor neurons at P11 (Figure 
2.9). Taken together, these findings mechanistically link snRNP dysfunction induced by SMN 
deficiency to dysregulation of Mdm2 and Mdm4 splicing and upregulation of p53, consistent with 
a snRNP-mediated mechanism of p53 activation in SMA. 
 
Mdm2 and Mdm4 alternatively spliced isoforms can induce p53 activation 
 In order to determine the functionality of the alternatively spliced isoforms of Mdm2 and 
Mdm4, I analyzed the effects on p53 following transient transfection of constructs designed to 
mimic the skipped transcripts. The skipping of Mdm2 exon 3 results in a later start codon being 
used, leading to a protein product with an N-terminal truncation removing the p53 binding domain 
and p53 induction (Giglio et al., 2010; Perry et al., 2000; Saucedo et al., 1999). In contrast, Mdm4 
exon 7 exclusion results in a shift in the reading frame for 13 amino acids followed by a premature 
stop codon. This spliced isoform has been previously reported to produce a potent p53 inhibitor 
in vitro; however in vivo experiments suggest a loss of function potentially through mRNA 
degradation by nonsense-mediated decay (Bardot et al., 2015; Bezzi et al., 2013; Dewaele et al., 




(Mdm2∆3) and Mdm4 (Mdm4∆7), each with an N-terminal myc tag (Figure 2.10A). I then 
transiently transfected NIH3T3 cells and found that overexpression of full-length Mdm2 – but not 
Mdm4 – was sufficient to suppress nuclear accumulation of p53 following UV treatment (Figure 
2.10B). This result is consistent with the role of Mdm2 as an E3 ubiquitin ligase for p53, while 
Mdm4 inhibits p53 transcriptional activity. Additionally, neither truncated form was able to 
suppress UV-induced p53 induction. Importantly, overexpression of either Mdm2∆3 or Mdm4∆7 
was sufficient to induce p53 activation in the absence of UV-treatment, while the full-length 
isoforms were not (Figure 2.10C), indicating that either product can exert dominant negative 
effects leading to p53 induction. These results support a role for increased exon skipping of Mdm2 
and Mdm4 exons as a mechanism for p53 upregulation. 
 
 
Skipping of SMN-regulated Mdm2 and Mdm4 exons synergistically activates p53 
To determine whether accumulation of alternatively spliced Mdm2 and Mdm4 mRNAs 
induced by SMN deficiency is sufficient to induce p53 activation in vivo, I designed anti-sense 
morpholino oligonucleotides (MOs) complementary to the 5’ splice sites of mouse Mdm2 exon 3 
and Mdm4 exon 7 (Figure 2.11 and 2.12A), which are predicted to block U1 snRNP binding and 
promote exon skipping without altering endogenous mRNA levels. To assess the efficacy of the 
designed morpholinos, I monitored the effects on Mdm2 and Mdm4 alternative splicing both in 
vitro and in vivo. RT-PCR and RT-qPCR analysis showed that both Mdm2 and Mdm4 MOs acted 
selectively to induce skipping of their targeted exons in NIH3T3 fibroblasts (Figure 2.12B and 
2.12C). Further, RT-PCR and RT-qPCR analysis of Mdm2 exon 3 and Mdm4 exon 7 splicing in 
the spinal cord of injected mice following delivery by intracerebroventricular (ICV) injection in WT 
mice at P0 either alone or in combination, showed that Mdm2 and Mdm4 MOs acted selectively 





Next, I analyzed whether treatment with these splice-switching MOs had an effect on the 
p53 pathway. To determine the individual contribution of these splicing events to p53 activation, 
I investigated the effects of treatment with Mdm2 and Mdm4 MOs either alone or in combination 
on p53 both in vitro and in vivo. Strikingly, immunostaining experiments revealed that either MO 
alone induced little if any upregulation of p53 in NIH3T3 cells, while treatment with both MOs 
triggered robust and widespread p53 accumulation (Figure 2.12D). However, MO treatment did 
not lead to p53 phosphorylation at serine 18, which is observed upon UV treatment used as a 
positive control (Figure 2.12D). Similar results were observed in mouse spinal cord at P11 where 
either MO alone had little effects while treatment with both MOs induced robust p53 accumulation 
(Figure 2.13D). Moreover, analysis of p53 protein levels in WT spinal cord by Western blot showed 
robust upregulation of p53 following treatment with both MOs (Figure 2.13C), and quantification 
of the percentage of p53+ L5 LMC and MMC motor neurons further highlighted the synergistic 
effects of combined treatment (Figure 2.13E and 2.13F). 
Importantly, RT-qPCR analysis of p53 transcriptional targets – which are also induced in 
SMA mice (Jangi et al., 2017; Murray et al., 2015; Simon et al., 2017) (see also Figures 2.20, 2.21 
and 2.22) – showed relatively small increases upon treatment with either MO individually and 
strong induction when MOs were delivered in combination (Figure 2.14A-E). Moreover, activation 
of the p53 pathway induced by MOs targeting Mdm2 and Mdm4 occurred without changes in the 
expression of Smn or p53 mRNAs (Figure 2.14F and 2.14G), consistent with a post-transcriptional 
mechanism involving impairment of p53 degradation with consequent protein stabilization. 
Together, these experiments reveal the remarkable potency with which p53 can be activated 
through concurrent perturbation of Mdm2 exon 3 and Mdm4 exon 7 splicing. 
To further assess the effects of morpholino delivery on p53 activation, I delivered two-fold 
increasing amounts of MOs to WT mice as well as the highest dose of a non-targeting MO used 
as a control. Importantly, RT-PCR analysis demonstrated dose-dependent accumulation of 




WT mice (Figure 2.15A). This was confirmed by RT-qPCR analysis that also showed dose-
dependent reductions in the inclusion of Mdm2 exon 3 and Mdm4 exon 7 (Figure 2.15B). 
Furthermore, the synergistic effects on p53 activation were also dose-dependent as assessed by 
both the upregulation of p53 transcriptional targets in the spinal cord (Figure 2.15C) as well as 
immunostaining of nuclear p53 (Figure 2.16). 
Last, I analyzed the effects of Mdm2 and Mdm4 morpholino delivery on motor neurons and 
found that ~15% of L5 medial motor column (MMC) motor neurons were p53+ following delivery 
of Mdm2 and Mdm4 MOs in WT mice (Figure 2.17A and B), demonstrating that increased Mdm2 
and Mdm4 skipping is sufficient to induce p53 accumulation in a motor neuron population that is 
vulnerable in SMA. We previously showed that SMA motor neuron death requires convergence 
of p53 upregulation with p53 phosphorylation (Simon et al., 2017). Accordingly, phosphorylation 
of serine 18 of mouse p53 (phospho-p53S18) is a specific marker of degenerating SMA motor 
neurons, and overexpression of unphosphorylated p53 is not sufficient to induce degeneration of 
WT motor neurons in vivo (Simon et al., 2017). I therefore performed motor neuron counts and 
immunostaining for phospho-p53S18 in the spinal cord of WT mice following co-injection of Mdm2 
and Mdm4 MOs. Consistent with observations in vitro (Figure 2.12D), I did not observe phospho-
p53S18 expression in motor neurons or other spinal cells (Figure 2.17C). Furthermore, in 
accordance with our previous findings, there was no change in the number of L5 MMC motor 
neurons relative to control mice (Figure 2.17D). Thus, skipping of SMN-regulated Mdm2 and 
Mdm4 exons can act as an initiating step for p53 stabilization, but not for phosphorylation of serine 
18 in vivo.  
 
Mdm2 and Mdm4 gene delivery inhibits p53 activation in SMA mice 
To determine whether changes in Mdm2 and Mdm4 alternative splicing were responsible 
for p53 activation in SMA, I utilized adeno-associated virus serotype 9 (AAV9) mediated gene 




2.18A). SMA mice injected with AAV9-GFP and uninjected WT mice were used as controls in 
these experiments. RT-qPCR analysis demonstrated robust expression of Mdm2 and Mdm4 
mRNAs over endogenous levels in the spinal cord of mice injected with the corresponding AAV9 
vectors relative to controls at P11 (Figure 2.18B and 2.18C). I also attempted to monitor Mdm2 
and Mdm4 protein levels, but failed to identify commercially available antibodies that detected 
endogenous or overexpressed levels of these proteins by either immunohistochemistry or 
Western blot. Importantly, AAV9-Mdm2 and AAV9-Mdm4 did not alter the low levels of SMN 
produced by the SMN2 gene at the mRNA or protein level (Figure 2.18D and 2.18E). 
I then investigated whether AAV9-Mdm2 or AAV9-Mdm4 affected the expression of p53 in 
vulnerable motor neurons of SMA mice. In agreement with our previous study (Simon et al., 2017), 
I found that ~60% of L2 motor neurons and ~70% of L5 MMC motor neurons are p53+ in SMA 
mice injected with AAV-GFP at P11 (Figure 2.19A-D), while no p53 expression is detectable in 
WT motor neurons. Importantly, injection of AAV9-Mdm2 and AAV9-Mdm4 either individually or 
in combination strongly reduced p53 expression in these SMA motor neurons (Figure 2.19A-D), 
with p53 suppression being more effective upon co-injection of both vectors. The observation that 
overexpression of either Mdm2 or Mdm4 efficiently inhibits nuclear accumulation of p53 in SMA 
motor neurons is consistent with p53 induction requiring the synergistic effects of exon skipping 
in both Mdm2 and Mdm4, which are invariably muted when the full-length mRNA isoform of either 
gene is reinstated.  
To determine whether Mdm2 and Mdm4 overexpression selectively inhibits p53 
transcriptional activity in SMA mice, I monitored the mRNA levels of several p53 target genes in 
the spinal cord of SMA mice relative to WT mice by RT-qPCR at P11. First, I assessed a panel of 
p53 transcriptional targets including several which were reported in prior studies to be upregulated 
in SMA motor neurons (Murray et al., 2015; Simon et al., 2017). While increases in some p53 
transcriptional targets were not detected in spinal cord – perhaps because upregulation is 




regulated genes (Figure 2.20). In order to validate whether activation of these genes is p53-
dependent, I monitored mRNA levels by RT-qPCR in SMA mice which are p53 null and found that 
transactivation of all target genes was nearly completely suppressed, validating that they are p53-
dependent target genes in SMA (Figure 2.21A). I next determined the effects of AAV9-p53shRNA, 
which was delivered at P0 by ICV injection. Viral mediated p53 knockdown also led to significant 
suppression of the induction of select transcriptional targets of p53 (Figure 2.21B). As expected, 
the correction was not complete likely because AAV9 mainly transduces motor neurons but not 
many other spinal cells that express p53 at a late disease stage in SMA mice (Simon et al., 2017) 
(see also Figure 2.4). These findings confirmed that upregulation of p53 downstream target genes 
induced by SMN deficiency can be monitored by whole tissue analysis in SMA spinal cord at late 
disease stages, and their transcriptional activation indeed occurs in a p53-dependent manner.  
Importantly, I found that co-injection of AAV9-Mdm2 and AAV9-Mdm4 but not AAV9-GFP 
robustly decreased the mRNA levels of p53-regulated genes that are induced by SMN deficiency 
in the spinal cord of SMA mice (Figure 2.22A-F), demonstrating functional inhibition of p53. 
Interestingly, I observed differential suppression of upregulated p53 targets upon delivery of either 
Mdm2 or Mdm4 individually. Upregulation of p53 targets was Mdm2-dependent (Cdkn1a and 
Gtse1), Mdm4-dependent (Ptprv) as well as responsive to restoration of either (Fas) or both 
( Pmaip, and Perp1) Mdm2 and Mdm4 (Figure 2.22A-F).  
To establish the specificity of the effects of Mdm2 and Mdm4 for the suppression of p53-
dependent gene changes in SMA, I monitored known RNA processing events in other SMN 
regulated pathways disrupted in SMA. Specifically, I analyzed U12-dependent splicing of 
Stasimon (Lotti et al., 2012), U7-dependent 3’-end processing of histone mRNAs (Tisdale et al., 
2013), and the expression of Chondrolectin mRNA (Bäumer et al., 2009; Zhang et al., 2008) all 
of which were altered in the spinal cord of SMA mice relative to WT mice but not corrected by 




Together, these results demonstrate that overexpression of full-length Mdm2 and/or Mdm4 
selectively suppresses the SMN-dependent activation of p53 and induction of its downstream 
transcriptional targets in SMA mice.  
 
Mdm2 and Mdm4 restoration inhibits motor neuron degeneration and improves motor 
function in SMA mice 
Based on the link between SMN-dependent dysregulation of Mdm2 and Mdm4 alternative 
splicing and the induction of p53, I sought to determine the effect of overexpressing Mdm2 and 
Mdm4 on motor neuron survival in SMA mice. To do so, I delivered AAV9-Mdm2 and AAV9-Mdm4 
either individually or in combination in SMA mice by ICV injection at P0 and then quantified the 
number of vulnerable L2 and L5 MMC motor neurons at P11 which are significantly decreased in 
SMA mice, according to previous studies (Fletcher et al., 2017; Mentis et al., 2011; Simon et al., 
2017). Remarkably, I found that overexpression of either Mdm2 or Mdm4 alone strongly 
suppressed degeneration of L2 and L5 MMC SMA motor neurons with an efficacy comparable to 
that achieved with their co-expression (Figure 2.23). Thus, restoration of either Mdm2 or Mdm4 
full-length mRNAs is sufficient to prevent p53 upregulation induced by SMN deficiency through 
the synergistic effects of Mdm2 and Mdm4 missplicing and the subsequent p53-dependent 
cascade leading to degeneration of SMA motor neurons.  
In addition to motor neuron degeneration, SMN deficiency leads to several deficits in the 
motor circuit (Tisdale and Pellizzoni, 2015). To assess further the impact of Mdm2 and Mdm4 
overexpression on the SMA neuromuscular phenotype, I investigated functional and 
morphological parameters of the sensory-motor circuit that are severely affected in the mouse 
model of the disease (Fletcher et al., 2017; Mentis et al., 2011). First, we analyzed changes in 
sensory-motor function by monitoring the spinal reflex in the L2 segment of the spinal cord at P11. 
We found that AAV-mediated Mdm2 and Mdm4 overexpression moderately but significantly 




with AAV9-GFP relative to WT mice (Figure 2.24A and 2.24B). This partial functional recovery 
likely reflects the sparing of SMA motor neurons rather than specific benefits on the number and 
function of the proprioceptive (VGluT1+) synapses that impinge on motor neuron somata, the loss 
of which was not prevented by AAV9-Mdm2 and AAV9-Mdm4 injection in SMA mice (Figure 
2.24C and 2.24D). These experiments also indicate that SMA motor neurons rescued from death 
by Mdm2 and Mdm4 gene delivery are capable of eliciting functional responses (i.e. firing action 
potentials) following synaptic activation.  
Next, we analyzed the impact of Mdm2 and Mdm4 overexpression on innervation and 
function of neuromuscular junctions (NMJs) in the QL muscle of SMA mice. AAV9-Mdm2 and 
AAV9-Mdm4 neither improved the severe NMJ denervation (Figure 2.24E and F) nor the strong 
reduction in the amplitude of the compound muscle action potential (Figure 2.24G and 2.24H) 
found in AAV9-GFP injected SMA mice relative to WT mice.  
Lastly, I found that overexpression of Mdm2 and Mdm4 transiently improved the righting 
time of SMA mice (Figure 2.25A), while it had no toxic effects in normal mice and did not enhance 
weight gain or survival in SMA mice (Figure 2.25B and 2.25C). These results are consistent with 
both the beneficial effects of genetic or pharmacological inhibition of p53 in the same model being 
limited to improved motor behavior (Simon et al., 2017) and the contribution of peripheral 
pathology to the growth and survival phenotype of SMA mice (Hamilton and Gillingwater, 2013; 
Hua et al., 2011). They also indicate that Mdm2 and Mdm4 restoration improves motor function 
by acting on the p53-mediated pathway governing motor neuron degeneration but not on the 
mechanisms underlying synaptic loss in SMA mice. 
 
2.3 Discussion 
Establishing clear mechanistic links between the multiple roles of SMN in RNA regulation 
and specific downstream phenotypic effects relevant to SMA pathology is critical in understanding 




that can impact many downstream cellular processes (Li et al., 2014), an outstanding challenge 
in the field has been to identify which functions and specific targets of SMN are causally related 
to clinical features of SMA. Here, I addressed this issue by focusing on the molecular mechanisms 
underlying a hallmark of SMA (motor neuron degeneration) that have long remained elusive. 
Building on our recent discovery that p53 activation is central to the degenerative process of SMA 
motor neurons (Simon et al., 2017), I demonstrate that SMN function in snRNP biogenesis is 
required for coordinated regulation of Mdm2 and Mdm4 alternative splicing and that defective 
inclusion of a key regulatory exon in each of these genes acts synergistically to drive p53 anti-
repression and motor neuron degeneration in a mouse model of SMA. Collectively, these findings 
establish a causal link between disrupted assembly of spliceosomal snRNPs and 
neurodegeneration and reveal the identity of the upstream molecular events that underlie this 
pathogenic process in SMA (Figure 2.26). 
The discovery that p53 activation drives motor neuron degeneration in SMA mice raised 
important mechanistic questions regarding the identity of the upstream triggers induced by SMN 
deficiency (Simon et al., 2017). Given that SMA motor neurons showed no evidence for DNA 
damage (Simon et al., 2017), which is a well-known inducer of p53 activation, I focused on other 
possible mechanisms. Using both cellular and animal models, I show that SMN deficiency disrupts 
the balance between inclusion and exclusion of key regulatory exons in Mdm2 and Mdm4 which 
are two well-established inhibitors of p53 expression and function (Marine et al., 2006), leading 
to a switch in their biological activity from repression to activation of p53. The requirement of SMN 
for the regulation of Mdm2 exon 3 and Mdm4 exon 7 alternative splicing is demonstrated in 
mammalian cells in vitro using a well-controlled homogeneous model system (Lotti et al., 2012; 
Tisdale et al., 2013) as well as in vivo through the analysis of both the spinal cords and motor 
neurons from SMA mice. I observe that the protein products of the skipped isoforms Mdm2D3 and 




in cellular models. These findings, taken together with previous studies, provide the basis to 
explain how increased levels of alternatively spliced Mdm2 and Mdm4 mRNAs and a 
corresponding reduction in the levels of full-length transcripts trigger p53 anti-repression through 
loss-of-function and dominant-negative effects on the activity of Mdm2 (Giglio et al., 2010; Perry 
et al., 2000) and Mdm4 (Bardot et al., 2015; Bezzi et al., 2013). 
From a mechanistic standpoint, these findings indicate that Mdm2 and Mdm4 exon 
skipping induced by SMN deficiency is a direct consequence of impaired assembly of 
spliceosomal snRNPs, which is the best-characterized activity of SMN (Burghes and Beattie, 
2009; Li et al., 2014). First, the reduction of snRNP levels upon SMN depletion is well documented 
in both NIH3T3 cells (Lotti et al., 2012) and SMA motor neurons (Ruggiu et al., 2012; Tisdale and 
Pellizzoni, 2015) in which I identified Mdm2 and Mdm4 splicing defects (Figures 2.1 and 2.5). 
Second, the earliest and strongest effects of SMN depletion on alternative splicing of Mdm2 and 
Mdm4 mRNAs are found in disease-relevant vulnerable SMA motor neurons relative to other 
spinal cells (Figure 2.5), coincident with more pronounced snRNP reduction and p53 up-
regulation (Figures 2.8 and 2.9). Third, selective impairment of snRNP biogenesis through SmB 
knockdown in NIH3T3 cells induces robust skipping of both Mdm2 exon 3 and Mdm4 exon 7 as 
well as p53 activation in the presence of normal SMN levels (Figures 2.6 and 2.7), thereby directly 
linking dysregulation of these alternative splicing events to snRNP dysfunction. Potential 
mechanisms underlying motor neuron selectivity at early disease stages include the intrinsically 
low efficiency of SMN2 exon 7 splicing and activation of a negative feedback that specifically 
exacerbates SMN2 splicing defects and downstream effects of SMN deficiency through snRNP 
dysfunction in SMA motor neurons (Jodelka et al., 2010; Ruggiu et al., 2012). At later symptomatic 
stages, wider dysregulation of Mdm2 and Mdm4 splicing and accumulation of p53 in the spinal 
cords of SMA mice likely involves similar mechanisms induced by hypoxia and other stressors 
that decrease SMN2 splicing (Bebee et al., 2012; Somers et al., 2016). In agreement with 




arginine methyltransferase 5—a protein that carries out symmetric dimethylation of a subset of 
Sm proteins prior to their transfer to the SMN complex (Friesen et al., 2001b; Meister et al., 2001b) 
—has been shown to promote skipping of Mdm4 exon 7 and p53 activation (Bezzi et al., 2013). 
Expanding on this study in which SMN function and Mdm2 splicing were not investigated, this 
data indicates that coordinated regulation of Mdm2 and Mdm4 alternative splicing acts as a 
sensor of impaired snRNP biogenesis and splicing dysfunction to elicit p53-mediated biological 
responses and that this SMN-dependent regulatory axis is disrupted in SMA. 
To assess directly the role of Mdm2 and Mdm4 alternative splicing in the regulation of p53, 
I used splice-switching oligonucleotides that specifically modify the inclusion of SMN-regulated 
exons. Remarkably, I found that exclusion of either Mdm2 exon 3 or Mdm4 exon 7 alone had mild 
effects on p53 activity, while concomitant induction of both Mdm2 and Mdm4 exon skipping events 
synergizes to elicit a much more robust p53 response, including widespread nuclear accumulation 
of p53 and up-regulation of its transcriptional targets in the spinal cords of WT mice (Figures 2.13 
and 2.14). Thus, coordinated skipping of SMN-regulated exons of Mdm2 and Mdm4 is both 
necessary and sufficient for robust p53 induction, likely through protein stabilization, based on the 
function of these factors in p53 regulation (Marine et al., 2006) and because mRNA levels of p53 
were unchanged (Figure 2.14). However, these splicing events alone do not cause the death of 
WT motor neurons in vivo. This is consistent with our previous demonstration that p53 
overexpression per se is not sufficient to induce degeneration of motor neurons but requires 
convergence of at least another activating event (N-terminal phosphorylation of p53, of which Ser 
18 phosphorylation is a marker) (Simon et al., 2017) that is independent from Mdm2 and Mdm4 
exon skipping (Figures 2.12 and 2.17). Importantly, functional analysis of the role of Mdm2 and 
Mdm4 splicing dysregulation in SMA revealed that overexpression of either target is sufficient to 
prevent p53 accumulation and rescue SMA motor neurons from degeneration to levels 
comparable with their co-expression in SMA mice (Figures 2.19 and 2.23). This further highlights 




sufficiency of correcting either deficit for suppression of p53-mediated death of SMA motor 
neurons. Therefore, while further investigation is needed to define the converging pathway(s) 
responsible for N-terminal phosphorylation of p53, these results conclusively establish that 
dysregulated alternative splicing of two specific target genes induced by SMN deficiency is the 
initiating event that underlies synergistic activation of p53 and neurodegeneration in a mouse 
model of SMA (Figure 2.26). 
These findings have potential therapeutic implications for human disease that include but 
are not limited to neurodegeneration in SMA. Mdm2 and Mdm4 are negative regulators of p53 
that prevent its undue activation under normal conditions (Vousden and Prives, 2009). However, 
they are also oncogenes, as their overexpression promotes uncontrolled cell proliferation through 
excess inhibition of the tumor suppressor activity of p53 in certain cancers (Wade et al., 2013). 
Moreover, enhanced skipping of Mdm4 exon 7 (exon 6 in human MDM4) has been proposed as 
a candidate therapeutic approach to activate the p53 response in specific cancers such as 
melanomas and diffuse large B-cell lymphoma that retain a functional p53 allele (Dewaele et al., 
2016; Valianatos et al., 2017). Considering the strong synergistic effects that I demonstrate here, 
induction of both Mdm2 exon 3 and Mdm4 exon 7 skipping has the potential for much more 
pronounced activation of p53 and increased therapeutic benefit in cancer. Conversely, promoting 
the inclusion of either SMN-regulated exon in Mdm2 or Mdm4 mRNAs could represent a 
candidate approach to counteract the loss of SMA motor neurons in an SMN-independent manner.  
My results indicate that selective blockade of motor neuron death results in partial 
functional recovery and improved motor ability early in the disease course of SMA mice (Figure 
2.19), while the overall benefit on the neuromuscular phenotype is likely limited by the progressive 
loss of central synapses and NMJ innervation, which are distinct p53-independent pathogenic 
events. At a time when disease-modifying treatments are emerging but comprehensive 
understanding of what aspects of SMA pathology are insufficiently addressed in patients is lacking 




combinatorial approaches that might complement SMN-based therapeutics (Groen et al., 2018; 
Van Alstyne and Pellizzoni, 2016). Thus, despite the fact that rescue of motor neuron survival 
alone is expectedly not sufficient to reverse the severe SMA phenotype (Fletcher et al., 2017; 
Gogliotti et al., 2012; Martinez et al., 2012; McGovern et al., 2015), selectively targeting the motor 
neuron death pathway has the potential to enhance the clinical benefit of SMN-inducing 
therapeutics by preventing the irreplaceable loss of the most affected cell type in SMA and 
extending the window of opportunity for amelioration of synaptic pathology.  
Induction of p53 has also been documented in patient tissue and experimental models of 
several chronic and acute neurodegenerative diseases (Culmsee and Mattson, 2005), including—
but not limited to—Alzheimer's disease (Kitamura et al., 1997; de la Monte et al., 1997), 
Parkinson's disease (Duan et al., 2002; Mogi et al., 2007; Qi et al., 2016), ischemic stroke, and 
traumatic brain injury (Yang et al., 2016). In light of my results, it would be relevant to evaluate 
the involvement of Mdm2 and Mdm4 splicing dysregulation in neuronal loss in this diverse group 
of neurological disorders. 
In conclusion, these findings mechanistically link dysregulation of alternative splicing 
induced by SMN deficiency with motor neuron death, the key hallmark of SMA. Furthermore, they 
identify decreased SMN function in snRNP biogenesis as the initial trigger and defective 
alternative splicing of Mdm2 and Mdm4 as the downstream effectors responsible for the up-
regulation of p53 that underlies the neurodegenerative process in SMA. In addition to elucidating 
a fundamental pathogenic mechanism of SMA, the molecular cascade of events emerging from 
our study provides new entry points for exploring SMN-independent neuroprotective approaches 
for preventing motor neuron death that may also have broader implications in other 










Figure 2.1. SMN regulates alternative splicing of Mdm2 and Mdm4 in vitro. (A) RT-PCR 
analysis of Mdm2 exon 3 splicing in NIH3T3-SmnRNAi and NIH3T3-SMN/SmnRNAi cells cultured 
with or without Dox using primers in exon 2 (E2) and exon 5 (E5). A schematic of the alternatively 
spliced exon is shown at the top. Arrowheads indicate the locations of primers. (B) RT–PCR 
analysis of Mdm4 exon 7 splicing in NIH3T3-SmnRNAi and NIH3T3-SMN/SmnRNAi cells cultured 
with or without Dox using primers in exon 5 (E5) and exon 8 (E8). A schematic of the alternatively 
spliced exon is shown at the top. Arrowheads indicate the locations of primers. (C) The 
percentage of Mdm2 exon 3 inclusion from RT–PCR data in (A). Data represent mean and 
standard error of the mean (SEM). n = 3. Statistics were performed with two-tailed unpaired 
Student's t-test. (***) P < 0.001; (ns) no significance. (D) The percentage of Mdm4 exon 7 
inclusion from RT–PCR data in (B). Data represent mean and SEM. n = 3. Statistics were 
performed with two-tailed unpaired Student's t-test. (**) P < 0.01; (ns) no significance. (E) RT-
qPCR analysis of Mdm2 E3 inclusion in NIH3T3-SmnRNAi cells cultured with or without Dox. Data 
represent mean and SEM. n = 3. Normalized E3 inclusion was measured by analysis of the 
expression of E3 included relative to total transcript levels. Statistics were performed with two-
tailed unpaired Student's t-test. (*) P < 0.05. (F) RT-qPCR analysis of Mdm4 E7 inclusion in 
NIH3T3-SmnRNAi cells cultured with or without Dox. Data represent mean and SEM. n = 3. 
Normalized E7 inclusion was measured by analysis of the expression of E7 included relative to 












Figure 2.2. SMN deficiency selectively affects key regulatory exons in Mdm2 and Mdm4. 
(A) Gene structure of mouse Mdm2 depicting protein-coding exons in blue and non-coding 
portions in grey, except for the SMN-regulated exon 3 that is shown in red. Arrowheads point to 
the location of primers and brackets indicate the portion of the mRNA analyzed by RT-PCR in 
panels (B) and (C). (B) RT-PCR analysis of Mdm2 mRNA in NIH3T3-SmnRNAi cells cultured with 
or without Dox using primers located in exon 2 (E2) and at the junction between exon 6 and 7 
(E6/7). DNA size in base pairs is shown on the left. (C) RT-PCR analysis of Mdm2 mRNA in 
NIH3T3-SmnRNAi cells cultured with or without Dox using primers located in exon 12 (E12) and at 
the junction between exon 6 and 7 (E6/7). DNA size in base pairs is shown on the left. (D) Gene 
structure of mouse Mdm4 depicting protein-coding exons in blue and non-coding portions in grey, 
except for the SMN-regulated exon 7 that is shown in red. Arrowheads point to the location of 
primers and brackets indicate the portion of the mRNA analyzed by RT-PCR in panels E and F. 
(E) RT-PCR analysis of Mdm4 mRNA in NIH3T3-SmnRNAi cells cultured with or without Dox using 
primers located in exon 1 (E1) and exon 5 (E5). DNA size in base pairs is shown on the left. (F) 
RT-PCR analysis of Mdm4 mRNA in NIH3T3-SmnRNAi cells cultured with or without Dox using 














Figure 2.3. SMN regulates Mdm2 and Mdm4 alternative splicing in vivo. (A) RT–PCR of 
Mdm2 exon 3 splicing in wild-type and SMA spinal cord at postnatal day 1 (P1), P6, and P11 
using exon 2 and exon 5 primers. (B) The percentage of Mdm2 exon 3 inclusion in wild-type and 
SMA spinal cords from RT–PCR data in (A). Data represent mean and SEM. n = 3. Statistics were 
performed with two-tailed unpaired Student's t-test. (*) P < 0.05; (***) P< 0.001. (C) RT-qPCR 
analysis of Mdm2 E3 inclusion in WT and SMA spinal cord at P11. Data represent mean and 
SEM. n = 6. Normalized E3 inclusion was measured by analysis of the expression of E3 included 
relative to total transcript levels. Statistics were performed with two-tailed unpaired Student's t-
test. (*) P < 0.05. (D) RT–PCR of Mdm4 exon 7 splicing in wild-type and SMA spinal cords at P1, 
P6, and P11 using exon 5 and exon 8 primers. (*) P < 0.05. (E) The percentage of Mdm4 exon 7 
inclusion in wild-type and SMA spinal cords from RT–PCR data in (D). Data represent mean and 
SEM. n=3. Statistics were performed with two-tailed unpaired Student's t-test. (*) P < 0.05. (F) 
RT-qPCR analysis of Mdm4 E7 inclusion in WT and SMA spinal cord at P11. Data represent 
mean and SEM. n = 6. Normalized E7 inclusion was measured by analysis of the expression of 
E7 included relative to total transcript levels. Statistics were performed with two-tailed unpaired 

















Figure 2.4. p53 upregulation occurs earliest in SMA motor neurons and becomes more 
widespread with disease progression. (A) Choline acetyltransferase (ChAT) and p53 
immunostaining of L2 spinal segments from wild-type and SMA mice at P1, P6, and P11. Scale 





Figure 2.5. Mdm2 and Mdm4 alternative splicing is prominently disrupted in vulnerable 
SMA motor neurons. (A) Schematic of the experimental approach used to isolate retrogradely 
labeled muscle-identified motor neurons from wild-type and SMA mice. (B) Bright-field and 
fluorescent images of a representative L1–L3 spinal segment used to isolate cholera toxin B 
subunit (CTb)-labeled motor neurons before and after laser capture microdissection (LCM). Scale 
bar = 200 µm. (C) RT–PCR analysis of Mdm2 exon 3 and Mdm4 exon 7 splicing in L1–L3 motor 
neurons from wild-type and SMA mice at P6. Exon 2 and exon 5 primers were used for Mdm2. 
Exon 5 and exon 8 primers were used for Mdm4. (D) The percentage of Mdm2 exon 3 and Mdm4 
exon 7 inclusion in wild-type and SMA motor neurons from RT–PCR data in (C). Data represent 










Figure 2.6. Defective snRNP biogenesis dysregulates Mdm2 and Mdm4 alternative splicing. 
(A) RT–PCR analysis of Mdm2 exon 3 splicing in NIH3T3-SmBRNAi cells cultured with or without 
Dox using exon 2 (E2) and exon 5 (E5) primers. (B) RT–PCR analysis of Mdm4 exon 7 splicing 
in NIH3T3-SmBRNAi cells cultured with or without Dox using exon 5 (E5) and exon 8 (E8) primers. 
(C) The percentage of Mdm2 exon 3 inclusion from RT–PCR data in (A). Data represent mean 
and SEM. n=3. Statistics were performed with two-tailed unpaired Student's t-test. (***) P < 0.001. 
(D) The percentage of Mdm4 exon 7 inclusion from RT–PCR data in (B). Data represent mean 
and SEM. n=3. Statistics were performed with two-tailed unpaired Student's t-test. (**) P < 0.01. 
(E) RT-qPCR analysis of Mdm2 E3 inclusion in NIH3T3-SmBRNAi cells cultured with or without 
Dox. Data represent mean and SEM. n = 3. Normalized E3 inclusion was measured by analysis 
of the expression of E3 included relative to total transcript levels. Statistics were performed with 
two-tailed unpaired Student's t-test. (**) P < 0.01. (F) RT-qPCR analysis of Mdm4 E7 inclusion in 
NIH3T3-SmBRNAi cells cultured with or without Dox. Data represent mean and SEM. n = 3. 
Normalized E7 inclusion was measured by analysis of the expression of E7 included relative to 







Figure 2.7. Defective snRNP biogenesis induces p53 activation. (A) RT-qPCR analysis of 
SmB mRNA levels in NIH3T3-SmBRNAi cells cultured with or without Dox. Data represent mean 
and SEM. n=3. Statistics were performed with two-tailed unpaired Student's t-test. (***) P< 0.001. 
(B) Western blot analysis of NIH3T3-SmBRNAi cells cultured with and without Dox. (C) p53 and 
phospho-p53S18 immunostaining of NIH3T3-SmBRNAi cells cultured with or without Dox. Scale bar 
= 50 µm. (D) RT-qPCR analysis of mRNA levels of p53 transcriptional targets in NIH3T3-
SmBRNAi cells cultured with or without Dox. Normalized data from Dox-treated cells relative to 
untreated cells are shown as mean and SEM. n=3. Statistics were performed with two-tailed 











Figure 2.8. p53 activation correlates with reduced snRNP levels in SMA motor neurons. (A) 
ChAT, SmB, and p53 immunostaining of L2 spinal segments from wild-type and SMA mice at P1. 
Scale bar = 25 µm. Arrowheads point to p53+ SMA motor neurons. (B) Normalized SmB 
fluorescence intensity in wild-type as well as p53+ and p53− SMA L2 motor neurons at P1 from 
experiments as in (A). Each point represents SmB fluorescent intensity in a single L2 motor 
neuron, and data were collected from one biological replicate. Statistics were performed with one-
way ANOVA with Tukey's post-hoc test. (***) P < 0.001. (C) ChAT, SmB, and p53 immunostaining 
of L2 spinal segments from wild-type and SMA mice at P6. Scale bar = 25 µm. Arrowheads point 
to p53+ SMA motor neurons. (D) Normalized SmB fluorescence intensity in wild-type as well as 
p53+ and p53− SMA L2 motor neurons at P6 from experiments as in (C). Each point represents 
SmB fluorescent intensity in a single L2 motor neuron, and data were collected from three mice. 
Statistics were performed with one-way ANOVA with Tukey's post-hoc test. (***) P < 0.001. (E) 
ChAT, SmB, and p53 immunostaining of L2 spinal segments from wild-type and SMA mice at P11. 
Scale bar = 25 µm. Arrowheads point to p53+ SMA motor neurons. (F) Normalized SmB 
fluorescence intensity in wild-type as well as p53+ and p53− SMA L2 motor neurons at P11 from 
experiments as in (E). Each point represents SmB fluorescent intensity in a single L2 motor 
neuron, and data were collected from one biological replicate. Statistics were performed with one-





Figure 2.9. p53 activation correlates with reduced snRNP levels in L5 SMA motor neurons. 
(A) ChAT, SmB, and p53 immunostaining of L5 spinal segments (L5 MMC in inset) from SMA 
mice at P11. Scale bar = 100 µm. Inset Scale bar = 20 µm. Arrowheads point to p53+ SMA motor 
neurons. (B) Normalized SmB fluorescence intensity in p53+ and p53− SMA L5 LMC motor 
neurons at P11 from experiments as in (A). Each point represents SmB fluorescent intensity in a 
single L5 LMC motor neuron, and data was collected from one biological replicate. Statistics were 
performed with two-tailed unpaired Student's t-test. (***) P < 0.001. (C) Normalized SmB 
fluorescence intensity in p53+ and p53− SMA L5 MMC motor neurons at P11 from experiments as 
in (A). Each point represents SmB fluorescent intensity in a single L5 MMC motor neuron, and 
data were collected from one biological replicate. Statistics were performed with two-tailed 









Figure 2.10. Mdm2 and Mdm4 exon skipping leads to p53 dysregulation. (A) Schematic of 
constructs designed to mimic Mdm2 and Mdm4 alternatively spliced isoforms. (B) 
Immunofluorescence of p53 presence in NIH3T3 transiently transfected with myc-tagged Mdm2 
and Mdm4 full-length and skipped isoforms following UV induction of 10 mJ/cm2. Scale bar = 10 
µm. (C) Immunofluorescence of p53 presence in NIH3T3 transiently transfected with myc-tagged 























Figure 2.11. Design of splice-switching anti-sense oligonucleotides. (A) Schematic 
demonstrating expected base pairing of morpholinos (AMO) targeting the 5’ splice sites of exons 
of interest, thereby preventing U1 snRNP recognition and inducing the exclusion of the exon. (B) 
Base pairing of Mdm2 MO targeting the 5’ splice site of exon 3. (C) Base pairing of Mdm4 MO 






Figure 2.12. Skipping of SMN-regulated Mdm2 and Mdm4 exons synergistically triggers 
p53 activation in vitro. (A) Schematic of splice-switching MOs targeting the 5′ splice sites of 
Mdm2 exon 3 and Mdm4 exon 7. (B) RT–PCR analysis of Mdm2 exon 3 and Mdm4 exon 7 
splicing in NIH3T3 following treatment with 10 µM control MO or each splice-switching MO 
individually or together for 72 hours. Exon 2 and exon 5 primers were used for Mdm2. Exon 5 and 
exon 8 primers were used for Mdm4. (C)  RT-qPCR analysis of Mdm2 E3 and Mdm4 E7 inclusion 
in NIH3T3 cells following treatment with 10 µM control MO or each splice-switching MO for 72 
hours. Data represent mean and 95% CI for technical triplicates. Normalized inclusion was 
measured by analysis of the expression of E3 or E7 included relative to total transcript levels. (D) 
p53 and p-p53 immunofluorescence of NIH3T3 following treatment with 10 µM control MO or each 












Figure 2.13. Skipping of SMN-regulated Mdm2 and Mdm4 exons synergistically triggers 
p53 activation in vivo. (A) RT–PCR analysis of Mdm2 exon 3 and Mdm4 exon 7 splicing in the 
spinal cords of wild-type mice at P11 following injection of 400 µg of control MO or 200 µg of each 
splice-switching MO individually or together at P0. Exon 2 and exon 5 primers were used for 
Mdm2. Exon 5 and exon 8 primers were used for Mdm4. (B) RT-qPCR analysis of Mdm2 E3 and 
Mdm4 E7 inclusion in in the spinal cords of wild-type mice at P11 following injection of 400 µg of 
control MO or 200 µg of each splice-switching MO individually or together at P0. Data represent 
mean and 95% CI for technical triplicates. Normalized inclusion was measured by analysis of the 
expression of E3 or E7 included relative to total transcript levels. (C) Western blot analysis of 
spinal cords of wild-type mice at P11 following injection of 400 µg of control MO or 200 µg of each 
splice-switching MO individually or together at P0. (D) ChAT and p53 immunostaining of L5 spinal 
segments at P11 from wild-type mice injected with 400 µg of control or 200 µg of each splice-
switching MO at P0. Scale bar = 250 µm. (E) The percentage of p53+ L5 LMC motor neurons from 
experiments as in (A). n = 1. (F) The percentage of p53+ L5 MMC motor neurons from experiments 












Figure 2.14. Skipping of SMN-regulated Mdm2 and Mdm4 exons synergistically induces 
activation of the p53 pathway. (A-E) RT-qPCR analysis of p53 transcriptional targets in the 
spinal cords of wild-type mice at P11 following injection of 400 µg of control or 200 µg of each 
splice-switching MO at P0. Data represent mean and SEM. n = 3. Statistics were performed with 
one-way ANOVA with Tukey's post-hoc test. (*) P < 0.05; (**) P < 0.01; (***) P < 0.001. (F-G) RT-
qPCR analysis of p53 and Smn mRNA from the same groups as in (A-E). Data represent mean 









Figure 2.15. Dose-response analysis of p53 induction in the spinal cord of WT mice by MO 
mediated skipping of Mdm2 and Mdm4. (A) RT-PCR analysis of Mdm2 and Mdm4 splicing in 
the spinal cord at P11 from WT mice injected at P0 with increasing doses of equivalent amounts 
of splice switching MOs (25, 50, 100, 200, 400 µg total) or with control MO (400 µg). E2 and E5 
primers were used for Mdm2. E5 and E8 primers were used for Mdm4. (B) RT-qPCR analysis of 
Mdm2 E3 and Mdm4 E7 inclusion in in the spinal cord at P11 injected at P0 with increasing doses 
of equivalent amounts of splice switching MOs (50, 100, 200, 400 µg total) or with control MO 
(400 µg). Data represent mean and 95% CI for technical triplicates. Normalized inclusion was 
measured by analysis of the expression of E3 or E7 included relative to total transcript levels.  (C) 
RT-qPCR analysis of p53 transcriptional targets in the spinal cord at P11 from the same groups 






Figure 2.16. Dose-response analysis of p53 accumulation in the spinal cord of WT mice by 
MO mediated skipping of Mdm2 and Mdm4. (A) ChAT and p53 immunostaining of L5 spinal 
segments at P11 from WT mice injected at P0 with the indicated doses of splice-switching MOs 






Figure 2.17. Skipping of SMN-regulated Mdm2 and Mdm4 exons does not induce p53 
phosphorylation or motor neuron death. (A) ChAT and p53 immunostaining of L5 spinal 
segments at P11 from wild-type mice injected with 200 µg of control or 100 µg of each splice-
switching MO at P0. Insets show representative images of L5 medial motor column (MMC) motor 
neurons at higher magnification. Scale bar = 100 µm; Scalebar in inset = 25 µm. (B) The 
percentage of p53+ L5 MMC motor neurons from experiments as in (A). Data represent mean and 
SEM. n = 3. Statistics were performed with two-tailed unpaired Student's t-test. (*) P < 0.05. (C) 
ChAT and phospho-p53 Ser18 immunostaining of L5 spinal segments from experiments as 
in (A). Insets show representative images of L5 MMC motor neurons at higher magnification. 
Scale bar = 100 µm; Scalebar in inset = 25 µm. (D) The total number of L5 MMC motor neurons 
from experiments as in (A). Data represent mean and SEM. n = 3. Statistics were performed with 





Figure 2.18. Full-length Mdm2 and Mdm4 overexpression does not increase SMN levels in 
the spinal cord of SMA mice. (A) Schematic of the AAV9 vectors used to express full-length 
Mdm2 or Mdm4 cDNAs in vivo. (B-D) RT-qPCR analysis of Mdm2 (B), Mdm4 (C) and full-length 
human SMN2 (D) mRNAs in the spinal cord at P11 from uninjected WT mice and SMA mice 
injected at P0 with AAV9-GFP, AAV9-Mdm2 and AAV9-Mdm4 either alone or in combination as 
indicated. Data represent mean and SEM. n = 6. Statistics were performed with one-way ANOVA 
with Tukey’s post hoc test. (*) P < 0.05; (***) P < 0.001; (ns) no significance. (E) Western blot 
analysis of spinal cords isolated at P11 from uninjected WT mice and SMA mice injected at P0 
with AAV9-GFP or AAV9-Mdm2 and AAV9-Mdm4 together. Three independent mice per group 









Figure 2.19. Mdm2 and Mdm4 gene delivery suppresses p53 upregulation in SMA motor 
neurons. (A) ChAT and p53 immunostaining of L2 spinal segments at P11 from uninjected wild-
type mice and SMA mice injected at P0 with adeno-associated virus serotype 9 (AAV9)-GFP, 
AAV9-Mdm2, and AAV9-Mdm4 either alone or in combination as indicated. Scale bar = 50 µm. 
(B) The percentage of p53+ L2 motor neurons at P11 from the same groups as in (A). Data 
represent mean and SEM. n = 3. Statistics were performed with one-way ANOVA with Tukey’s 
post hoc test. (*) P < 0.05; (**) P < 0.01; (***) P < 0.001. (C) ChAT and p53 immunostaining of L5 
spinal segments at P11 from the same groups as in (A). Scale bar = 50 µm. (D) The percentage 
of p53+ L5 MMC motor neurons at P11 in the same groups as in (A). Data represent mean and 
SEM. n = 3. Statistics were performed with one-way ANOVA with Tukey’s post hoc test. (*) P < 












Figure 2.20. Upregulation of p53 target genes in spinal cord of SMA mice. RT-qPCR analysis 
of p53 transcriptional targets identified from microarray (Simon et al., 2017) or RNAseq analysis 
(Murray et al., 2015) of SMA motor neurons, or additional known p53 targets in the spinal cord at 
P11 from wild-type and SMA mice. Data represent mean and SEM. n = 6. Statistics were 











Figure 2.21. p53-dependent upregulation of target genes in spinal cord of SMA mice. (A) 
RT-qPCR analysis of p53 transcriptional targets in the spinal cords at P11 from wild-type (n = 6), 
SMA (n = 6), and SMA p53 null (n = 4) mice. Data represent mean and SEM. Statistics were 
performed with two-way ANOVA. (*) P < 0.05; (**) P < 0.01; (****) P < 0.0001. (B) RT-qPCR 
analysis of p53 transcriptional targets in the spinal cords at P11 from uninjected wild-type mice 
and SMA mice injected at P0 with either AAV9-GFP or AAV9-p53shRNA. Data represent mean 
and SEM. n = 6. Statistics were performed with two-way ANOVA. (*) P < 0.05; (***) P < 0.001; 











Figure 2.22. Mdm2 and Mdm4 gene delivery suppresses p53 activation in SMA. (A-F) RT-
qPCR analysis of p53 transcriptional targets in the spinal cords at P11 from uninjected wild-type 
mice and SMA mice injected at P0 with either AAV9-GFP, AAV9-Mdm2, AAV9-Mdm4 and AAV9-
Mdm2 and AAV9-Mdm4 together. Data represent mean and SEM. n = 6. Statistics were 
performed with one-way ANOVA with Tukey's post-hoc test. (*) P < 0.05; (**) P < 0.01; (***) P < 
0.001. (G-I) RT-qPCR analysis of the levels of aberrantly spliced Stasimon (Stas Aber) mRNA 
(G), 3′ end-extended H1c (H1c pre) mRNA (H), and chondrolectin (Chodl) mRNA (I) in the spinal 
cords at P11 from wild-type mice and SMA mice injected at P0 with either AAV9-GFP or AAV9-
Mdm2 and AAV9-Mdm4 together. Data represent mean and SEM. n = 6. Statistics were 
performed with one-way ANOVA with Tukey's post-hoc test. (*) P < 0.05; (**) P < 0.01; (***) P < 









Figure 2.23. Full-length Mdm2 and Mdm4 overexpression prevents motor neuron 
degeneration in SMA mice. (A) ChAT immunostaining of L2 spinal segments at P11 from 
uninjected wild-type mice and SMA mice injected with AAV9-GFP, AAV9-Mdm2, and AAV9-
Mdm4 either alone or in combination. Scale bar = 50 µm. (B) The total number of L2 motor 
neurons from the same groups as in (A) at P11. Data represent mean and SEM. n ≥ 3. Statistics 
were performed with one-way ANOVA with Tukey's post hoc test. (*) P < 0.05; (**) P < 0.01; 
(***) P < 0.001. (C) ChAT immunostaining of L5 spinal segments at P11 from the same groups as 
in (A). Scale bar = 100 µm. (D) The total number of L5 MMC motor neurons from the same groups 
as in (A) at P11. Data represent mean and SEM. n ≥ 4. Statistics were performed with one-way 










Figure 2.24. Full-length Mdm2 and Mdm4 overexpression moderately improves spinal 
reflexes but does not restore synaptic deficits in SMA. (A) Traces of extracellular recordings 
of L2 ventral roots following L2 dorsal root stimulation from uninjected wild-type mice and SMA 
mice injected with either AAV9-GFP or AAV9-Mdm2 and AAV9-Mdm4 at P11. Arrowheads 
indicate the stimulus artifact. Arrows indicate the monosynaptic response. Scale bars = 5msec 
and 0.5 mV. (B) Spinal reflex amplitudes from the same groups as in (A). Data represent mean 
and SEM. n ≥ 3. Statistics were performed with one-way ANOVA with Tukey's post hoc test. 
(*) P < 0.05; (***) P < 0.001. (C) ChAT and VGluT1 immunostaining of L2 spinal segments from 
the same groups as in (A) at P11. Scale bar = 25 µm. (D) Total number of VGluT1+ synapses on 
L2 motor neuron somata from the same groups as in (A) at P11. Data represent mean and SEM. n 
≥ 22 neurons from three mice per group. Statistics were performed with one-way ANOVA with 
Tukey's post hoc test. (***) P < 0.001; (ns) no significance. (E) Immunostaining of presynaptic 
(with NF-M and SYP antibodies) and post-synaptic (with BTX) terminals of neuromuscular 
junctions (NMJs) in the QL muscle from the same groups as in (A) at P11. Arrowheads indicate 
fully denervated NMJs. Scale bar = 25 µm. (F) The percentage of fully denervated NMJs in the 
QL muscle from the same groups as in (A) at P11. Data represent mean and SEM. n ≥ 3. Statistics 
were performed with one-way ANOVA with Tukey's post hoc test. (**) P< 0.01; (ns) no significance. 
(G) Compound muscle action potential (CMAP) traces recorded from the QL muscle following L2 
ventral root stimulation in the same groups as in (A) at P11. Arrowheads indicate the stimulus 
artifact. Arrows indicate the peak of the M response. Scale bars = 5 msec and 0.5 mV. (H) The 
amplitude of the M response from the QL muscle in the same groups as in (A) at P11. Data 
represent mean and SEM. n ≥ 3. Statistics were performed with one-way ANOVA with Tukey's 









Figure 2.25. Full-length Mdm2 and Mdm4 overexpression moderately improves motor 
behavior in SMA mice. (A–C) Righting time (A), weight gain (B), and survival (C) of uninjected 
wild-type mice (n = 15) and wild-type and SMA mice injected with AAV9-GFP (n = 16) or AAV9-
Mdm2 and AAV9-Mdm4 (n = 10) as indicated. Statistics were performed with two-way ANOVA 











Figure 2.26. Splicing mechanisms of p53 anti-repression and motor neuron death in SMA. 
Schematic summary of the molecular cascade initiated by SMN deficiency, followed by reduction 
in the levels of spliceosomal snRNPs of the major spliceosome and consequent dysregulation of 
Mdm2 exon 3 and Mdm4 exon 7 alternative splicing, resulting in their increased skipping. 
Dysregulation of both splicing events is required to synergistically induce p53 stabilization, which 





Stasimon contributes to the loss of sensory synapses and motor neuron 
loss in a mouse model of spinal muscular atrophy3 
 
3.1 Introduction 
Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder 
characterized by the progressive loss of spinal motor neurons and skeletal muscle atrophy 
(Burghes and Beattie, 2009; Groen et al., 2018; Tisdale and Pellizzoni, 2015). SMA is a 
consequence of ubiquitous reduction in the levels of the survival motor neuron (SMN) protein due 
to homozygous deletion or mutation of the SMN1 gene with retention of the hypomorphic SMN2 
gene (Lefebvre et al., 1995). SMN has a well-characterized role in the assembly of small nuclear 
ribonucleoproteins  (snRNPs) of the splicing machinery (Meister et al., 2001b; Pellizzoni et al., 
2002b) as well as U7 snRNP that functions in 3’ end processing of histone mRNAs (Pillai et al., 
2003; Tisdale et al., 2013). SMN has also been implicated in other aspects of RNA regulation 
including mRNA transport (Donlin-Asp et al., 2017). Consistent with its central role in RNA 
processing (Donlin-Asp et al., 2016; Li et al., 2014), SMN deficiency has been shown to induce 
widespread splicing dysregulation and transcriptome alterations in a variety of in vivo models 
(Bäumer et al., 2009; Doktor et al., 2017; Jangi et al., 2017; Zhang et al., 2008, 2013).  The 
identification of downstream RNA targets of SMN deficiency that directly contribute to SMA 
pathology is of critical importance for elucidating disease mechanisms and revealing SMN-
independent therapeutic approaches. To date, however, this has proven to be challenging due to 
the diversity of RNA pathways controlled by SMN and the complexity of SMA pathology in mouse 
models that more closely resemble the most severe form of the human disease. 
                                               
3 This chapter is adapted from an article I co-authored entitled “Stasimon contributes to the loss of sensory 





Motor neurons are the cell type most severely affected by SMN deficiency, and their 
degeneration is a hallmark of SMA pathology (Burghes and Beattie, 2009; Groen et al., 2018; 
Tisdale and Pellizzoni, 2015). Importantly, selective genetic restoration of SMN in motor neurons 
of SMA mice has demonstrated that neuronal death is a cell autonomous process (Fletcher et al., 
2017; Gogliotti et al., 2012; Martinez et al., 2012; McGovern et al., 2015), which could be 
exacerbated by non-autonomous contributions (Hua et al., 2015). We previously demonstrated 
that activation of the tumor suppressor p53 drives motor neuron degeneration in the SMND7 
mouse model of SMA (Simon et al., 2017). We also showed that selectivity is established through 
the convergence of distinct mechanisms of p53 regulation including stabilization and 
phosphorylation of its N-terminal transactivation domain (TAD) (Simon et al., 2017), which only 
occur in the pool of vulnerable SMA motor neurons destined to die. I also demonstrated that p53 
upregulation results from dysregulated alternative splicing of Mdm2 and Mdm4 – the two main 
inhibitors of p53’s stability and function (Toledo and Wahl, 2006; Vousden and Prives, 2009) – 
due to reduced snRNP levels in SMA motor neurons (Van Alstyne et al., 2018a) (see also Chapter 
2), thereby directly linking neurodegeneration to specific splicing changes induced by SMN 
deficiency. However, the converging mechanism(s) responsible for selective phosphorylation of 
the TAD of p53 required for degeneration of SMA motor neurons is unknown. 
Characterization of SMA pathogenesis has identified multiple synaptic deficits in the motor 
circuit beyond motor neuron death that include dysfunction and loss of neuromuscular junctions 
(NMJs) as well as central proprioceptive sensory synapses onto motor neurons (Shorrock et al., 
2019; Van Alstyne and Pellizzoni, 2016), which likely exert compounding effects on 
neuromuscular function. Studies in mouse models indicated that NMJ denervation occurs as a 
consequence of intrinsic effects of SMN deficiency in SMA motor neurons rather than skeletal 
muscle (Fletcher et al., 2017; Gavrilina et al., 2008; Iyer et al., 2015; Martinez et al., 2012) and 
that the pathogenic processes underlying NMJ denervation and death of motor neurons might be 




synapses on somata and dendrites of SMA motor neurons is an early pathogenic event in SMA 
mice (Mentis et al., 2011), which is caused by the effects of SMN deficiency within proprioceptive 
neurons (Fletcher et al., 2017). The resulting reduction of excitatory drive from proprioceptive 
synapses induces hyperexcitability and reduces the firing of motor neurons contributing to 
impaired muscle contraction in SMA mice (Fletcher et al., 2017). Moreover, the deafferentation 
and dysfunction of motor neurons are mechanistically uncoupled from motor neuron death 
(Fletcher et al., 2017; Simon et al., 2016). However, while multiple insults to the synaptic integrity 
of sensory-motor circuits originate from defects in distinct neurons that coalesce to cause SMA 
pathology, the underlying SMN-dependent mechanisms are poorly understood. 
This work aimed to address the outstanding questions described above by investigating 
the potential contribution of Stasimon dysfunction to SMA pathology in a mouse model of the 
disease. Stasimon (also known as Tmem41b) was previously identified as an evolutionarily 
conserved, U12 intron-containing gene regulated by SMN that is required for proper synaptic 
transmission in the motor circuit of Drosophila larvae and motor axon outgrowth in zebrafish (Lotti 
et al., 2012). Importantly, Stasimon contributes to motor circuit deficits in Drosophila and zebrafish 
models of SMA as its overexpression suppresses specific neuronal phenotypes induced by SMN 
deficiency in these model organisms (Lotti et al., 2012). Furthermore, SMN deficiency disrupts 
U12 splicing (Boulisfane et al., 2011; Doktor et al., 2017; Jangi et al., 2017; Lotti et al., 2012), and 
both misprocessing and reduced expression of Stasimon mRNA was found in disease-relevant 
motor circuit neurons of SMA mice (Lotti et al., 2012). Recent studies have also shown that 
Stasimon is a transmembrane protein localized to the ER that is essential for mouse embryonic 
development (Van Alstyne et al., 2018b) and involved in autophagy (Moretti et al., 2018; Morita 
et al., 2018; Shoemaker et al., 2019). However, Stasimon’s normal requirement in the mammalian 





Here, I investigated the effects of Stasimon restoration in the SMND7 mouse model of 
SMA by means of adeno-associated virus serotype 9 (AAV9)-mediated gene delivery. I found that 
overexpression of Stasimon rescues the loss of proprioceptive synapses on motor neurons, 
improves synaptic transmission, and suppresses motor neuron degeneration. Mechanistically, I 
demonstrate that the loss of Stasimon is sufficient to induce p53 phosphorylation – a key event 
underlying the selective degeneration of SMA motor neurons (Simon et al., 2017) – through 
stimulation of p38 mitogen activated protein kinase (MAPK) signaling. Furthermore, 
pharmacological inhibition of p38 MAPK selectively suppresses p53 phosphorylation and motor 
neuron death but not synaptic loss in SMA mice. Together, these results establish Stasimon’s 
direct involvement in distinct pathogenic cascades induced by SMN deficiency in proprioceptive 
neurons and motor neurons, revealing a dual contribution by Stasimon to sensory-motor circuit 
dysfunction in a mouse model of SMA. They also suggest that p38 MAPK inhibition might be a 




AAV9-mediated Stasimon gene delivery improves motor function in SMA mice 
I sought to investigate the effects of increased expression of human STASIMON 
(abbreviated as STAS) on the phenotype of SMNΔ7 SMA mice by intracerebroventricular (ICV) 
injection of self-complementary AAV9 vectors at P0, an established method to study SMA disease 
mechanisms in vivo (Passini et al., 2010; Robbins et al., 2014; Simon et al., 2017, Van Alstyne et 
al., 2018a). RT-qPCR analysis confirmed that injection of AAV9-STAS as well as AAV9-GFP and 
AAV9-SMN, which were used as negative and positive controls, respectively, resulted in robust 
expression of the corresponding mRNAs in the spinal cord of SMA mice at P11 (Figure 3.1A). 




of SMA mice (Figure 3.1A and 3.1B). To rule out any potential indirect effects of AAV9-STAS on 
SMN function, I also looked at representative downstream targets of SMN-regulated RNA 
pathways. AAV9-STAS did not correct aberrant U12 splicing of endogenous Stasimon pre-mRNA 
(Lotti et al., 2012) or other RNA processing events such as U7-dependent histone H1c 3ʹ-end 
misprocessing (Tisdale et al., 2013), p53-dependent induction of Cdkn1a mRNA (Simon et al., 
2017; Van Alstyne et al., 2018a) and reduced Chodl mRNA expression (Bäumer et al., 2009; 
Zhang et al., 2008) in the spinal cord of SMA mice at P11 (Figure 3.2). In contrast, all of these 
SMN-dependent events were robustly corrected by AAV9-SMN as expected (Figure 3.2). 
Consistent with Stasimon being a downstream mRNA target of U12 splicing dysfunction induced 
by SMN deficiency (Lotti et al., 2012), these results demonstrate that AAV9-STAS does not 
enhance SMN expression or function. 
I next investigated the effects of AAV9-STAS on the disease phenotype of SMND7 SMA 
mice (Le et al., 2005), which exhibit reduced weight, shortened life span and impaired motor 
behavior. WT mice injected with AAV9-STAS showed no phenotypic abnormalities relative to 
uninjected WT littermates (Figure 3.3), indicating no toxic effects of Stasimon overexpression 
during postnatal mouse development. Furthermore, AAV9-SMN corrected all behavioral 
parameters and robustly extended survival in SMA (Figure 3.3) as described previously (Foust et 
al., 2010; Passini et al., 2010). Remarkably, while AAV9-STAS had no effects on weight gain and 
survival, it improved motor behavior of SMA mice assessed by righting time (Figure 3.3). Thus, 
Stasimon contributes to the motor phenotype of SMA mice, and the functional improvement 
elicited by AAV9-STAS occurs through SMN-independent mechanisms. 
 
AAV9-STAS rescues the loss of proprioceptive synapses on SMA motor neurons 
To identify morphological improvements underlying the motor benefit of Stasimon 




disease-relevant axial muscles. First, I analyzed the number of proprioceptive synapses onto 
motor neurons in the L1 lumbar spinal segment, which are strongly reduced in SMA mice (Mentis 
et al., 2011). To do so, I used immunohistochemistry with antibodies against the vesicular 
glutamate transporter 1 (VGluT1) to label proprioceptive synapses, and choline acetyltransferase 
(ChAT) as a motor neuron marker. SMA mice injected with AAV9-GFP exhibited a strong 
reduction of proprioceptive synapses onto somata and dendrites of L1 motor neurons at P11 
relative to WT mice (Figure 3.4). Strikingly, AAV9-STAS rescued the numbers of proprioceptive 
inputs on the somata and dendrites of motor neurons in SMA mice to levels similar to AAV9-SMN 
(Figure 3.4).  
To examine the selectivity of Stasimon’s effects on synaptic loss, I investigated NMJ 
innervation of the quadratus lumborum (QL), a disease-relevant axial muscle innervated by 
vulnerable L1-L3 motor neurons that is severely denervated in SMA mice (Fletcher et al., 2017; 
Simon et al., 2017; Van Alstyne et al., 2018a). To do so, I used antibodies against neurofilament 
(NF-M) and synaptophysin (SYP) as presynaptic markers and fluorescently-labeled α-
bungarotoxin (BTX) to label the acetylcholine receptor clusters on muscle fibers. At P11, NMJs of 
the QL in SMA animals injected with AAV9-GFP display ~40% denervation in contrast to being 
fully innervated in WT mice (Figure 3.5). Moreover, while AAV9-SMN injection restored NMJ 
innervation of the QL to near normal levels, AAV9-STAS did not have any effect on NMJ 
denervation in SMA mice (Figure 3.5).  
Taken together, these results reveal that Stasimon selectively restores the number of 





Stasimon acts in proprioceptive neurons to improve sensory-motor synaptic 
transmission in SMA mice 
I sought to determine whether restoration of proprioceptive synapses on SMA motor 
neurons by AAV9-STAS resulted in functional improvement of sensory-motor neurotransmission, 
which is severely disrupted in SMA mice (Fletcher et al., 2017; Mentis et al., 2011). To do so, we 
used the spinal cord ex vivo preparation and determined the amplitude of the sensory-motor 
monosynaptic reflex in the L1 spinal segment by simultaneous stimulation of the L1 dorsal root 
and recording from the ventral root of WT and SMA mice at P11 (Mentis et al., 2011). The 
amplitude of the monosynaptic reflex was reduced by ~95% in SMA mice injected with AAV9-
GFP and robustly enhanced upon SMN restoration with AAV9-SMN (Figure 3.6A and 3.6C). 
When we analyzed SMA mice injected with AAV9-STAS, we identified two distinct physiological 
responses in approximately equal proportions: a group of AAV9-STAS mice that exhibited a 
robust improvement of the monosynaptic reflex comparable to that of AAV9-SMN-injected SMA 
mice (Figures 3.6A, 3.6C and 3.7A), and another group that did not show increased response 
relative to AAV9-GFP treated SMA mice (Figure 3.7A). There were no significant differences 
between the two groups of SMA mice treated with AAV9-STAS with regards to their body weight 
(Figure 3.7B), the levels of viral-mediated STAS mRNA overexpression in the spinal cord (Figure 
3.7C), or the number of proprioceptive synapses on SMA motor neurons (aggregated data are 
shown in Figure 3.4B and 3.4C) that could account for this observation. However, there was 
correlation with the motor performance of these SMA mice. We found that AAV9-STAS (R, 
righting) treated SMA mice that were able to right at the time of the assay (Figure 3.7D) had robust 
spinal reflex amplitudes (Figures 3.6A, 3.6C and 3.7A), while AAV9-STAS (NR, non-righting) SMA 
mice with poor righting ability (Figure 3.7D) had small amplitudes (Figure 3.7A). Moreover, the 
levels of exon 7-containing, full-length SMN2 mRNA were higher in the spinal cord of AAV9-STAS 
(R) relative to AAV9-STAS (NR) SMA mice (Figure 3.7E). A marked reduction of SMN2 exon 7 




which exacerbate disease progression (Bebee et al., 2012; Sahashi et al., 2012) likely by 
enhancing a negative feedback loop that suppresses exon 7 splicing (Jodelka et al., 2010; Ruggiu 
et al., 2012). Thus, the observed differences in the electrophysiological responses of AAV9-STAS 
treated mice might reflect a degree of heterogeneity in the underlying severity of the SMA 
phenotype. Nevertheless, these experiments suggest that AAV9-STAS-mediated restoration of 
proprioceptive synapses can result in functional improvement of sensory-motor 
neurotransmission that correlates with enhanced motor function in SMA mice.           
We next investigated NMJ function by stimulating motor axons in the L1 ventral root and 
recording the resultant compound muscle action potential (CMAP) in the QL muscle at P11. The 
CMAP of SMA mice injected with AAV9-GFP is strongly reduced compared to WT mice and 
significantly improved by AAV9-SMN injection (Figure 3.6B and 3.6D). AAV9-STAS-injected SMA 
mice did not show any improvement in the CMAP (Figure 3.6B and 3.6D), which was the case 
irrespective of their motor behavior or spinal reflex amplitudes at the time of the assay (Figure 
3.7F), and consistent with the lack of effects on NMJ innervation (Figure 3.5A and 3.5B). Thus, 
the effects of Stasimon are selective for proprioceptive sensory synapses in SMA mice. 
 To further dissect the Stasimon-dependent functional improvement of the sensory motor 
circuit, we first determined the cellular contribution of motor neurons and proprioceptive synapses 
to the amplitude of the monosynaptic reflex in SMA mice. To do so, we restored SMN selectively 
in either proprioceptive neurons (SMA+SMN (PV-Cre)) or motor neurons (SMA+SMN (ChAT-Cre)) 
of SMA mice using a conditional allele for Cre-dependent SMN restoration (Lutz et al., 2011). It 
has been previously demonstrated that this approach rescues the number and function of 
proprioceptive neurons in SMA+SMN (PV-Cre) mice and motor neuron survival in SMA+SMN 
(ChAT-Cre), respectively (Fletcher et al., 2017). Here, we found that motor neurons and 
proprioceptive neurons equally contribute to the reduction in the amplitude of the monosynaptic 
reflex of SMA mice (Figure 3.8A and 3.8C). To determine the reliability of neurotransmission of 




repetitive stimulation of the sensory dorsal root L1 with simultaneous recording of the ventral root 
at high frequency (10 Hz) and compared the monosynaptic amplitude of the 1st with the 5th 
stimulus as in previous studies (Fletcher et al., 2017; Simon et al., 2017). The ventral root 
amplitude following a single stimulus is the result of motor neuron activation and depends on the 
number and function of proprioceptive synapses and the number of motor neurons present. 
However, at higher stimulation frequencies (10Hz) the ventral root amplitude change depends 
only on the function of proprioceptive synapses since the number of synapses and the number of 
motor neurons is the same for the different sequential stimuli. We found a decrease of the 
monosynaptic amplitude of ~40% in WT and ~70% in SMA mice (Figure 3.8B and 3.8D), revealing 
higher synaptic depression in SMA mice likely due to impaired neurotransmission. While selective 
SMN restoration in motor neurons of SMA+SMN (ChAT-Cre) mice did not have any benefit, SMN 
expression in proprioceptive neurons of SMA+SMN (PV-Cre) mice reduced the synaptic 
depression of the monosynaptic reflex to WT levels (Figure 3.8B and 3.8D), confirming that this 
experimental approach distinguishes the presynaptic contribution of proprioceptive 
neurotransmission in SMA. Importantly, SMA mice injected with AAV9-STAS showed correction 
of synaptic depression to levels comparable to WT and AAV9-SMN treated SMA mice (Figure 
3.9A and 3.9B). Collectively, these results indicate that AAV9-STAS ameliorates SMN-dependent 
sensory-motor circuit deficits at least in part by improving synaptic transmission in proprioceptive 
neurons of SMA mice.  
 
Stasimon contributes to motor neuron degeneration in SMA mice 
Loss of motor neurons is a hallmark of SMA pathology (Burghes and Beattie, 2009; Groen 
et al., 2018; Tisdale and Pellizzoni, 2015) and I investigated whether Stasimon was implicated in 
this neurodegenerative process. To do so, I performed immunohistochemistry experiments and 
visualized motor neurons in the L1 and L5 spinal segments with antibodies against ChAT (Figure 




medial motor column (MMC) motor neurons at P11 (Figure 3.10C and 3.10D). Importantly, AAV9-
STAS corrected this loss of SMA motor neurons with an efficacy similar to AAV9-SMN (Figure 
3.10C and 3.10D).  
We recently showed that motor neuron death is caused by distinct, converging 
mechanisms of p53 activation in the SMND7 mouse model (Simon et al., 2017; Van Alstyne et al., 
2018a). To investigate whether Stasimon suppresses motor neuron death through the p53 
pathway, I first performed immunostaining against p53 and found no effects of AAV9-STAS on 
the number of p53+ L5 MMC motor neurons relative to AAV9-GFP treated SMA mice (Figure 
3.11A and 3.11B), consistent with p53 upregulation being dependent on dysregulation of Mdm2 
and Mdm4 alternative splicing (Van Alstyne et al., 2018a). Death of SMA neurons requires at least 
one other event converging on p53 that includes, but is not limited to, phosphorylation of p53 
serine 18 (Simon et al., 2017) – a  selective marker of degenerating SMA motor neurons. I found 
that AAV9-STAS significantly reduced the percentage of vulnerable L5 MMC motor neurons 
expressing phosphorylated p53S18 (p-p53S18) in SMA motor neurons (Figure 3.11C and 3.11D), 
consistent with Stasimon overexpression preventing SMA motor neuron death through 
modulation of p53 phosphorylation. Altogether, these experiments place Stasimon dysfunction 
upstream of the cascade of events driving phosphorylation of p53 and the subsequent process of 
motor neuron degeneration in SMA mice. 
 
Stasimon deficiency is sufficient to induce p53S18 phosphorylation 
Recent studies have shown that Stasimon is required for autophagy in cultured 
mammalian cells (Moretti et al., 2018; Morita et al., 2018; Shoemaker et al., 2019). There have 
been also reports of autophagy dysregulation in SMA (Custer and Androphy, 2014; Gonçalves et 
al., 2018; Periyakaruppiah et al., 2016; Piras et al., 2017; Rodriguez-Muela et al., 2018), 




defects in SMA pathogenesis. First, I established a stable NIH3T3 cell line (NIH3T3-StasRNAi) in 
which Stasimon mRNA levels are reduced by RNAi to ~10% of normal as monitored by RT-qPCR 
(Figure 3.12A). I then analyzed by Western blot the levels of the autophagy proteins p62 and LC3 
in WT and StasRNAi NIH3T3 cells under basal conditions and following autophagy induction with 
serum starvation or inhibition by Bafilomycin A1 treatment (Figure 3.12B). I found that the levels 
of p62 and lipidated LC3 (LC3-II) were moderately increased in Stasimon-deficient relative to WT 
cells, consistent with dysregulation of autophagy (Moretti et al., 2018; Morita et al., 2018; 
Shoemaker et al., 2019). However, Western blot analysis showed no changes in the levels of both 
p62 and LC3 in spinal cords from WT and SMA mice at P6 and P11 (Figure 3.12C and 3.12D). 
Additionally, I performed immunohistochemistry experiments to investigate p62 expression in L1 
motor neurons and proprioceptive neurons from L1 dorsal root ganglia (DRGs) of WT and SMA 
mice (Figure 3.13A and 3.13B), but did not find any major difference in the levels and localization 
of p62 induced by SMN deficiency in these disease-relevant neurons in vivo. These results 
suggest that autophagy dysregulation is unlikely to underlie the Stasimon-dependent deficits in 
the SMA motor circuit. 
Next, I sought to determine whether loss of Stasimon is sufficient to induce p53S18 
phosphorylation as suggested by the reduction of p-p53S18 in SMA motor neurons described 
above. I have previously shown that upregulation but not N-terminal phosphorylation of p53 in 
SMA motor neurons is due to dysregulation of Mdm2 and Mdm4 alternative splicing (Van Alstyne 
et al., 2018a). Therefore, I devised a cell-based assay to investigate the role of Stasimon 
deficiency on p-p53S18 phosphorylation following p53 anti-repression induced by modulation of 
Mdm2 and Mdm4 splicing (Figure 3.14A). To do so, I treated WT and StasRNAi NIH3T3 cells either 
with control morpholino oligonucleotides (MOs) or with splice-switching MOs that induce selective 
skipping of Mdm2 exon 3 and Mdm4 exon 7 (see Figure 2.12B and 2.12C) as previously reported 
(Van Alstyne et al., 2018a). I then performed immunofluorescence analysis and determined the 




with Mdm2/4 MOs induced strong stabilization and nuclear accumulation of p53 in nearly all WT 
and StasRNAi NIH3T3 cells (Figure 3.14B and 3.14C), while there was no detectable nuclear p53 
in cells treated with control MO. Importantly, I found that p53S18 was phosphorylated in nearly 80% 
of StasRNAi NIH3T3 cells treated with Mdm2/4 MOs (Figure 3.14D and 3.14E), while little if any p-
p53S18 was detected in all other treatment groups. These results show that Stasimon deficiency 
does not induce stabilization and nuclear accumulation of p53 in mammalian cells; however, loss 
of Stasimon is sufficient to induce N-terminal phosphorylation of p53 when converging with pre-
existing mechanisms of p53 upregulation, mechanistically paralleling the paradigm driving 
degeneration of SMA motor neurons. 
 
Stasimon-dependent p53S18 phosphorylation is mediated by p38 MAPK 
SMN deficiency has been shown to activate several kinases (Genabai et al., 2015; Kannan 
et al., 2018; Miller et al., 2015; Ng et al., 2015; Wu et al., 2011), including p38 MAPK that directly 
phosphorylates serine 18 of p53 (Toledo and Wahl, 2006; Vousden and Prives, 2009). Western 
blot analysis of p38 phosphorylation in WT and SMA spinal cord throughout disease progression 
showed a significant increase in p38 activation in SMA mice at P6 (Figure 3.15). Therefore, to 
gain insight into the mechanisms of Stasimon-mediated p53 phosphorylation, I investigated the 
potential involvement of the p38 MAPK pathway. First, I analyzed the effects of MW150 – a highly 
selective inhibitor of the a isoform of p38 MAPK (Roy et al., 2015; Watterson et al., 2013) – on 
phosphorylation of p53 induced by Stasimon deficiency in the NIH3T3 based model system 
(Figure 3.13A). To do so, NIH3T3-StasRNAi cells were cultured in the presence of vehicle (saline) 
or MW150 before addition of control and Mdm2/4 MOs followed by analysis of p53 expression 
and p53S18 phosphorylation by immunocytochemistry. Remarkably, while MW150 treatment did 
not affect the induction of p53 by Mdm2/4MOs (Figure 3.16A and B), it strongly suppressed the 




stimulated p38 MAPK activation in NIH3T3 cells as indicated by increased levels and nuclear 
accumulation of p38 MAPK phosphorylated at threonine 180 and tyrosine 182 (Figure 3.17) 
(Plotnikov et al., 2011). These results indicate that Stasimon deficiency induces p53S18 
phosphorylation through activation of p38a MAPK signaling. 
Next, I investigated whether p38a MAPK activation contributes to p53S18 phosphorylation 
in SMA motor neurons by taking advantage of the established permeability of MW150 (Roy et al., 
2019) in the central nervous system (CNS). I treated SMA mice daily by intra-peritoneal (IP) 
injection with either saline or 5mg/kg of MW150 – a dose previously demonstrated to effectively 
inhibit p38a MAPK in the CNS and to improve the phenotype of mouse models of neurological 
disease (Robson et al., 2018; Roy et al., 2015; Rutigliano et al., 2018; Zhou et al., 2017). 
Importantly, MW150 treatment robustly decreased the levels of p53S18 phosphorylation but not 
the induction of p53 in vulnerable L5 MMC SMA motor neurons relative to vehicle-treated SMA 
mice at P11 (Figure 3.18), directly linking p38a MAPK activation to the phosphorylation of p53S18 
in SMA motor neurons. 
 
Pharmacological inhibition of p38 MAPK prevents degeneration of SMA motor neurons 
I reasoned that p38a MAPK inhibition might have neuroprotective effects in SMA mice 
based on the suppression of p53 phosphorylation observed with MW150 treatment. To test this 
possibility, I treated SMA mice with daily IP injections of vehicle or MW150 (5mg/kg) and then 
determined the number of motor neurons relative to untreated WT mice at P11 by 
immunohistochemistry with anti-ChAT antibodies. Remarkably, I found that MW150 treatment 
was able to suppress the death of vulnerable L1 and L5 MMC motor neurons in SMA mice (Figure 
3.19). I also tested the effects of MW150 treatment on the number of VGluT1+ proprioceptive 
synapses on L1 motor neurons (Figure 3.20A and 3.20B) as well as on the percentage of NMJ 




for correction of either of these synaptic deficits in SMA mice treated with MW150 relative to 
vehicle-treated SMA mice. Importantly, MW150 enhanced motor function of SMA mice but did not 
affect weight or survival (Figure 3.21C-E). Furthermore, these effects occurred without altering 
SMN expression at the mRNA or protein level (Figure 3.21A and 3.21B). Together these results 
reveal a direct pathogenic contribution of p38a MAPK activation to p53-mediated motor neuron 
death and the robust neuroprotective effects of MW150 treatment in a mouse model of SMA. 
 
 3.3 Discussion 
Motor dysfunction in SMA involves integration of multiple pathogenic insults induced by 
SMN deficiency in distinct neurons of the motor circuit (Shorrock et al., 2019; Van Alstyne and 
Pellizzoni, 2016). SMN has key functions in several RNA pathways that control gene expression 
(Donlin-Asp et al., 2016; Li et al., 2014) and establishing causal links between dysregulation of 
downstream mRNA targets of SMN and SMA pathogenesis is fundamental for understanding 
disease mechanisms as well as identifying genes and pathways relevant for sensory-motor 
function that may also represent therapeutic targets. Here I show that AAV9-mediated Stasimon 
gene delivery improves motor function and corrects select pathogenic events in the motor circuit 
of SMA mice. Stasimon overexpression prevents the loss of proprioceptive synapses on somata 
and dendrites of SMA motor neurons with consequent functional improvement of sensory-motor 
neurotransmission that correlates with improved motor function. Stasimon restoration also 
rescues vulnerable SMA motor neurons from degeneration, which we have previously shown to 
involve distinct mechanisms of p53 activation including both upregulation as well as 
phosphorylation of the N-terminal TAD of p53 (Simon et al., 2017). Importantly, my results indicate 
that Stasimon dysfunction induced by SMN deficiency triggers a p38 MAPK-dependent signaling 
cascade that drives p53 phosphorylation and motor neuron death in SMA mice. Taken together, 




circuit of SMA mice. They also highlight also an unexpected link of Stasimon dysfunction with p38 
MAPK activation and p53-dependent mechanisms of neurodegeneration as well as a novel 
pharmacological approach for neuroprotection in SMA.  
 The finding that Stasimon restoration improves some but not all of the disease-related 
deficits in SMA mice supports the view that a composite set of defects involving SMN-dependent 
RNA splicing alterations in specific genes and possibly disruption of other RNA pathways 
contribute to SMA pathology. Stasimon was previously discovered as a U12-intron containing 
gene regulated by SMN whose dysfunction results in specific neuronal deficits in the motor circuit 
of Drosophila and zebrafish models of SMA (Lotti et al., 2012). Here, I reveal the contribution of 
Stasimon to SMA pathology in a mouse model that more accurately recapitulates genetic and 
phenotypic aspects of the human disease, establishing Stasimon as a disease-relevant target of 
SMN deficiency across evolution. Furthermore, as Stasimon expression is affected by U12 
splicing dysfunction induced by SMN deficiency (Doktor et al., 2017; Lotti et al., 2012), this study 
strengthens the proposed pathogenic role of minor splicing disruption and the identification of 
Stasimon as an effector of U12-dependent motor circuit deficits in SMA, expanding our 
understanding of the RNA-mediated mechanisms of the disease.  
Based on these findings and earlier genetic studies in SMA mice, it is plausible to draw 
conclusions with regard to the spatial contribution of Stasimon to motor circuit pathology (Figure 
3.22). On one hand, selective restoration of SMN in motor neurons indicated that induction of p53 
(Simon et al., 2017) and cell death (Fletcher et al., 2017; Gogliotti et al., 2012; Martinez et al., 
2012; McGovern et al., 2015) are cell autonomous, suggesting that the effects of AAV9-STAS on 
SMA motor neuron survival are mediated by Stasimon restoration in these cells. Consistent with 
this conclusion, both AAV9-STAS and p38 MAPK inhibition suppress p53 phosphorylation in SMA 
motor neurons. On the other hand, deafferentation is caused by the effects of SMN deficiency in 
proprioceptive neurons (Fletcher et al., 2017) and these results directly implicate Stasimon 




independent of p53 (Simon et al., 2017; Van Alstyne et al., 2018a) and that p38 MAPK inhibition 
does not improve deafferentation in SMA mice point to distinct pathogenic cascades downstream 
of Stasimon dysfunction in motor neurons and proprioceptive neurons. In agreement with the 
spatial requirement of SMN and Stasimon in the Drosophila motor circuit (Imlach et al., 2012; Lotti 
et al., 2012), the studies of synaptic depression further indicate that Stasimon acts in 
proprioceptive neurons to improve the function of sensory-motor synapses. Given that silencing 
proprioceptive neurotransmission alone does not induce synaptic loss (Fletcher et al., 2017; 
Mendelsohn et al., 2015), it is possible that synaptic dysfunction and deafferentation may result 
from disruption of distinct Stasimon-dependent events within proprioceptive neurons. These 
events are also different from those underlying the loss of NMJ synapses as indicated by the lack 
of improvement in neuromuscular innervation by Stasimon overexpression in SMA mice. Lastly, 
consistent with previous studies (Kim et al., 2017; Van Alstyne et al., 2018a), the protective effect 
of Stasimon on motor neuron survival but not NMJ innervation supports the view that these 
pathogenic hallmarks of SMA – while both originating in motor neurons – are mechanistically 
uncoupled.  
Based on previous studies in the SMND7 mouse model of SMA (Simon et al., 2017), we 
have proposed a model in which selective degeneration of vulnerable SMA motor neurons 
requires the convergence of p53 stabilization with one or more additional events, which include 
post-translational modifications of p53 such as phosphorylation of its N-terminal TAD that 
specifically direct the p53 response towards degeneration (Figure 3.18). In Chapter 2, I 
demonstrated that dysregulation of Mdm2 and Mdm4 alternative splicing induced by SMN 
deficiency underlies the upregulation but not the phosphorylation of p53 in SMA motor neurons 
(Van Alstyne et al., 2018a). Consistent with the proposed model, I also showed that these splicing 
events are necessary but not sufficient to induce motor neuron death in vivo (Van Alstyne et al., 
2018a), leaving open the question as to which downstream targets of SMN are involved in p53 




of p53S18 and rescue survival in SMA motor neurons in vivo together with the observation that 
Stasimon deficiency is sufficient to induce p38 MAPK-mediated p53S18 phosphorylation in vitro fill 
this knowledge gap, placing Stasimon dysfunction upstream of a p38 MAPK/p53-dependent 
neurodegenerative axis (Figure 3.22).  
SMN deficiency induces the activation of several kinases that have been implicated in the 
degeneration of SMA motor neurons (Genabai et al., 2015; Kannan et al., 2018; Miller et al., 2015; 
Ng et al., 2015) and are known to phosphorylate p53 (Toledo and Wahl, 2006; Vousden and 
Prives, 2009), including the stress-activated protein kinases JNK and p38 MAPK (Genabai et al., 
2015; Wu et al., 2011). It was recently suggested that loss of SMA motor neurons is not associated 
with JNK/c-Jun signaling (Pilato et al., 2019). Here, leveraging on the availability of MW150 – a 
highly selective, CNS-permeable inhibitor of p38a MAPK (Roy et al., 2015), I implicate a direct 
pathogenic contribution of p38 MAPK activation to p53-mediated motor neuron death in SMA 
mice. Furthermore, degeneration of SMA motor neurons requires phosphorylation of the N-
terminal TAD of mouse p53 at multiple residues beyond serine 18 (Simon et al., 2017), including 
serines 37 and 58 (corresponding to serines 33 and 46 of human p53) that are known to be 
phosphorylated by p38 MAPK (Toledo and Wahl, 2006). Although my data does not distinguish 
whether p38 MAPK phosphorylates p53 directly or through downstream kinases in SMA motor 
neurons, Stasimon dysfunction and p38 MAPK activation likely trigger some of these additional 
p53 modifications required for neurodegeneration. The lack of specific reagents prevents further 
analysis at this time. Future mechanistic studies are also needed to determine whether Stasimon 
deficiency and activation of p38 MAPK-dependent pathways are necessary and sufficient to drive 
SMA motor neuron death in the context of Mdm2- and Mdm4-mediated p53 upregulation.  
Recent studies have shown that Stasimon is an ER-resident, six-transmembrane pass 
protein that is essential for mouse embryonic development (Van Alstyne et al., 2018b) (see also 
Chapter 4) and functions in autophagy (Moretti et al., 2018; Morita et al., 2018; Shoemaker et al., 




disagreement as to whether this pathway is inhibited (Custer and Androphy, 2014; 
Periyakaruppiah et al., 2016; Rodriguez-Muela et al., 2018) or stimulated (Gonçalves et al., 2018; 
Piras et al., 2017) by SMN deficiency. Therefore, while autophagy inhibition has been shown to 
ameliorate the phenotype of SMA mice by blocking p62-mediated SMN degradation (Rodriguez-
Muela et al., 2018),  it remains to be established whether autophagy defects directly contribute to 
SMA pathology. I found no evidence for overt autophagy dysregulation in the spinal motor circuit 
of SMA mice, suggesting that the Stasimon-dependent effects in these neurons might be 
mediated by disruption of other cellular functions. To this regard, Stasimon is enriched at ER-
mitochondrial contact sites (Van Alstyne et al., 2018b) (see also Chapter 4), which are implicated 
in a variety of biological processes beyond autophagy that are important for neuronal physiology 
and disease (Paillusson et al., 2016). Elucidation of the specific cellular deficits underlying 
Stasimon-dependent motor circuit pathology in SMA will require greater knowledge of the full 
breadth of Stasimon functions. It will also need to integrate previous, seemingly unrelated findings 
linking dysregulation of endocytosis (Ackermann et al., 2013; Hosseinibarkooie et al., 2016; 
Janzen et al., 2018; Riessland et al., 2017) and UBA1/GARS-dependent pathways (Shorrock et 
al., 2018) to the loss of SMA proprioceptive synapses into a coherent model. 
In summary, my work identifies Stasimon as a determinant of defective synaptic 
connectivity and function in the SMA sensory-motor circuit as well as an upstream trigger of a 
signaling cascade that feeds into p53 and the motor neuron cell death pathway through p38 MAPK 
activation. Moreover, MW150 is in early stage clinical trials for disorders where p38a MAPK-
mediated pathways are part of pathophysiology progression and our findings argue for future 











Figure 3.1. AAV9-mediated Stasimon gene delivery does not change SMN levels. (A) RT-
qPCR analysis of full-length human SMN (SMN FL), GFP, and human STAS mRNAs in the 
spinal cord of SMA mice injected with AAV9-GFP, AAV9-STAS or AAV9-SMN as well as 
uninjected WT mice at P11. Data represent mean and SEM. n=6. Statistics were performed with 
one-way ANOVA with Tukey’s post hoc test. (***) P < 0.001; (ns) no significance. (B) Western 
blot analysis of SMN protein levels in the spinal cord of AAV9-injected SMA mice and uninjected 












Figure 3.2. AAV9-mediated Stasimon gene delivery does not correct SMN-dependent 
splicing changes. (A-D) RT-qPCR analysis of aberrantly spliced Stasimon mRNA (A), 3ʹ end-
extended histone H1c mRNA (B), and total Cdkn1a (C) and Chodl (D) mRNAs in the spinal cord 
at P11 from SMA mice injected with AAV9-GFP, AAV9-STAS or AAV9-SMN as well as uninjected 
WT mice. Schematics of the RNA processing events monitored in the assay are shown at the top. 
Data represent mean and SEM. n ≥ 4. Statistics were performed with one-way ANOVA with 










Figure 3.3. AAV9-mediated Stasimon gene delivery improves motor behavior in SMA mice. 
(A-C) Righting time (A), weight gain (B) and Kaplan-Meyer analysis of survival (C) of uninjected 
(n = 10) and AAV9-STAS-injected (n = 10) WT mice as well as SMA mice injected with AAV9-

















Figure 3.4. AAV9-STAS rescues the loss of proprioceptive synapses on SMA motor 
neurons. (A) Immunostaining of VGluT1+ synapses (green) and ChAT+ motor neurons (blue) in 
L1 spinal cord sections from SMA mice injected with AAV9-GFP, AAV9-STAS or AAV9-SMN as 
well as uninjected WT mice at P11. Scale bar = 50 µm. Lower panels show a magnified view of 
VGluT1 synaptic density on proximal dendrites, scale bar = 10 µm. (B) Number of VGluT1+ 
synapses on the somata of L1 motor neurons from the same groups as in (A) at P11. Data 
represent mean and SEM from WT (n = 22), SMA+AAV9-GFP (n = 35), SMA+AAV9-STAS (n = 
32) and SMA+AAV9-SMN (n = 21). Statistics were performed with one-way ANOVA with Tukey’s 
post hoc test. (**) P < 0.01; (***) P < 0.001. (C) Density of VGluT1+ synapses on the proximal 
dendrites of L1 motor neurons from the same groups as in (A) at P11. Two dendritic compartments 
were defined based on distance from the soma. Number of dendrites scored from the 0-50 µm 
compartment: WT (n = 27), SMA+AAV9-GFP (n = 21), SMA+AAV9-STAS (n = 20) and 
SMA+AAV9-SMN (n = 15). Number of dendrites scored from the 50-100 µm compartment: WT (n 
= 12), SMA+AAV9-GFP (n = 14), SMA+AAV9-STAS (n = 10) and SMA+AAV9-SMN (n = 8). Data 
represent mean and SEM. Statistics were performed with one-way ANOVA with Tukey’s post hoc 







Figure 3.5. AAV9-STAS does not rescue NMJ denervation. (A) NMJ staining with bungarotoxin 
(BTX, red), synaptophysin (Syp, green), and neurofilament (NF-M, blue) of QL muscles from SMA 
mice injected with AAV9-GFP, AAV9-STAS or AAV9-SMN as well as uninjected WT mice at P11. 
Scale bar = 15 µm. (B) Percentage of fully denervated NMJs in the QL muscle from the same 
groups as in (A) at P11. Data represent mean and SEM. n = 5. Statistics were performed with 












Figure 3.6. AAV9-STAS improves the spinal reflex in SMA mice. (A) Representative traces of 
extracellular recordings from L1 ventral root (VR) following L1 dorsal root (DR) stimulation from 
SMA mice injected with AAV9-GFP, AAV9-STAS or AAV9-SMN as well as uninjected WT mice 
at P11. Arrows indicate the maximum amplitude of the monosynaptic reflex. Arrowheads indicate 
the stimulus artifact. Scale bars = 0.5 mV and 10 ms. (B) CMAP recordings from the QL muscle 
following L1 ventral root stimulation in the same groups as in (A) at P11. Arrows indicate maximum 
amplitude. Arrowheads indicate the stimulus artifact. Scale bars = 0.5 mV and 5 ms. (C) 
Quantification of spinal reflex amplitudes recorded from the same groups as in (A) at P11. Data 
represent mean and SEM. n ≥ 4. Statistics were performed with one-way ANOVA with Tukey’s 
post hoc test. (***) P < 0.001. (D) Quantification of M response amplitudes recorded from the QL 
muscle in the same groups as in (A) at P11. Data represent mean and SEM. n ≥ 3. Statistics were 













Figure 3.7. Comparison of parameters between AAV9-STAS righting and non-righting SMA 
mice. (A) Quantification of spinal reflex amplitudes recorded from SMA mice injected with AAV9-
STAS that were either righting (R) or non-righting (NR) at P11. Data represent mean and SEM. n 
= 4. Statistics were performed with two-tailed unpaired Student’s t-test. (**) P < 0.01. (B) Body 
weight in the same groups as in (A) at P11. Data represent mean and SEM. n = 4. Statistics were 
performed with two-tailed unpaired Student’s t-test. (ns) no significance. (C) RT-qPCR analysis 
of human STAS mRNA in spinal cords from the same groups as in (A). Data represent mean and 
SEM. n = 3. Statistics were performed with two-tailed unpaired Student’s t-test. (ns) no 
significance. (D) Righting time in the same groups as in (A) at P11. Data represent mean and 
SEM. n = 4. Statistics were performed with two-tailed unpaired Student’s t-test. (*) P < 0.05. (E) 
RT-qPCR analysis of human full-length SMN2 (SMN2 FL) mRNA in spinal cords from the same 
groups as in (A). Data represent mean and SEM. n = 3. Statistics were performed with two-tailed 
unpaired Student’s t-test. (*) P < 0.05. (F) M response amplitudes recorded from the QL muscle 
in the same groups as in (A) at P11. Data represent mean and SEM. n = 3. Statistics were 









Figure 3.8. Increased synaptic depression of the monosynaptic reflex in SMA mice is due 
to proprioceptive neuron dysfunction. (A) Representative traces of extracellular recordings 
from L1 ventral root (VR) following L1 dorsal root (DR) stimulation from WT and SMA mice as well 
as SMA mice with selective SMN restoration in either proprioceptive neurons (PVCRE) or motor 
neurons (ChATCRE) at P11. Arrows indicate the maximum amplitude of the monosynaptic reflex. 
Arrowheads indicate the stimulus artifact. Scale bars = 0.5 mV and 10 ms. (B) Representative 
traces of the first (black) and fifth (red) ventral root (VR) responses recorded following stimulation 
of the homonymous L1 dorsal root (DR) at 10 Hz from WT and SMA mice as well as SMA mice 
with selective SMN restoration in either proprioceptive neurons (PVCRE) or motor neurons 
(ChATCRE) at P11. Arrows indicate the maximum amplitude of the monosynaptic reflex. 
Arrowheads indicate the stimulus artifact. Scale bars = 0.2 mV and 5 ms. (C) Quantification of 
spinal reflex amplitudes recorded from the same groups as in (A) at P11. Data represent mean 
and SEM. n ≥ 3. Statistics were performed with one-way ANOVA with Tukey’s post hoc test. (*) 
P < 0.05; (***) P < 0.001. (D) Quantification of amplitude changes in the monosynaptic reflex 
following 10 Hz stimulation from the same groups as in (A). Data represent mean and SEM. n ≥ 
5. Statistics were performed with two-way ANOVA with Tukey’s post hoc test. (*) P < 0.05; (**) P 









Figure 3.9. AAV9-SMN gene delivery improves synaptic transmission in proprioceptive 
neurons of SMA mice. (A) Representative traces of the first (black) and fifth (red) VR responses 
recorded at P11 following stimulation of the homonymous L1 DR at 10 Hz from SMA mice injected 
with AAV9-GFP, AAV9-STAS or AAV9-SMN as well as uninjected WT mice at P11. Scale bars = 
0.2 mV and 5 ms.  (B) Quantification of amplitude changes in the monosynaptic reflex following 
10 Hz stimulation from the same groups as in (B). Data represent mean and SEM. n ≥ 3. Statistics 











Figure 3.10. AAV9-STAS rescues vulnerable SMA motor neurons from degeneration. (A) 
ChAT immunostaining of L1 spinal cords from SMA mice injected with AAV9-GFP, AAV9-STAS 
or AAV9-SMN as well as uninjected WT mice at P11. Scale bar = 50 µm. (B) ChAT 
immunostaining of L5 spinal cords from the same groups as in (A) at P11. L5 MMC motor neurons 
are indicated by dotted circles and magnified in the insets. Scale bar = 125 µm. (C) Total number 
of L1 motor neurons in the same groups as in (A) at P11. Data represent mean and SEM from 
WT (n = 4), SMA+AAV9-GFP (n = 6), SMA+AAV9-STAS (n = 7) and SMA+AAV9-SMN (n = 6). 
Statistics were performed with one-way ANOVA with Tukey’s post hoc test. (*) P < 0.05; (**) P < 
0.01; (***) P < 0.001. (D) Total number of L5 MMC motor neurons in the same groups as in (A) at 
P11. Data represent mean and SEM from WT (n = 5), SMA+AAV9-GFP (n = 5), SMA+AAV9-
STAS (n = 7) and SMA+AAV9-SMN (n = 6). Statistics were performed with one-way ANOVA with 












Figure 3.11. AAV9-STAS decreases p53S18 phosphorylation in vulnerable SMA motor 
neurons. (A) ChAT (red) and p53 (green) immunostaining of L5 spinal cords from uninjected WT 
mice and SMA mice injected with AAV9-GFP or AAV9-STAS at P11. L5 MMC motor neurons are 
indicated by dotted circles and magnified in the insets. Scale bar = 100 µm. (B) Percentage of 
p53+ L5 MMC motor neurons in the same groups as in (A). Data represent mean and SEM from 
WT (n = 5), SMA+AAV9-GFP (n = 5) and SMA+AAV9-STAS (n = 5). Statistics were performed 
with one-way ANOVA with Tukey’s post hoc test. (***) P < 0.001; (ns) no significance. (C) ChAT 
(red) and p-p53S18 (green) immunostaining of L5 spinal cords from the same groups as in (A). L5 
MMC motor neurons are indicated by dotted circles and magnified in the insets. Scale bar = 100 
µm. (D) Percentage of p-p53S18+ L5 MMC motor neurons in the same groups as in (A). Data 
represent mean and SEM from WT (n = 4), SMA+AAV9-GFP (n = 5) and SMA+AAV9-STAS (n = 











Figure 3.12. Analysis of autophagy in Stasimon-deficient NIH3T3 cells and SMA mice. (A) 
RT-qPCR analysis of Stasimon mRNA levels in WT and StasRNAi NIH3T3 cells. Data represent 
mean and SEM. n = 3. Statistics were performed with two-tailed unpaired Student’s t-test. (**) P 
< 0.01. (B) Western blot analysis of the autophagy markers p62 and LC3 in WT and StasRNAi 
NIH3T3 cells that were either untreated or treated with Bafilomycin A1 and serum starvation as 
indicated. (C) Western blot analysis of p62 and LC3 in spinal cords of WT and SMA mice at P6. 
Three biological replicates per groups are shown. (D) Western blot analysis of p62 and LC3 in 








Figure 3.13. Analysis of autophagy in SMA motor neurons and proprioceptive neurons. (A) 
Immunostaining of L1 DRGs from WT and SMA mice at P11 with p62 (green) and PV (red). Nuclei 
were counterstained with DAPI (blue). Scale bar = 25 μm. (B) Immunostaining of L1 spinal cords 
from WT and SMA mice at P11 with p62 (green) and ChAT (red). Nuclei were counterstained with 












Figure 3.14. Stasimon deficiency is sufficient to induce p53S18 phosphorylation in NIH3T3 
cells. (A) Schematic of the experimental design. NIH3T3 cells (WT or StasRNAi) were treated either 
with control MOs or with splice-switching antisense MOs targeting the 5ʹ splice sites of Mdm2 
exon 3 and Mdm4 exon 7. Nuclear accumulation of p53 and p-p53S18 was then assessed by 
immunofluorescence analysis. (B) Immunofluorescence analysis of total p53 (green) in WT and 
StasRNAi NIH3T3 cells treated with the indicated MOs. Nuclei were counterstained with DAPI (blue). 
Scale bar = 25 µm. (C) Percentage of p53+ NIH3T3 cells from the same treatment groups as in 
(B). Data represent mean and SEM. n ≥ 3. Statistics were performed with two-tailed unpaired 
Student’s t-test. (ns) no significance. (D) Immunofluorescence analysis of p-p53S18 (green) in WT 
and StasRNAi NIH3T3 cells treated with the indicated MOs. Nuclei were counterstained with DAPI 
(blue). Scale bar = 25 µm. (E) Percentage of p-p53S18+ NIH3T3 cells from the same treatment 
groups as in (D). Data represent mean and SEM. n ≥ 3. Statistics were performed with two-tailed 










Figure 3.15. p38 MAPK is activated in the spinal cord of SMA mice. (A) Western blot analysis 
of spinal cord from wild-type and SMA mice at P1. (B) Quantification of p-p38 levels normalized 
to total p38 levels as in (A). n = 3. Statistics were performed with two-tailed unpaired Student’s t-
test. (ns) no significance. (C) Western blot analysis of spinal cord from wild-type and SMA mice 
at P6. (B) Quantification of p-p38 levels normalized to total p38 levels as in (C). n = 3. Statistics 
were performed with two-tailed unpaired Student’s t-test. (*) P < 0.05 (E) Western blot analysis of 
spinal cord from wild-type and SMA mice at P11. (F) Quantification of p-p38 levels normalized to 
total p38 levels as in (E).  n = 3. Statistics were performed with two-tailed unpaired Student’s t-











Figure 3.16. Stasimon-dependent p53S18 phosphorylation is mediated by p38a MAPK. (A) 
Immunofluorescence analysis of total p53 (green) in NIH3T3-StasRNAi cells treated either with 
vehicle or with MW150 and the indicated MOs. Nuclei were counterstained with DAPI (blue). 
Scale bar = 25 µm. (B) Percentage of p53+ NIH3T3-StasRNAi cells from the same treatment groups 
as in (A). Data represent mean and SEM. n = 3. Statistics were performed with two-tailed unpaired 
Student’s t-test. (ns) no significance. (C) Immunofluorescence analysis of p-p53S18 (green) in 
NIH3T3-StasRNAi cells treated either with vehicle or with MW150 and the indicated MOs. Nuclei 
were counterstained with DAPI (blue). Scale bar = 25 µm. (D) Percentage of p-p53S18+ NIH3T3-
StasRNAi cells from the same treatment groups as in (C). Data represent mean and SEM. n = 3. 







Figure 3.17. Stasimon deficiency induces p38 MAPK activation in NIH3T3 cells. (A-B) 
Immunostaining of NIH3T3 WT, StasRNAi and WT UV-treated with 60 mJ/cm2 cells with antibodies 
against total (A) and phosphorylated (B) p38 MAPK. Note that p38 MAPK redistributes from the 
cytoplasm to the nucleus following activation by phosphorylation. (C) Western blot analysis of the 
levels of total and phosphorylated p38 MAPK in WT, StasRNAi, and WT+UV NIH3T3 cells. Two-








Figure 3.18.  p38a MAPK inhibition prevents p53 phosphorylation in vulnerable SMA motor 
neurons. (A) ChAT (red) and p53 (green) immunostaining of P11 L5 spinal cords from uninjected 
WT mice and SMA mice treated daily either with saline or with MW150 (5mg/kg). L5 MMC motor 
neurons are indicated by dotted circles and magnified in the insets. Scale bar = 100 µm. (B) 
Percentage of p53+ L5 MMC motor neurons in the same groups as in (A). Data represent mean 
and SEM from WT (n = 4), SMA+Vehicle (n = 4) and SMA+MW150 (n = 4). Statistics were 
performed with one-way ANOVA with Tukey’s post hoc test. (***) P < 0.001; (ns) no significance. 
(C) ChAT (red) and p-p53S18 (green) immunostaining of P11 L5 spinal cords from uninjected WT 
mice and SMA mice treated daily either with saline or with MW150 (5mg/kg). L5 MMC motor 
neurons are indicated by dotted circles and magnified in the insets. Scale bar = 100 µm. (D) 
Percentage of p-p53S18+ L5 MMC motor neurons in the same groups as in (C). Data represent 
mean and SEM from WT (n = 4), SMA+Vehicle (n = 4) and SMA+MW150 (n = 4). Statistics were 









Figure 3.19. Pharmacological inhibition of p38a MAPK prevents degeneration of SMA 
motor neurons. (A) ChAT immunostaining of P11 L1 spinal cords from uninjected WT mice and 
SMA mice treated daily either with saline or with MW150 (5mg/kg). Scale bar = 50 µm. (B) Total 
number of L1 motor neurons in the same groups as in (A) at P11. Data represent mean and SEM 
from WT (n = 6), SMA+Vehicle (n = 5) and SMA+MW150 (n = 3).  Statistics were performed with 
one-way ANOVA with Tukey’s post hoc test. (*) P < 0.05; (***) P < 0.001. (C) ChAT 
immunostaining of P11 L5 spinal cords from the same groups as in (A). L5 MMC motor neurons 
are indicated by dotted circles and magnified in the insets. Scale bar = 125 µm. (D) Total number 
of L5 MMC motor neurons in the same groups as in (A) at P11. Data represent mean and SEM 
from WT (n = 6), SMA+Vehicle (n = 6) and SMA+MW150 (n = 5).  Statistics were performed with 






Figure 3.20. Pharmacological inhibition of p38a MAPK does not improve synaptic 
connectivity in SMA. (A) Immunostaining of VGluT1+ synapses (grey) and ChAT+ motor neurons 
(blue) in P11 L1 spinal cords from uninjected WT mice and SMA mice treated daily either with 
saline or with MW150 (5mg/kg). Scale bar = 20 µm. (B) Number of VGluT1+ synapses on the 
somata of L1 motor neurons from the same groups as in (A) at P11. Data represent mean and 
SEM from WT (n = 39), SMA+Vehicle (n = 39) and SMA+MW150 (n = 36). Statistics were 
performed with one-way ANOVA with Tukey’s post hoc test. (***) P < 0.001; (ns) no significance. 
(C) NMJ staining with bungarotoxin (BTX, red), synaptophysin (Syp, green), and neurofilament 
(NF-M, blue) of P11 QL muscles from uninjected WT mice and SMA mice treated daily either with 
saline or with MW150 (5mg/kg). Scale bar = 25 µm. (D) Percentage of fully denervated NMJs in 
the QL muscle from the same groups as in (C) at P11. Data represent mean and SEM. n = 3. 











Figure 3.21. p38MAPK inhibition improves motor behavior in SMA mice. (A) RT-qPCR 
analysis of full-length human SMN2 (SMN2FL) in the spinal cord of mice from vehicle or MW150 
injected SMA mice and uninjected WT controls at P11. n ³ 5. Statistics were performed with one-
way ANOVA with Tukey’s post hoc test. (***) P < 0.001; (ns) no significance. (B) Western blot 
analysis of SMN protein levels in the spinal cord of mice from the same groups as (A). (C-E) 
Righting time (C), Weight gain (D), and Kaplan-Meyer analysis of survival (E) of uninjected (n = 
10) WT mice as well as SMA mice injected daily with saline (n = 10) or with MW150 (5mg/kg) (n 








Figure 3.22. Dual contribution of Stasimon to sensory-motor circuit pathology in SMA. Stasimon 
dysfunction induced through impairments in the minor spliceosomal machinery leads to p53 
phosphorylation through the activation of p38a MAPK which is a key activating mechanism driving 
SMA motor neuron degeneration. This phosphorylation converges with p53 upregulation induced 
by U2 dependent dysregulation of Mdm2 and Mdm4 alternative splicing. Additionally, Stasimon 
also plays a spatially distinct role in proprioceptive neurons where it mediated the loss of excitatory 





Stasimon localizes to mitochondria-associated ER membranes and is 
essential for mouse embryonic development4 
 
4.1 Introduction 
Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder caused by 
ubiquitous reduction in the levels of the survival motor neuron (SMN) protein (Tisdale and 
Pellizzoni, 2015). SMN is part of a protein complex that functions in the assembly of 
ribonucleoproteins required for pre-mRNA splicing (Tisdale and Pellizzoni, 2015), and SMN-
dependent splicing dysregulation of specific genes has been causally linked to select pathogenic 
events in animal models of SMA (Lotti et al., 2012; Van Alstyne et al., 2018a). The study of 
proximal target genes of SMN deficiency that contribute to the SMA phenotype affords unique 
opportunities to discover novel aspects of basic neurobiology as well as disease mechanisms.  
 A prominent example is Stasimon (also known as Tmem41b), a novel gene we discovered 
as a target of splicing dysfunction induced by SMN deficiency in both cellular and animal models 
of SMA (Lotti et al., 2012). Functional studies showed that Stasimon is normally required for 
synaptic transmission in motor circuit neurons that provide excitatory drive to motor neurons in 
Drosophila larvae as well as for motor axon outgrowth during zebrafish development (Lotti et al., 
2012). Importantly, not only does its loss of function elicit neuronal phenotypes that mirror aspects 
of SMN deficiency in vivo (Imlach et al., 2012; Lotti et al., 2012), but Stasimon restoration corrects 
neurotransmission deficits in the motor circuit of Drosophila SMN mutants and aberrant motor 
neuron development in SMN-deficient zebrafish embryos (Lotti et al., 2012). These studies 
provided first proof-of-concept causally linking the defective splicing of a gene with important 
                                               
4  This chapter is adapted from an article I co-authored entitled “Stasimon localizes to mitochondria-
associated ER membranes and is essential for mouse embryonic development”, Biochemical and 





neuronal functions to specific phenotypic consequences of SMN deficiency in animal models of 
SMA. However, the localization and function of Stasimon as well as its requirement in the 
mammalian system remain poorly understood. 
Stasimon is a ubiquitously expressed gene with particularly high levels in the Drosophila 
and mouse central nervous system (CNS) that encodes an evolutionarily conserved protein 
containing six transmembrane domains (Lotti et al., 2012). Here, I investigated the Stasimon 
interactome and found a network of interactions with cellular components of the endomembrane 
system and in particular, with the endoplasmic reticulum (ER), mitochondria, and the COPI vesicle 
trafficking machinery (Beck et al., 2009). Importantly, I also found that Stasimon is an ER-resident 
protein that localizes at specialized sites of juxtaposition between ER and mitochondria known as 
mitochondria-associated ER membranes (MAM) (Herrera-Cruz and Simmen, 2017). Lastly, 
analysis of novel knockout mice showed that Stasimon is an essential gene required for mouse 




Stasimon associates with the ER, mitochondria and the COPI complex 
I sought to identify proteins associated with human STASIMON (hereafter abbreviated as 
STAS) by proteomic approaches. To do so, we performed anti-GFP immunoprecipitation 
experiments using cell extracts from HEK293 transfected with either N-terminally tagged GFP-
STAS or GFP alone as well as untransfected cells as negative controls followed by SDS-PAGE 
and silver staining (Figure 4.1A). This analysis revealed the association of several proteins with 
GFP-STAS but not GFP, the identity of which was then determined by LC-MS/MS. I identified 152 
proteins that were found specifically in GFP-STAS immunoprecipitates but not in control 
immunoprecipitates with GFP alone (Table 4.1). Bioinformatics analysis of the STAS interactome 




prominently features components of ER and mitochondria (Figure 4.2). This was further confirmed 
by gene ontology search that revealed strong enrichment for the endomembrane system and 
membrane organelles such as ER and mitochondria (Figure 4.1C). Additionally, all the subunits 
(COPA, COPB1, COPB2, COPD, COPG1, COPG2, COPE) of the COPI complex involved in 
vesicle coating for trafficking from Golgi to ER were among the most enriched proteins in the GFP-
STAS immunoprecipitates (Figures 4.1C and 4.2). To validate the proteomics results, we 
performed co-immunoprecipitation experiments with GFP and GFP-STAS expressed in HEK293 
cells followed by Western blot analysis and confirmed the association of STAS with select, 
representative components of the ER (ERLIN2), mitochondria (VDAC1) and COPI complexes 
(COPA and COPB1) (Figure 4.1B). SMN was used as a negative control and, as expected, was 
not found in GFP-STAS immunoprecipitates (Figure 4.1B). Collectively, these experiments 
indicate that STASIMON associates with ER and mitochondria proteins as well as components of 
the COPI vesicle trafficking machinery. 
 
 
Stasimon localizes to mitochondria-associated membranes 
To further elucidate the relationship with ER and mitochondria, we sought to determine the 
subcellular localization of STASIMON using biochemical fractionation of these membrane 
organelles. Given that antibodies which detect endogenous levels of STASIMON could not be 
found, we relied on the analysis of HEK293 cells transfected with GFP or GFP-STAS followed by 
Western blot analysis. To validate the accuracy of the fractionation procedure, we tested the 
distribution of known markers of subcellular compartments such as TUBULIN (cytoplasm), SDHA 
(mitochondria), and ERLIN2 (ER and MAM), all of which displayed their expected distribution 
(Figure 4.3A). Remarkably, while GFP was found only in the soluble cytoplasmic fraction, GFP-
STAS was prominently associated with ER-containing fractions (Figure 4.3A). Furthermore, GFP-
STAS was particularly enriched in the ER fractions associated with mitochondria, including the 




was not found in purified mitochondria (Figure 4.3A). Consistent with its role in retrograde vesicle 
trafficking from Golgi to ER (Brandizzi and Barlowe, 2013), the COPI complex subunit COPA was 
found in the cytoplasmic and ER fractions but not in the MAM. 
Next, I investigated Stasimon localization in mammalian cells by immunofluorescence 
analysis. To do so, I transiently transfected mouse NIH3T3 fibroblasts with GFP-tagged mouse 
Stasimon as well as mCherry-Calnexin to mark the ER, and then carried out triple-label 
immunostaining experiments with antibodies against GFP, mCherry and mitochondria as 
previously described (Hirabayashi et al., 2017). Confocal microscopy analysis showed striking co-
localization of GFP-Stas with mCherry-Calnexin but not mitochondria (Figure 4.3B). To gain 
further insight into the localization of Stasimon with respect to ER and mitochondria, I performed 
super-resolution imaging by SIM microscopy followed by 3D reconstruction (Figure 4.3C and 
4.3D). Remarkably, these experiments revealed that GFP-Stas localizes at the contact sites 
between the ER and mitochondria, which is also consistent with its enrichment in biochemically 
purified MAM fractions. 
Taken together, these experiments identify Stasimon as a novel ER-resident 
transmembrane protein that localizes to the specific lipid-raft-rich ER domains at contact sites 
with the outer mitochondria membrane. 
 
Stasimon knockout causes early lethality during mouse embryonic development 
 To study Stasimon in mouse models, I analyzed a knockout allele that was generated by 
insertion of a lentiviral gene trap vector in the first intron of the Stasimon gene (Figure 4.4A), which 
is expected to be a complete loss of function. Although detailed phenotypic analysis was not 
performed, heterozygous Stas mice harboring one copy of this allele are viable and fertile. 
Importantly, while heterozygous crosses yielded the expected 2 to 1 ratio of heterozygotes to WT 
mice, they failed to produce any homozygous knockout offspring (Figure 4.4B), revealing an 




determine the time of embryonic lethality associated with Stasimon ablation. I performed analysis 
at several stages during mouse gestation and was able to identify Stasimon knockout embryos in 
the expected Mendelian ratio at ~E8.5, but not at later stages (Figure 4.4C). Stasimon knockout 
in E8.5 embryos was confirmed at the molecular level by both genotyping (Figure 4.4D) and 
mRNA analysis (Figure 4.4E), which showed that knockout embryos do not express Stasimon 
mRNA, while heterozygotes express approximately 50% of WT mRNA levels (Figure 4.4E). Lastly, 
morphological assessment of E8.5 embryos showed that Stasimon knockout embryos were 
developmentally arrested at around E7.5 (Figure 4.4F). These studies demonstrate that Stasimon 
is an essential gene whose ablation causes embryonic lethality at the post-implantation stage of 
mouse development.  
 
4.3 Discussion 
In this chapter, I report three main findings that are supported by a combination of 
biochemistry, proteomics, high-resolution microscopy and mouse genetics data: i) the association 
of Stasimon with ER, mitochondria and the COPI vesicle trafficking machinery; ii) the identification 
of Stasimon as a novel ER-resident transmembrane protein that localizes at specialized 
membrane contact sites between ER and mitochondria known as MAM; and iii) the essential 
requirement of Stasimon for mouse embryonic development (Figure 4.5). Collectively, these 
findings provide new insights into Stasimon biology and highlight the importance that further 
studies on this protein may yield for understanding MAM function, membrane trafficking and 
neurodegenerative disease mechanisms. 
Investigation of the Stasimon interactome uncovered a network of associations implicating 
biological pathways central to the functions of ER and mitochondria, and subsequent analysis 
highlighted its localization to the ER. Recently, unbiased genome-wide screens for regulators of 
autophagy identified Stasimon as an ER-resident protein required for autophagosome formation 




Our independent work agrees with and significantly expands these observations, showing for the 
first time that Stasimon is specifically localized to the specialized MAM compartment at the 
interface between the ER and mitochondria membranes. While these ER-mitochondria contact 
sites can serve as a source of membranes during early stages of autophagosome formation 
(Hailey et al., 2010; Hamasaki et al., 2013) – consistent with a role for Stasimon in autophagy 
(Moretti et al., 2018; Morita et al., 2018) – the MAM is a multifunctional site involved in several 
additional key cellular processes (Marchi et al., 2014; Wu et al., 2018). The close juxtaposition at 
the MAM facilitates cross-talk between the organelles enabling phospholipid transfer and the rapid 
exchange of calcium, thereby playing a critical role in the maintenance of lipid homeostasis and 
regulation of calcium levels, which can have compounding impact on mitochondrial health and 
bioenergetics (Raturi and Simmen, 2013; van Vliet et al., 2014). Therefore, Stasimon could have 
broader impact on the maintenance of MAM integrity or function and potentially play a role in 
additional cellular processes beyond autophagy, which are regulated by these ER-mitochondria 
contacts. Importantly, there has been increasing evidence for a potential role of MAM dysfunction 
in neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease among 
others (Area-Gomez and Schon, 2017; Paillusson et al., 2016). Evidence of autophagy and 
proteostasis impairment as well as mitochondrial dysfunction in SMA models has also been 
reported (Chaytow et al., 2018), but MAM dysregulation has not yet been implicated in these 
deficits. In light of Stasimon’s link to SMA pathology (Lotti et al., 2012), the emerging role in 
autophagy (Moretti et al., 2018; Morita et al., 2018), and the localization to the MAM that I report 
here, further characterization of Stasimon’s biology in mouse models may unravel unanticipated 
links with MAM-associated biological processes and with both development and disease of motor 
circuits. 
A prominent feature of the Stasimon interactome is the multisubunit COPI complex, the 
association of which I further confirmed biochemically and is also consistent with results of a 




(KXKXX), a canonical consensus sequence for COPI binding enabling retrieval of ER-resident 
proteins by retrograde transport (Brandizzi and Barlowe, 2013). Upon fractionation, COPA is 
mostly cytoplasmic and partially overlaps with Stasimon in the ER, but not in the mitochondria-
associated ER membranes. It is therefore plausible, although yet to be experimentally validated, 
that the Stasimon and COPI interaction is physically and functionally distinct from those in which 
Stasimon engages at the MAM (Figure 4.5). Interestingly, COPI has previously been implicated 
in SMA pathology and COPA overexpression has been shown to correct motor axon deficits 
induced by SMN deficiency in zebrafish embryos (Li et al., 2015), analogous to the requirement 
for Stasimon in this model system (Lotti et al., 2012). While a current model proposes that COPI 
role in SMA involves direct binding to SMN (Li et al., 2015), the identification of Stasimon 
association with COPI provides an alternative view that may reconcile these seemingly unrelated 
experimental observations. 
Here, I demonstrate that Stasimon is an essential gene required for mouse embryonic 
development as ablation induces early developmental arrest. These findings reveal that complete 
loss of Stasimon is not simply lethal to all cells, but halts the progression of mouse embryogenesis 
during a post-implantation phase likely comprised between E7.5 and E8.5 as inferred from the 
aberrant morphology of E8.5 knockout embryos. Although embryonic lethality is consistent with 
its ubiquitous expression, Stasimon’s high levels of expression in the CNS also suggest a key 
role in neurons, consistent with its requirement for motor circuit function (Lotti et al., 2012). 
Unfortunately, the early embryonic lethality associated with constitutive Stasimon knockout 
precludes direct evaluation of its requirement for development and function of the mouse motor 
system, and calls for the development of conditional knockout mice.  
In the future, the study of the spatial and temporal requirement for Stasimon in vivo, 
combined with further molecular characterization of its functions is likely to yield new fundamental 
insights into the biology of ER-mitochondria contacts, autophagy and membrane trafficking in 











Figure 4.1. Characterization of the Stasimon interactome. (A) Silver staining of GFP-Trap 
immunoprecipitates from HEK293 cells either untransfected (Control) or transfected with GFP 
and GFP-STAS. 10% of the material used for mass spectrometry is shown (B) Western blot 
analysis of GFP-Trap immunoprecipitates from HEK293 cells expressing GFP or GFP-STAS. 
Total represents 5% of the protein input. (C) Gene Ontology (GO) analysis of the most enriched 
cellular compartments associated with the specific proteins identified in GFP-STAS 














Figure 4.2. Functional protein association network of specific proteins identified in GFP-
STAS immunoprecipitates using STRING. Protein components of mitochondria (blue), ER (red) 















Figure 4.3. Stasimon is an ER-resident protein that localizes to the MAM. (A) Western blot 
analysis of the subcellular localization of GFP and GFP-STAS following biochemical fractionation 
of transiently transfected HEK293 cells. Equal amounts (20 µg) of proteins for each fraction were 
analyzed. (B) Confocal imaging of NIH3T3 cells co-transfected with GFP-Stas and mCherry-Canx 
and immunostained with antibodies for dsRed, GFP and a cocktail of mitochondrial oxidative 
phosphorylation proteins (mitochondria). Scale bar = 10 µm. (C) Super-resolution 3D SIM 
microscopy of NIH3T3 cells immunolabeled as in (B). A single plane image of all three channels 
and a merged image are shown. Scale bar = 0.2 µm. (D) 3D reconstruction of SIM microscopy 
images from (C). Arrowheads indicate GFP-Stas localization at ER-mitochondria contacts. Scale 











Figure 4.4. Stasimon is essential for mouse embryonic development. (A) Schematic of the 
Tmem41bGt(OST208407)Lex  knockout allele of the Stasimon gene. The location of genotyping primers 
across the insertion site in intron 1 and on the gene-trap vector are shown. (B) Ratio and number 
of mice with the indicated genotypes observed at postnatal day 1 (P1) from crosses of Stasimon 
heterozygous mice. (C) Ratio and number of E8.5 embryos with the indicated genotypes from 
crosses of Stasimon heterozygous mice. (D) Genomic PCR of wild-type (WT) and knockout (KO) 
alleles from E8.5 embryos of the indicated genotypes. (E) RT-qPCR of Stasimon mRNA levels 
normalized to Gapdh mRNA expression in E8.5 embryos of the indicated genotypes. Data 
represent mean and SEM. n = 3. Statistics were performed with one-way ANOVA with Tukey’s 
post hoc test. (***) P < 0.001. (F) Images of E8.5 embryos of the indicated genotypes. Scale bars 






















Figure 4.5. Stasimon is a component of the endomembrane system and localizes at 











Table 4.1. Proteins identified by mass spectrometry analysis of GFP and GFP-STAS 
immunoprecipitates with GFP-Trap from HEK293 cells. 








Isoform 2 of Coatomer subunit alpha COPA sp|P53621-2|COPA_HUMAN (+1) 139 0 280 
DNA-dependent protein kinase catalytic subunit PRKDC sp|P78527|PRKDC_HUMAN 469 0 150 
Coatomer subunit beta COPB1 sp|P53618|COPB_HUMAN 107 0 131 
Cluster of Coatomer subunit beta' COPB2 
(sp|P35606|COPB2_HUMAN) sp|P35606|COPB2_HUMAN [3] 102 0 119 
Cluster of Dolichyl-diphosphooligosaccharide--protein 
glycosyltransferase subunit 1 RPN1 (sp|P04843|RPN1_HUMAN) sp|P04843|RPN1_HUMAN 69 0 118 
Isoform 2 of Mitochondrial inner membrane protein IMMT sp|Q16891-2|IMMT_HUMAN (+3) 83 0 104 
Voltage-dependent anion-selective channel protein 1 VDAC1 sp|P21796|VDAC1_HUMAN 31 0 96 
Cluster of Monocarboxylate transporter 1 SLC16A1 
(sp|P53985|MOT1_HUMAN) 
sp|P53985|MOT1_HUMAN [2] 54 0 93 
Very-long-chain (3R)-3-hydroxyacyl-[acyl-carrier protein] 
dehydratase 3 PTPLAD1 sp|Q9P035|HACD3_HUMAN 43 0 86 
Cluster of Isoform 1 of Voltage-dependent anion-selective 
channel protein 2 VDAC2 (sp|P45880-1|VDAC2_HUMAN) sp|P45880-1|VDAC2_HUMAN [5] 33 0 85 
Transmembrane protein 41B TMEM41B sp|Q5BJD5|TM41B_HUMAN 33 0 79 
Lamin-B1 LMNB1 sp|P20700|LMNB1_HUMAN 66 0 68 
Coatomer subunit gamma-2 COPG2 sp|Q9UBF2|COPG2_HUMAN 98 0 60 
Coatomer subunit delta ARCN1 sp|P48444|COPD_HUMAN (+1) 57 0 59 
Cluster of Ubiquitin-40S ribosomal protein S27a RPS27A 
(sp|P62979|RS27A_HUMAN) sp|P62979|RS27A_HUMAN [3] 18 0 55 
D-3-phosphoglycerate dehydrogenase PHGDH sp|O43175|SERA_HUMAN 57 0 52 
Cluster of ADP/ATP translocase 2 SLC25A5 
(sp|P05141|ADT2_HUMAN) 
sp|P05141|ADT2_HUMAN [3] 33 0 51 
Isoform 2 of 4F2 cell-surface antigen heavy chain SLC3A2 sp|P08195-2|4F2_HUMAN (+5) 58 0 51 
Neutral amino acid transporter B(0) SLC1A5 sp|Q15758|AAAT_HUMAN 57 0 50 
Cluster of Calnexin CANX (tr|B4DGP8|B4DGP8_HUMAN) tr|B4DGP8|B4DGP8_HUMAN 72 0 49 
Coatomer subunit gamma-1 COPG1 sp|Q9Y678|COPG1_HUMAN 98 0 42 
Exportin-1 XPO1 sp|O14980|XPO1_HUMAN 123 0 41 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit 2 RPN2 sp|P04844|RPN2_HUMAN 69 0 39 
Prohibitin-2 PHB2 sp|Q99623|PHB2_HUMAN (+1) 33 0 38 
Transitional endoplasmic reticulum ATPase VCP sp|P55072|TERA_HUMAN 89 0 37 
Nucleolin NCL sp|P19338|NUCL_HUMAN 77 0 34 
Phosphate carrier protein, mitochondrial SLC25A3 sp|Q00325|MPCP_HUMAN 40 0 33 
Cluster of Heat shock protein HSP 90-beta HSP90AB1 
(sp|P08238|HS90B_HUMAN) sp|P08238|HS90B_HUMAN [2] 83 0 32 
Prohibitin PHB sp|P35232|PHB_HUMAN (+2) 30 0 30 
Isoform 2 of Surfeit locus protein 4 SURF4 sp|O15260-2|SURF4_HUMAN (+2) 18 0 29 
Translational activator GCN1 GCN1L1 sp|Q92616|GCN1L_HUMAN 293 0 27 
Isoform 2 of ATPase family AAA domain-containing protein 3A 
ATAD3A sp|Q9NVI7-2|ATD3A_HUMAN (+1) 66 0 27 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit STT3A STT3A sp|P46977|STT3A_HUMAN 81 0 26 
Isoform 2 of Minor histocompatibility antigen H13 HM13 sp|Q8TCT9-2|HM13_HUMAN (+3) 47 0 25 
Transmembrane protein 43 TMEM43 sp|Q9BTV4|TMM43_HUMAN 45 0 24 
Transmembrane 9 superfamily member 3 TM9SF3 sp|Q9HD45|TM9S3_HUMAN 68 0 24 
Cluster of Isoform 2 of Transportin-1 TNPO1 (sp|Q92973-
2|TNPO1_HUMAN) sp|Q92973-2|TNPO1_HUMAN [3] 101 0 23 
Leucine-rich PPR motif-containing protein, mitochondrial LRPPRC sp|P42704|LPPRC_HUMAN 158 0 23 
Cluster of Isoform XA of Plasma membrane calcium-transporting 
ATPase 3 ATP2B3 (sp|Q16720-2|AT2B3_HUMAN) 












Transmembrane protein 165 TMEM165 sp|Q9HC07|TM165_HUMAN 35 0 21 
7-dehydrocholesterol reductase DHCR7 sp|Q9UBM7|DHCR7_HUMAN 54 0 20 
PRA1 family protein 3 ARL6IP5 sp|O75915|PRAF3_HUMAN 22 0 20 
Exportin-5 XPO5 sp|Q9HAV4|XPO5_HUMAN 136 0 19 
Cluster of Ras-related protein Rab-8A RAB8A 
(sp|P61006|RAB8A_HUMAN) sp|P61006|RAB8A_HUMAN [8] 24 0 18 
Isoform 2 of Voltage-dependent anion-selective channel protein 3 
VDAC3 sp|Q9Y277-2|VDAC3_HUMAN (+2) 31 0 18 
Potassium-transporting ATPase alpha chain 1 ATP4A sp|P20648|ATP4A_HUMAN 114 0 18 
Cluster of Isoform 2 of Neutral alpha-glucosidase AB GANAB 
(sp|Q14697-2|GANAB_HUMAN) 
sp|Q14697-2|GANAB_HUMAN [3] 109 0 17 
Isoform 2 of GPI ethanolamine phosphate transferase 2 PIGG sp|Q5H8A4-2|PIGG_HUMAN (+2) 107 0 17 
Erlin-1 ERLIN1 sp|O75477|ERLN1_HUMAN 39 0 16 
Bifunctional glutamate/proline--tRNA ligase EPRS sp|P07814|SYEP_HUMAN 171 0 15 
Cluster of ATP-binding cassette sub-family D member 3 ABCD3 
(sp|P28288|ABCD3_HUMAN) 
sp|P28288|ABCD3_HUMAN [3] 75 0 15 
Cluster of Protein transport protein Sec61 subunit alpha isoform 1 
SEC61A1 (sp|P61619|S61A1_HUMAN) sp|P61619|S61A1_HUMAN [3] 52 0 15 
Isoform 3 of Apoptosis-inducing factor 1, mitochondrial AIFM1 sp|O95831-3|AIFM1_HUMAN (+1) 66 0 15 
Cluster of Isoform 2 of Zinc transporter ZIP14 SLC39A14 
(sp|Q15043-2|S39AE_HUMAN) sp|Q15043-2|S39AE_HUMAN [5] 53 0 15 
Cluster of Elongation factor 1-alpha 1 EEF1A1 
(sp|P68104|EF1A1_HUMAN) sp|P68104|EF1A1_HUMAN [3] 50 0 14 
Sodium/potassium-transporting ATPase subunit beta-3 ATP1B3 sp|P54709|AT1B3_HUMAN 32 0 14 
Large neutral amino acids transporter small subunit 1 SLC7A5 sp|Q01650|LAT1_HUMAN 55 0 13 
Elongation factor Tu, mitochondrial TUFM sp|P49411|EFTU_HUMAN 50 0 13 
Sterol O-acyltransferase 1 SOAT1 sp|P35610|SOAT1_HUMAN (+1) 65 0 13 
Serine palmitoyltransferase 1 SPTLC1 sp|O15269|SPTC1_HUMAN 53 0 13 
Isoform 2 of ER membrane protein complex subunit 1 EMC1 sp|Q8N766-2|EMC1_HUMAN (+2) 112 0 13 
Vesicle transport protein GOT1B GOLT1B sp|Q9Y3E0|GOT1B_HUMAN (+1) 15 0 13 
Erlin-2 ERLIN2 sp|O94905|ERLN2_HUMAN (+1) 38 0 13 
Isoform 2 of Calcium-binding mitochondrial carrier protein Aralar2 
SLC25A13 sp|Q9UJS0-2|CMC2_HUMAN (+1) 74 0 12 
Isoform 2 of Reticulon-4 RTN4 sp|Q9NQC3-2|RTN4_HUMAN 40 0 12 
Cluster of Putative Golgi pH regulator C GPR89C 
(sp|A6NKF9|GPHRC_HUMAN) sp|A6NKF9|GPHRC_HUMAN [4] 37 0 12 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
48 kDa subunit DDOST 
sp|P39656|OST48_HUMAN 51 0 11 
CAD protein CAD sp|P27708|PYR1_HUMAN (+1) 243 0 11 
Isoform 2 of Basigin BSG sp|P35613-2|BASI_HUMAN (+1) 29 0 11 
DnaJ homolog subfamily A member 1 DNAJA1 sp|P31689|DNJA1_HUMAN 45 0 11 
Heat shock protein 75 kDa, mitochondrial TRAP1 sp|Q12931|TRAP1_HUMAN (+1) 80 0 11 
Cluster of Nodal modulator 1 NOMO1 
(sp|Q15155|NOMO1_HUMAN) 
sp|Q15155|NOMO1_HUMAN 134 0 10 
Cluster of Transferrin receptor protein 1 TFRC 
(sp|P02786|TFR1_HUMAN) sp|P02786|TFR1_HUMAN 85 0 10 
Cluster of Heterogeneous nuclear ribonucleoprotein U HNRNPU 
(sp|Q00839|HNRPU_HUMAN) 
sp|Q00839|HNRPU_HUMAN [2] 91 0 10 
Apolipoprotein B-100 APOB sp|P04114|APOB_HUMAN 516 0 10 
Importin-7 IPO7 sp|O95373|IPO7_HUMAN 120 0 10 
Fanconi anemia group I protein FANCI sp|Q9NVI1|FANCI_HUMAN 149 0 10 
Cluster of Delta(24)-sterol reductase DHCR24 
(sp|Q15392|DHC24_HUMAN) 
sp|Q15392|DHC24_HUMAN [2] 60 0 10 
High affinity cationic amino acid transporter 1 SLC7A1 sp|P30825|CTR1_HUMAN 68 0 10 
Isoform B of Probable cation-transporting ATPase 13A1 ATP13A1 sp|Q9HD20-2|AT131_HUMAN (+1) 121 0 9 
Isoform 2 of Lysophospholipid acyltransferase 7 MBOAT7 sp|Q96N66-2|MBOA7_HUMAN 
(+1) 












Cluster of Rab-like protein 3 RABL3 (sp|Q5HYI8|RABL3_HUMAN) sp|Q5HYI8|RABL3_HUMAN 26 0 9 
Sorting and assembly machinery component 50 homolog 
SAMM50 sp|Q9Y512|SAM50_HUMAN 52 0 9 
Isoform 2 of Stomatin-like protein 2, mitochondrial STOML2 sp|Q9UJZ1-2|STML2_HUMAN (+1) 33 0 9 
Sodium-dependent multivitamin transporter SLC5A6 sp|Q9Y289|SC5A6_HUMAN 69 0 9 
Isoform 3 of Transportin-3 TNPO3 sp|Q9Y5L0-3|TNPO3_HUMAN (+2) 103 0 9 
Phosphatidate cytidylyltransferase 2 CDS2 sp|O95674|CDS2_HUMAN 51 0 9 
Lamin-B receptor LBR sp|Q14739|LBR_HUMAN 71 0 8 
Transmembrane emp24 domain-containing protein 10 TMED10 sp|P49755|TMEDA_HUMAN 25 0 8 
Protein spinster homolog 1 (Fragment) SPNS1 tr|H3BR82|H3BR82_HUMAN 57 0 8 
Cluster of 40S ribosomal protein S27 RPS27 
(sp|P42677|RS27_HUMAN) 
sp|P42677|RS27_HUMAN 9 0 8 
Mitochondrial Rho GTPase 2 RHOT2 sp|Q8IXI1|MIRO2_HUMAN (+1) 68 0 8 
Cytochrome b-c1 complex subunit 2, mitochondrial UQCRC2 sp|P22695|QCR2_HUMAN 48 0 7 
Exportin-T XPOT sp|O43592|XPOT_HUMAN 110 0 7 
Isoform 2 of Multidrug resistance-associated protein 1 ABCC1 sp|P33527-2|MRP1_HUMAN (+8) 165 0 7 
Isoform 2 of Myb-binding protein 1A MYBBP1A sp|Q9BQG0-2|MBB1A_HUMAN 
(+1) 
149 0 7 
Sideroflexin-1 SFXN1 sp|Q9H9B4|SFXN1_HUMAN (+1) 36 0 7 
E3 ubiquitin-protein ligase AMFR AMFR sp|Q9UKV5|AMFR_HUMAN (+1) 73 0 7 
Stress-70 protein, mitochondrial HSPA9 sp|P38646|GRP75_HUMAN 74 0 6 
AFG3-like protein 2 AFG3L2 sp|Q9Y4W6|AFG32_HUMAN 89 0 6 
60S ribosomal protein L7 RPL7 sp|P18124|RL7_HUMAN 29 0 6 
Long-chain-fatty-acid--CoA ligase 3 ACSL3 sp|O95573|ACSL3_HUMAN 80 0 6 
Isoform 2 of 26S protease regulatory subunit 8 PSMC5 sp|P62195-2|PRS8_HUMAN (+1) 45 0 6 
Cleft lip and palate transmembrane protein 1 CLPTM1 sp|O96005|CLPT1_HUMAN (+1) 76 0 6 
Malectin MLEC sp|Q14165|MLEC_HUMAN 32 0 6 
Cytochrome c oxidase subunit 2 MT-CO2 sp|P00403|COX2_HUMAN 26 0 6 
Isoform 2 of NADH-ubiquinone oxidoreductase 75 kDa subunit, 
mitochondrial NDUFS1 sp|P28331-2|NDUS1_HUMAN 81 0 5 
Nuclear pore complex protein Nup205 NUP205 sp|Q92621|NU205_HUMAN 228 0 5 
Protein-S-isoprenylcysteine O-methyltransferase ICMT sp|O60725|ICMT_HUMAN 32 0 5 
Phosphatidylserine synthase 1 PTDSS1 sp|P48651|PTSS1_HUMAN 56 0 5 
Isoform 2 of DnaJ homolog subfamily C member 11 DNAJC11 sp|Q9NVH1-2|DJC11_HUMAN (+4) 59 0 5 
Isoform 2 of Nucleoporin NUP188 homolog NUP188 sp|Q5SRE5-2|NU188_HUMAN (+1) 182 0 5 
Phosphatidylserine synthase 2 PTDSS2 sp|Q9BVG9|PTSS2_HUMAN 56 0 5 
Feline leukemia virus subgroup C receptor-related protein 1 
FLVCR1 
sp|Q9Y5Y0|FLVC1_HUMAN 60 0 5 
Gem-associated protein 4 GEMIN4 sp|P57678|GEMI4_HUMAN (+1) 120 0 5 
Insulin receptor substrate 4 IRS4 sp|O14654|IRS4_HUMAN 134 0 4 
NADH-cytochrome b5 reductase 3 CYB5R3 sp|P00387|NB5R3_HUMAN 34 0 4 
T-complex protein 1 subunit zeta CCT6A sp|P40227|TCPZ_HUMAN (+1) 58 0 4 
Nuclear pore membrane glycoprotein 210 NUP210 sp|Q8TEM1|PO210_HUMAN 205 0 4 
YTH domain-containing family protein 2 YTHDF2 sp|Q9Y5A9|YTHD2_HUMAN 62 0 4 
Isoform 2 of Fanconi anemia group D2 protein FANCD2 sp|Q9BXW9-2|FACD2_HUMAN 164 0 4 
Serine/threonine-protein phosphatase 2A 65 kDa regulatory 
subunit A alpha isoform PPP2R1A tr|B3KQV6|B3KQV6_HUMAN 46 0 4 
Isoform 2 of Structural maintenance of chromosomes protein 2 
SMC2 
sp|O95347-2|SMC2_HUMAN (+1) 125 0 4 
HEAT repeat-containing protein 1 HEATR1 sp|Q9H583|HEAT1_HUMAN (+1) 242 0 4 
Cytochrome b-c1 complex subunit 1, mitochondrial UQCRC1 sp|P31930|QCR1_HUMAN 53 0 4 
Glycerol-3-phosphate acyltransferase 4 AGPAT6 sp|Q86UL3|GPAT4_HUMAN 52 0 4 
Sodium- and chloride-dependent creatine transporter 1 SLC6A8 sp|P48029|SC6A8_HUMAN 71 0 4 
Isoform 2 of Importin-5 IPO5 sp|O00410-2|IPO5_HUMAN (+4) 117 0 4 
Isoform 2 of Calcium-binding mitochondrial carrier protein Aralar1 












26S proteasome non-ATPase regulatory subunit 2 PSMD2 sp|Q13200|PSMD2_HUMAN 100 0 3 
Sodium-dependent neutral amino acid transporter B(0)AT2 
SLC6A15 sp|Q9H2J7|S6A15_HUMAN 82 0 3 
Isoform 2 of Clathrin heavy chain 1 CLTC sp|Q00610-2|CLH1_HUMAN (+1) 188 0 3 
T-complex protein 1 subunit theta CCT8 sp|P50990|TCPQ_HUMAN 60 0 3 
Isoform 2 of PERQ amino acid-rich with GYF domain-containing 
protein 2 GIGYF2 
sp|Q6Y7W6-3|PERQ2_HUMAN 
(+5) 
152 0 3 
Importin-8 IPO8 sp|O15397|IPO8_HUMAN 120 0 3 
Isoform 3 of Coatomer subunit epsilon COPE sp|O14579-3|COPE_HUMAN (+2) 29 0 3 
ATP-dependent RNA helicase A DHX9 sp|Q08211|DHX9_HUMAN 141 0 3 
Cluster of HLA class I histocompatibility antigen, A-1 alpha chain 
HLA-A (sp|P30443|1A01_HUMAN) 
sp|P30443|1A01_HUMAN [2] ? 0 3 
Centromere/kinetochore protein zw10 homolog ZW10 sp|O43264|ZW10_HUMAN (+1) 89 0 3 
Transmembrane protein 115 TMEM115 sp|Q12893|TM115_HUMAN 38 0 3 
Transmembrane 9 superfamily member 1 TM9SF1 tr|E9PSI1|E9PSI1_HUMAN 92 0 3 
Isoform 2 of Adenosine 3'-phospho 5'-phosphosulfate transporter 
1 SLC35B2 
sp|Q8TB61-2|S35B2_HUMAN (+2) 43 0 3 
Cluster of Isoform 5 of MMS19 nucleotide excision repair protein 
homolog MMS19 (sp|Q96T76-8|MMS19_HUMAN) sp|Q96T76-8|MMS19_HUMAN 116 0 3 
Membrane-associated progesterone receptor component 1 
PGRMC1 sp|O00264|PGRC1_HUMAN 22 0 3 
Protein YIPF6 YIPF6 sp|Q96EC8|YIPF6_HUMAN 26 0 3 
Zinc finger ZZ-type and EF-hand domain-containing protein 1 
ZZEF1 
sp|O43149|ZZEF1_HUMAN 331 0 2 
T-complex protein 1 subunit gamma CCT3 sp|P49368|TCPG_HUMAN (+1) 61 0 2 
60S ribosomal protein L3 RPL3 sp|P39023|RL3_HUMAN (+2) 46 0 2 
Far upstream element-binding protein 2 KHSRP sp|Q92945|FUBP2_HUMAN 73 0 2 
Isoform 2 of 116 kDa U5 small nuclear ribonucleoprotein 
component EFTUD2 
sp|Q15029-2|U5S1_HUMAN (+2) 105 0 2 
Sulfhydryl oxidase 2 QSOX2 sp|Q6ZRP7|QSOX2_HUMAN 78 0 2 
26S protease regulatory subunit 7 PSMC2 sp|P35998|PRS7_HUMAN (+1) 49 0 2 
Cluster of Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 
ATP2A2 (sp|P16615|AT2A2_HUMAN) sp|P16615|AT2A2_HUMAN [11] 115 2 186 
60 kDa heat shock protein, mitochondrial HSPD1 sp|P10809|CH60_HUMAN 61 2 74 
Isoleucine--tRNA ligase, cytoplasmic IARS sp|P41252|SYIC_HUMAN (+1) 145 2 10 
Isoform 3 of Exportin-2 CSE1L sp|P55060-3|XPO2_HUMAN (+1) 108 3 33 
Importin subunit beta-1 KPNB1 sp|Q14974|IMB1_HUMAN 97 5 38 
Cluster of Heat shock 70 kDa protein 1A/1B HSPA1A 
(sp|P08107|HSP71_HUMAN) 
sp|P08107|HSP71_HUMAN [3] 70 8 54 
Cluster of Dermcidin DCD (sp|P81605|DCD_HUMAN) sp|P81605|DCD_HUMAN [2] 11 9 3 
Filaggrin-2 FLG2 sp|Q5D862|FILA2_HUMAN 248 10 8 
ATP synthase subunit beta, mitochondrial ATP5B sp|P06576|ATPB_HUMAN 57 11 114 
78 kDa glucose-regulated protein HSPA5 sp|P11021|GRP78_HUMAN 72 12 20 
Histone deacetylase 6 HDAC6 sp|Q9UBN7|HDAC6_HUMAN (+1) 131 18 4 
Cluster of Heat shock cognate 71 kDa protein HSPA8 
(sp|P11142|HSP7C_HUMAN) sp|P11142|HSP7C_HUMAN [3] 71 19 82 
Isoform 2 of ATP synthase subunit alpha, mitochondrial ATP5A1 sp|P25705-2|ATPA_HUMAN (+1) 54 20 69 
Cluster of Isoform 3 of Sodium/potassium-transporting ATPase 
subunit alpha-1 ATP1A1 (sp|P05023-3|AT1A1_HUMAN) 
sp|P05023-3|AT1A1_HUMAN [12] 110 21 194 
Cluster of Tubulin beta chain TUBB (sp|P07437|TBB5_HUMAN) sp|P07437|TBB5_HUMAN [7] 50 28 205 
Cluster of Tubulin alpha-1B chain TUBA1B 
(sp|P68363|TBA1B_HUMAN) sp|P68363|TBA1B_HUMAN [6] 50 30 231 
Hornerin HRNR sp|Q86YZ3|HORN_HUMAN 282 32 33 
Cluster of Albumin (sp|P02769|ALBU_BOVIN) sp|P02769|ALBU_BOVIN [2] 69 52 33 






Long-term AAV9-mediated SMN overexpression  
induces motor circuit dysfunction 
5.1 Introduction 
Spinal muscular atrophy (SMA) – the leading genetic cause of infant mortality – is an 
autosomal recessive disorder characterized by degeneration of motor neurons in the spinal cord 
and skeletal muscle atrophy (Burghes and Beattie, 2009; Tisdale and Pellizzoni, 2015). SMA 
patients have homozygous deletions or mutations in the survival motor neuron 1 (SMN1) gene 
and retain at least one copy of the nearly identical SMN2 gene (Burghes and Beattie, 2009; 
Tisdale and Pellizzoni, 2015). A single nucleotide difference functionally distinguishes SMN1 from 
SMN2 (Lorson et al., 1999; Monani et al., 1999), reducing the amount of exon 7 inclusion in the 
SMN mRNA transcribed from the SMN2 gene (Cartegni and Krainer, 2002; Kashima and Manley, 
2003), the skipping of which leads to a rapidly degraded form of the SMN protein (Burnett et al., 
2009; Cho and Dreyfuss, 2010; Lorson and Androphy, 2000). Therefore, the SMN2 gene 
produces only low levels of full-length SMN protein leading to SMA.  
The SMN protein functions in the assembly of small nuclear ribonucleoproteins (snRNPs) 
that carry out pre-mRNA splicing (Meister et al., 2001b; Pellizzoni et al., 2002b) and 3’-end 
processing of histone mRNAs (Pillai et al., 2003; Tisdale et al., 2013), and has also been 
implicated in the biology of other RNPs through less defined mechanisms (Donlin-Asp et al., 2017; 
Li et al., 2014). In recent years, greater knowledge of the central role of SMN in RNA regulation 
combined with deep characterization of animal models has significantly advanced our 
understanding of SMA pathogenesis (Shorrock et al., 2019; Tisdale and Pellizzoni, 2015; Van 
Alstyne and Pellizzoni, 2016), indicating that SMA could be the convergence of deficits in multiple 
RNA processing pathways induced by SMN deficiency (Lotti et al., 2012; Simon et al.; Van Alstyne 




is not limited to motor neurons, but rather involves dysfunction of motor circuits comprised of 
multiple neuronal subpopulations (Fletcher et al., 2017; Mentis et al., 2011) and possibly other 
cell types both within and outside the CNS (Hamilton and Gillingwater, 2013; Hua et al., 2011, 
2015).  
Therapeutic approaches for SMA have mainly focused on increasing expression of SMN 
through antisense oligonucleotides (ASO) (Hua et al., 2011; Porensky et al., 2012) or small 
molecules that correct SMN2 exon 7 splicing (Naryshkin et al., 2014; Palacino et al., 2015), as 
well as SMN replacement by gene therapy with adeno-associated AAV9 viral vectors (Dominguez 
et al., 2011; Foust et al., 2010; Passini et al., 2010; Valori et al., 2010), all of which have 
demonstrated efficacy in preclinical and clinical studies (Groen et al., 2018; Sumner and Crawford, 
2018; Van Alstyne and Pellizzoni, 2016). Repeated intrathecal injections of an SMN2 splicing-
modifying ASO (Spinraza, Biogen) have shown clinical benefit in SMA patients and been 
approved for treatment of severe and mild forms of the disease (Finkel et al., 2016, 2017; Mercuri 
et al., 2018). Furthermore, gene therapy via a single intravenous administration of AAV9-SMN 
(Zolgensma, Avexis/Novartis) was recently granted FDA approval for use in SMA patients prior 
to two years of age, and additional clinical trials are underway testing the safety and efficacy of 
intrathecal CNS delivery in clinically milder SMA patients (Mendell et al., 2017). Although it is well 
recognized that these treatments alone do not provide a complete cure for SMA (Sumner and 
Crawford, 2018), the recent approvals represent a milestone achievement for the SMA community 
and the neurodegenerative disease field altogether (Groen et al., 2018; Sumner and Crawford, 
2018). Unlike SMA therapeutics aimed at correcting splicing of endogenous SMN2, the potential 
for expression of SMN well beyond physiological levels is a unique feature associated with AAV9-
SMN gene therapy. Importantly, the biology of SMN overexpression is poorly understood and the 
long-term safety profile as well as potential for late-onset side effects of AAV9-SMN treatment in 




This study stemmed from my unexpected observation of toxicity associated with AAV9-
SMN gene delivery in mouse models and aimed to determine the underlying mechanisms. I found 
that long-term, AAV9-mediated overexpression of SMN leads to impairment in sensory-motor 
function of both wild-type and “rescued” SMA mice, affecting the same group of spinal motor 
circuit neurons that are particularly vulnerable to SMN deficiency in SMA. Furthermore, the 
exceedingly high levels of SMN in motor neurons and proprioceptive neurons associated with 
AAV9-SMN gene delivery induces aggregation and sequestration of Sm proteins in the cytoplasm 
interfering with snRNP biogenesis. Accordingly, RNA sequencing revealed widespread 
transcriptional abnormalities and RNA splicing changes in sensory neurons associated with 
AAV9-mediated SMN overexpression. These findings uncover a new facet of SMN biology and a 
previously unrecognized gain of toxic function induced by SMN overexpression which is of 
particular clinical relevance in light of current treatment of SMA patients with AAV9-SMN.  
 
 
5.2 Results  
AAV9-SMN induces late-onset motor dysfunction 
 AAV9-SMN has been shown to effectively rescue the SMA phenotype in mouse models 
(Bevan et al., 2010; Dominguez et al., 2011; Foust et al., 2010; Meyer et al., 2015; Passini et al., 
2010; Valori et al., 2010). Consistent with previous studies, I found strong improvement of several 
disease parameters of SMA mice following a one-time intracerebroventricular (ICV) delivery of a 
dose 5x1010vg/g of self-complementary AAV9-SMN driven by the GUSB promoter at P0 (Figure 
5.1). AAV9-SMN treated SMA mice show increased weight gain relative to AAV9-GFP treated 
SMA mice used as a negative control (Figure 5.1A). AAV9-SMN also greatly improves motor 
function of SMA mice as assessed by righting time (Figure 5.1B), and strongly extends the median 
survival relative to AAV9-GFP treated SMA mice from 14 days to 132 days (Figure 5.1C). 




hindlimb clasping phenotype (Figure 5.2A) – a neurological feature observed in mouse models of 
neurodegeneration such as Parkinson’s and Huntington’s disease (Carter et al., 1999; Lei et al., 
2014; Lieu et al., 2013; Mangiarini et al., 1996). AAV9-SMN treated SMA mice showed onset of 
this phenotype around four months of age which was not present in uninjected SMNΔ7 wild-type 
littermates (Figure 5.2A and 5.2B) and could not be assessed in SMA mice injected with AAV9-
GFP due to shortened survival (Figure 5.1C).  
To investigate potential toxicities associated with SMN overexpression without the 
confounding factors associated with an SMA model, I analyzed the long-term effects of AAV9-
mediated gene delivery in WT mice. I delivered AAV9-SMN by ICV injection in WT mice at P1 
using 4 two-fold escalating doses of 1.25x1010 vg/g (1.25), 2.5x1010 vg/g (2.5), 5x1010 vg/g (5), 
and 1x1011 vg/g (10), as well as 5x1010 vg/g of AAV9-GFP as a negative control. Remarkably, I 
found that AAV9-SMN but not AAV9-GFP selectively induced hindlimb clasping in a dose-
dependent manner in WT mice (Figure 5.2C and 5.2D). At doses in which hindlimb clasping was 
observed, the phenotype was fully penetrant in all treated animals (Figure 5.2D) and grew 
progressively more pronounced following initial onset. I also noted some premature deaths and 
reduced weight gain in WT mice treated with the highest dose of AAV9-SMN (Figure 5.3A and 
5.3B). 
To further dissect the deleterious effects of AAV9-SMN, I monitored the motor 
performance of WT mice that were untreated or injected with either AAV9-GFP or AAV9-SMN 
using additional assays. I performed the inverted grid assay to assess any deficits in grip and 
muscle strength and observed that WT mice treated with AAV9-SMN show dose-dependent, 
progressive impairment in performance relative to both uninjected and AAV9-GFP treated 
controls (Figure 5.3C). I also monitored motor coordination and endurance using the rotarod 
assay and again observed a progressive, dose-dependent decline in performance in AAV9-SMN 
injected WT mice (Figure 5.3D). In addition to effects in WT mice, I also monitored SMA mice 




“rescued” SMA mice are able to perform well on the rotarod during the time window analyzed, 
consistent with previous analysis (Valori et al., 2010), they never gain the ability to perform on the 
inverted grid assay (Figure 5.4A and B). 
Taken together, these results demonstrate that long-term AAV9-mediated SMN 
overexpression induces late-onset motor deficits in a dose-dependent manner in mouse models.  
 
AAV9-mediated SMN overexpression induces motor neuron deafferentation 
 To investigate the cellular basis of the motor deficits induced by AAV9-SMN, I analyzed the 
effects of long-term SMN overexpression on key neurons of the motor circuit. As hindlimb clasping 
is a characteristic neurological phenotype associated with dysfunction of proprioceptive neurons 
(Li et al., 2006; Taylor et al., 2001; Wang et al., 2007), we first performed functional analysis of 
the M-response and H-reflex by recording EMG activity from the interosseous muscle of the 
hindpaw of WT mice either uninjected or injected with AAV9-GFP or AAV9-SMN after sciatic nerve 
stimulation at low frequencies (Figure 5.5A-D). This analysis can reveal potential differences in 
proprioceptive synaptic function (H-amplitude) and motor neuron function (M-response), and 
calculation of the H/M ratio can determine whether either response is more affected. While there 
were no alterations in the amplitude of the M-response between the three groups, indicating no 
measurable synaptic impairment at the neuromuscular junction (NMJ) (Figure 5.5B), the 
amplitude of the H-reflex and the H/M ratio were significantly reduced in AAV9-SMN treated mice 
relative to controls (Figure 5.5C and 5.5D), providing evidence of proprioceptive synaptic 
dysfunction.  
Next, I quantified the proprioceptive synapses on L5 lateral motor column (LMC) motor 
neurons and found a strong reduction in the number of VGluT1+ synapses on both somata and 
proximal dendrites in AAV9-SMN injected mice relative to AAV9-GFP injected or uninjected WT 
mice that progressively worsened with aging (Figure 5.6). This loss was specific for VGluT1+ 




altered by AAV9-SMN (Figure 5.7A and B). Furthermore, quantification of the number of 
proprioceptive neurons in the L5 DRG showed a significant loss of parvalbumin (PV)+ neurons in 
AAV9-SMN injected WT mice relative to control at P300 (Figure 5.8). I also assessed the number 
of L5 LMC and MMC motor neurons that innervate hindlimb muscles involved in clasping and 
observed no changes (Figure 5.9). Lastly, I monitored innervation of the hindlimb extensor 
digitorum longus (EDL) muscle and found no effects of AAV9-SMN on NMJ innervation (Figure 
5.10). These results indicate that AAV9-mediated SMN overexpression in WT mice induces 
selective deafferentation of motor neurons and late degeneration of proprioceptive neurons. 
 Prompted by these findings, I sought to determine the status of motor circuit connectivity in 
AAV9-SMN treated SMA mice that might reflect the situation of severe SMA patients treated by 
gene therapy. SMA mice have multiple deficits throughout the motor circuit (Tisdale and Pellizzoni, 
2015), including motor neuron death, NMJ denervation, and the loss of proprioceptive inputs. 
Treatment with AAV9-SMN significantly improved all of these deficits when assessed at P11 as 
compared to AAV9-GFP treated SMA mice (Figures 5.11, 5.13, and 5.14) consistent with 
published studies (Dominguez et al., 2011; Foust et al., 2010; Passini et al., 2010). However, 
when I compared the number of proprioceptive synapses onto motor neuron somata in aged 
AAV9-SMN treated SMA mice relative to WT littermates (AAV9-GFP treated SMA mice could not 
be analyzed due to their short survival) I found that the VGluT1+ synapses that were robustly 
rescued at P11 showed a strong reduction by P190 (Figure 5.11). Unlike WT mice at P300 (Figure 
5.8A), however, there was no evidence of loss of proprioceptive neurons  in AAV9-SMN treated 
SMA mice at P190 (Figure 5.12). Moreover, the number of L2 motor neurons and the percentage 
of NMJ innervation in AAV9-SMN treated SMA mice did not change across time relative to control 
WT mice (Figures 5.13 and 5.14). Therefore, while the rescue of motor neuron number and NMJ 
denervation is maintained over time, proprioceptive inputs on motor neurons are initially restored, 




In sum, the selective deafferentation of motor neurons underlies AAV9-SMN induced 
sensory-motor toxicity in both WT and SMA mice.  
 
AAV9-SMN induces cytoplasmic aggregation in motor circuit neurons 
 To gain insight into the toxic mechanisms of long-term SMN overexpression in the motor 
circuit, I first assessed transgene expression over time in several relevant tissues after a single 
AAV9 injection in WT mice at P1 and SMA mice at P0. Immunohistochemistry showed strong 
GFP expression in motor neurons and proprioceptive neurons at both P11 and P300, indicating 
high transduction and prolonged expression in WT mice (Figure 5.15A). Further, the percent 
transduction at P300 is comparable to levels previously reported at P11 in motor neurons and 
proprioceptive neurons (Figure 5.15B-D) (Fletcher et al., 2017; Simon et al., 2017). In contrast to 
neurons, GFP expression is high and widespread at P11, but nearly absent by P300 in the liver, 
likely due to turnover of transduced cells (Figure 5.15A). These findings are further supported by 
both RNA (Figure 5.16) and protein (Figure 5.17) analysis showing that viral-mediated expression 
of both GFP and SMN in WT mice is greatly reduced in the liver, but not in the spinal cord and 
DRG at P300 relative to P11.  
Importantly, analysis of human SMN mRNA levels at P11 and P190 in SMA mice shows 
dramatic AAV9-mediated SMN overexpression that is maintained over time in neuronal tissue but 
lost in the liver (Figure 5.18). This was confirmed by protein analysis of tissue from SMA mice, 
which confirmed sustained high expression levels of GFP and SMN in the spinal cord but not the 
liver at late timepoints (Figure 5.19). Taken together, these results reveal that AAV9-mediated 
gene delivery leads to massive levels of prolonged overexpression in post-mitotic neuronal cells 
that are efficiently transduced, but is diluted over time in more regenerative tissue such as the 
liver. 
I then sought to analyze the subcellular distribution of SMN expressed by AAV9 over time. 




called Gems (Liu and Dreyfuss, 1996). This profile was observed in motor neurons and 
proprioceptive neurons from uninjected and AAV-GFP injected WT mice at all time points (Figures 
5.20, 5.21, and 5.22). Remarkably, I found that motor neurons and proprioceptive neurons from 
WT mice injected with AAV9-SMN show strong accumulation of SMN in cytoplasmic aggregates 
that grow larger and more spherical in appearance over time (Figures 5.20, and 5.21). SMN 
aggregates are widespread and present in over 85% of motor neurons and ~90% of 
proprioceptive neurons at P300 (Figures 5.20C, and 5.21C). Large cytoplasmic aggregates of 
SMN are also present in ~70% of motor neurons and ~80% of proprioceptive neurons from SMA 
mice injected with AAV9-SMN (Figure 5.22). Thus, AAV9-mediated overexpression of SMN is 
associated with its accumulation into large cytoplasmic aggregates that persist over time in motor 
circuit neurons. 
 
SMN overexpression disrupts snRNP biogenesis by sequestering Sm proteins in 
cytoplasmic aggregates 
To determine whether these SMN aggregates could exert toxic effects by trapping 
physiological substrates, I monitored SmB — one of the components of the Sm-core that is 
assembled on snRNAs by SMN in the cytoplasm prior to their nuclear import as snRNPs (Li et al., 
2014). Strikingly, in contrast to the expected nuclear localization which was observed in neurons 
from uninjected and AAV-GFP injected WT mice, I found that SmB was prominently accumulated 
in cytoplasmic aggregates in motor neurons and proprioceptive neurons of AAV9-SMN injected 
WT mice (Figures 5.23 and 5.24). Immunostaining in AAV9-SMN injected SMA mice revealed 
similar cytoplasmic redistribution of SmB in both motor neurons and proprioceptive neurons 
(Figure 5.25). Additionally, cytoplasmic aggregates of SmB in WT and SMA neurons from mice 
injected with AAV9-SMN show time-dependent increases in size similar to what was observed by 




proprioceptive neurons of WT mice injected with AAV9-SMN demonstrated their colocalization in 
cytoplasmic aggregates (Figure 5.26).  
Next, to determine whether sequestration of SmB in the cytoplasm was associated with 
an impairment in snRNP biogenesis, I quantified SmB nuclear intensity that can be used as a 
readout of nuclear snRNP levels and whose reduction is a feature of SMA motor neurons (Ruggiu 
et al., 2012; Tisdale and Pellizzoni, 2015; Van Alstyne et al., 2018a) (see also Figures 2.8 and 
2.9). Remarkably, I found that SmB levels in L5 LMC motor neurons and L5 DRG proprioceptive 
neurons were significantly reduced in AAV9-SMN injected mice relative to controls at P300 
(Figure 5.27), indicating that SMN overexpression affects the nuclear levels of snRNPs, likely as 
a result of impaired cytoplasmic assembly of Sm cores. 
To determine the selectivity of SmB sequestration in SMN aggregates, I next assessed 
the subcellular distribution of other factors that associate with SMN and/or are implicated in 
neuronally-relevant RNA pathways in motor neurons transduced by AAV9-SMN. I performed 
immunohistochemistry analysis of several RNA-binding proteins (RBPs): i) KSRP – a proposed 
interactor of SMN (Tadesse et al., 2008); ii) FUS – an ALS-linked gene that interacts with SMN 
and U1 snRNP (Gerbino et al., 2013; Groen et al., 2013; Mirra et al., 2017; Sun et al., 2015; 
Yamazaki et al., 2012); iii) hnRNPA1 – an RBP that shuttles between the nucleus and cytoplasm 
in association with mRNAs (Piñol-Roma and Dreyfuss, 1992) that has also been linked to ALS 
pathogenesis (Kim et al., 2013); and iv) HuR – an RBP that can regulate mRNA stability (Srikantan 
and Gorospe, 2012). All of these abundant RBPs showed their canonical nuclear staining and no 
cytoplasmic aggregation in AAV9-SMN transduced motor neurons (Figure 5.28A-D). I also 
performed immunostaining of Crm1 and Ran proteins to analyze the distribution of factors 
involved in RNA export including that of snRNAs (Fischer et al., 2011; Pellizzoni, 2007),  which 
showed no localization into cytoplasmic aggregates and normal appearance of the nuclear 
envelope (Figure 5.28E and 5.28F). To determine whether SMN aggregates were associated with 




P-bodies (Eystathioy et al., 2002, 2003) and stress granules (Eystathioy et al., 2003), respectively, 
and observed no overlap with SMN aggregates (Figure 5.28 G and H). Lastly, I also found that 
SMN aggregates are neither co-labeled by ubiquitin – a hallmark of protein aggregates in other 
neurodegenerative diseases (Eystathioy et al., 2003) – nor by the autophagic vesicles marker 
LC3B (Tanida et al., 2008), indicating that they are not actively engaged with  cellular pathways 
of protein degradation (Figure 5.28I and 5.28J). 
Taken together, these results indicate that AAV9-mediated long-term overexpression of 
SMN induces cytoplasmic aggregates of SMN that are highly selective and specifically sequester 
Sm-proteins, leading to a disruption of snRNP biogenesis and consequent reduction in the nuclear 
pool of spliceosomal snRNPs.  
 
AAV9-mediated SMN overexpression induces genome-wide RNA dysregulation in DRG 
neurons 
 In order to ascertain potential downstream consequences of overexpression and 
cytoplasmic aggregation SMN on gene expression, I sought to perform RNA-Seq analysis on 
relevant neurons. To do so, I collected lumbar DRGs from WT mice at P300 that were untreated 
or injected with either AAV9-GFP or AAV9-SMN at P1. I extracted total RNA from three 
independent biological replicates per experimental group and subjected them to deep-sequencing 
with the HiSeq 4000 platform at the Columbia Genome Center, which yielded about 80 million 
2x100 paired-end reads per sample, followed by bioinformatic analysis using the Quantas pipeline 
as previously described (Yan et al., 2015).  
Analysis of RNA processing identified a total of 405 high-confidence splicing changes 
(FDR<0,05; -0.1<dI>0.1) that are specifically induced by AAV9-SMN relative to both AAV9-GFP 
injected and uninjected WT mice (Figure 5.29A). Importantly, differentially spliced individual 
cassette exons (51%) as well as intron retention (18%) were the most common SMN-dependent 




changes in the inclusion of tandem cassette exons (10%) and mutually exclusive exons (3%) 
were also detected at lower frequency (Figure 5.29B). A detailed analysis of each type of splicing 
changes in the different experimental groups is shown in Figure 5.30. Closer inspection revealed 
that decreased inclusion of alternatively spliced cassette exons and increased retention of introns 
accounted for >75% of these types of splicing changes induced by SMN overexpression (Figure 
5.31), consistent with the expected effects of reduced snRNP availability on splicing (Hsieh et al., 
2019; Saltzman et al., 2011).  
RNA-seq analysis also revealed widespread transcriptome alterations associated with 
AAV9-SMN gene delivery while AAV9-GFP had essentially no effects at the mRNA level (Figure 
5.32). Among these changes, I identified 531 high-confidence differentially expressed mRNAs in 
DRGs of AAV9-SMN injected mice relative to both AAV9-GFP injected and uninjected WT mice 
(adjusted p<0,05; -1<Log2FC>1; 375 upregulated and 156 downregulated), while AAV9-GFP 
changed the expression levels of only 2 genes relative to uninjected WT controls (Figure 5.33A 
and 5.33B). By performing gene ontology analysis to identify cellular pathways particularly 
affected by AAV9-SMN dependent gene dysregulation, I found strong induction of genes 
associated with inflammation and the innate immune response (Figure 5.33C). Interestingly, I 
observed that AAV9-SMN induced significant upregulation of the mRNAs of all three subunits of 
the C1q complex (C1qa, C1qb and C1qc) as well as downregulation of Chondrolectin (Chodl) 
mRNA (Figure 5.34), which have previously been identified as downstream gene changes 
induced by SMN deficiency in mouse models of SMA (Bäumer et al., 2009; Wertz et al., 2016; 
Zhang et al., 2008; Zhang et al., 2013). 
Together, these results indicate that long-term AAV9-mediated SMN overexpression 
induces splicing dysregulation and widespread transcriptome alterations in neural tissue, 






The development of therapeutics for SMA have largely focused on alternative strategies 
to upregulate SMN expression, including the use of AAV9-mediated SMN gene therapy that has 
an intrinsic potential for inducing SMN beyond physiological levels. However, the biology of SMN 
overexpression is largely unknown. My findings provide direct evidence of toxicity induced by 
AAV9-mediated SMN gene delivery in the motor circuit of both WT and SMA mice that is 
associated with motor neuron deafferentation and degeneration of proprioceptive neurons. 
Sensory-motor toxicity is elicited by exceedingly high levels of SMN that accumulate over time in 
highly transduced, non-dividing motor and proprioceptive neurons and lead to inhibition of SMN’s 
normal activity in RNA regulation with consequent induction of SMA-like functional abnormalities 
through toxic gain of function mechanisms (Figure 5.35). Thus, I identify a paradoxical situation 
where a large excess of SMN and a deficiency of SMN both have prominent deleterious effects 
on the motor circuit, which likely act through the same molecular pathway involving impairment of 
snRNP biogenesis. The gain of toxic function of SMN overexpression is a newly identified aspect 
of SMN biology which has important clinical implications due to the use of AAV9-mediated gene 
delivery for SMA therapy in humans.  
 Here, I observe that long-term AAV9-mediated SMN overexpression leads to sensory-motor 
toxicity, which is driven at least in part by late-onset, progressive deafferentation of motor neurons 
that occurs in WT mice and in aged SMA mice treated with therapeutic doses of AAV9-SMN. 
Furthermore, AAV9-SMN is associated with degeneration of proprioceptive neurons in WT mice 
which is not observed in rescued SMA mice perhaps due to analysis being performed at an earlier 
timepoint or as a result of SMA mice having less basal levels of SMN and thus showing milder 
toxic effects. A recent study reported sensory deficits following systemic administration of an 
AAV9-like SMN vector in non-human primates and piglets (Hinderer et al., 2018), though whether 




assessed. I identify that sensory toxicity is strictly SMN-dependent as no effects are observed 
following GFP gene delivery. Other studies in transgenic mouse models expressing high levels of 
SMN or SMA mice treated with AAV9-SMN did not identify toxicities associated with SMN 
overexpression over relatively long time periods (Foust et al., 2010; Gavrilina et al., 2008; Meyer 
et al., 2015; Passini et al., 2010). However, in transgenic models the levels of SMN expression 
achieved in motor circuit neurons are much lower than those achieved with AAV9-SMN. In 
addition, prior AAV studies have lacked a detailed investigation of motor function or assessment 
of motor circuit connectivity at late timepoints, while focused primarily on extension in survival. 
Furthermore, pre-clinical pharmacology and safety studies in healthy animals have profiled AAV9 
transduction following systemic or CNS targeted delivery of AAV9-GFP (Bevan et al., 2011; Foust 
et al., 2009, 2010; Meyer et al., 2015), which would occlude the possibility of observing any SMN-
dependent toxicities. Acute toxicity following SMN gene delivery has been shown in pre-clinical 
studies to be associated with liver and heart pathology with doses two times above therapeutic 
levels proving lethal in mouse models (AveXis., 2019; Hinderer et al., 2018). Similarly, clinical 
trials have revealed liver-related toxicities in patients (AveXis., 2019; Mendell et al., 2017). 
Through the profiling of time-dependent changes in viral mediated transgene expression, I 
observe that high expression levels can be detected early in tissues such as the liver, but this is 
diluted due to turnover and expression is only maintained over long timeframes in post-mitotic 
neuronal tissues. Thus, in contrast to these known acute toxicities associated with high systemic 
doses of AAV9 in target organs such as the liver, my study is the first to characterize a different 
long-term toxicity that appears to be slow-progressing, neuron-specific and dependent on SMN 
overexpression which interferes with the synaptic connectivity of the motor circuit.  
 My findings show that AAV9-SMN induces progressive accumulation of SMN in cytoplasmic 
aggregates which sequester Sm-proteins, leading to a reduction in nuclear snRNP levels of 




SMN and AAV9-mediated SMN gene delivery have previously shown some evidence of 
cytoplasmic SMN aggregation in motor neurons (Gavrilina et al., 2008; Passini et al., 2010), 
though this has generally been considered benign. Characterization of SMN-induced toxicity 
necessitates reevaluation of the propensity of SMN to aggregate and how this leads to deleterious 
consequences on motor circuit neurons. SMN forms a large macromolecular complex with 
Gemins2-8 and Unrip (Pellizzoni, 2007; So et al., 2017) which is heterodisperse in nature 
reflecting the self-oligomerization properties of SMN (Lorson et al., 1998; Pellizzoni et al., 1999). 
It is conceivable that overexpression of SMN disrupts the normal balance of the complex in which 
it functions and the lack of stoichiometric amount of core binding partners along with SMN’s 
intrinsic ability to self-associate likely promotes accumulation of non-functional, cytoplasmic 
aggregates. This phenomenon is also reminiscent of a dominant negative SMN mutant which can 
sequester Sm-proteins and snRNAs in aggregates (Pellizzoni et al., 1998). Similarly, I observe 
that AAV9-SMN induced cytoplasmic aggregates of SMN sequester SmB protein, one of SMN’s 
normal physiological substrates of Sm core assembly whose direct interaction with SMN is 
enhanced by self-association (Pellizzoni et al., 1999). The pathogenic aggregation of RNA binding 
proteins has been implicated in numerous neurodegenerative diseases which can disrupt both 
RNA and protein homeostasis (Ling et al., 2013; Ramaswami et al., 2013). Importantly, SMN 
aggregates are devoid of other abundant RNA-binding proteins and SMN interactors, highlighting 
specificity and supporting a snRNP-dependent contribution towards toxicity. In line with this, I 
provide evidence that selective cytoplasmic sequestration of SmB is coincident with an 
impairment of SMN’s normal role in snRNP biogenesis leading to reduced steady-state levels of 
snRNPs in the nucleus of motor circuit neurons – a shared characteristic feature with SMA motor 
neurons (Ruggiu et al., 2012; Tisdale and Pellizzoni, 2015; Van Alstyne et al., 2018a) (see also 
Figures 2.8 and 2.9). Taken together, my results suggest a link between AAV9-mediated SMN 




Investigation of other therapeutic approaches for SMA such as small molecules and 
antisense oligonucleotides designed to correct SMN2 splicing have included transcriptome-wide 
analysis to evaluate specificity and off-target effects on gene regulation, which showed little if any 
impact on the mammalian transcriptome (Naryshkin et al., 2014; Sivaramakrishnan et al., 2017; 
Staropoli et al., 2015) Surprisingly, however, to my knowledge similar studies have never been 
performed in the context of AAV9-SMN gene delivery in animal models (Foust et al., 2010; Passini 
et al., 2010). In this study, I reveal widespread transcriptome alterations induced by AAV9-SMN 
in sensory neurons of WT mice. While I identify very few effects due to AAV9-GFP delivery, AAV9-
SMN is associated with extensive gene expression changes at the transcript level as well as 
dysregulation of splicing events – in particular cassette and tandem exons – that are associated 
predominantly with increased skipping and consistent with a reduction in snRNP abundance 
(Hsieh et al., 2019; Saltzman et al., 2011). Interestingly, gene ontology analysis revealed AAV9-
SMN dependent activation of the innate immune response, in particular the complement cascade 
including the C1q genes, which play important roles in neurological disease (Heneka et al., 2018; 
Presumey et al., 2017) and have been implicated as the mechanism of synaptic stripping leading 
to motor neuron deafferentation in SMA (Vukojicic et al.; Zhang et al., 2013). In addition, RNA-
seq analysis also uncovered a decrease in Chondrolectin expression – another RNA alteration 
shared with SMA (Bäumer et al., 2009; Wertz et al., 2016; Zhang et al., 2008). Thus, this study is 
the first to characterize widespread transcriptome alterations induced by AAV9-SMN gene 
therapy that include SMA-like signatures and has clinically relevant implications for the risk of 
unintended consequences of gene dysregulation associated with long-term SMN overexpression. 
My findings have uncovered a yet-to-be appreciated damaging role of SMN when 
expressed at high levels. The SMN1 and SMN2 genes are a result of a gene duplication which 
occurred prior to divergence between humans and chimpanzees, and was succeeded by 




(Rochette et al., 2001). Following gene duplication, the evolutionary emergence of SMN2 as a 
hypomorphic allele could have occurred as a compensatory mechanism to dampen SMN 
expression in humans. In line with this, several mechanisms appear to have evolved which serve 
to downregulate SMN levels. Most notably, the C to T transition from SMN1 to SMN2 which leads 
to exon 7 skipping and a dramatic reduction in the stability of SMN (Burnett et al., 2009; Cartegni 
and Krainer, 2002; Cho and Dreyfuss, 2010; Kashima and Manley, 2003; Lorson and Androphy, 
2000; Lorson et al., 1999; Monani et al., 1999). Human SMN1 and SMN2 are subject to additional 
alternative splicing events producing isoforms of SMN lacking exons 3 and/or exon 5 that are 
anticipated to be loss of function (Gennarelli et al., 1995; Hsieh-Li et al., 2000; Lefebvre et al., 
1995; Singh et al., 2009). Lastly, distinct long non-coding RNAs transcribed in the antisense 
direction from within the SMN loci have been identified which are neuronally enriched and 
downregulate SMN expression through recruitment of the transcriptional repressor complex 
Polycomb repressive complex 2 (d’Ydewalle et al., 2017; Woo et al., 2017). Thus, my discovery 
of a gain of toxic function associated with excess SMN is conceptually consistent with a selective 
pressure for modulation of SMN dosage and the evolution of regulatory mechanisms to prevent 
its overexpression in humans. 
 At a time when SMN-inducing therapies with different mechanisms of action are given to 
SMA patients, it is critical to compare and contrast their benefits and potential liabilities. SMN 
overexpression is a unique feature associated with gene therapy and my results have several 
implications regarding the use of AAV9-SMN as a gene therapy. I observe that CNS-targeted 
AAV9-SMN leads to exceptionally high levels of expression in DRG neurons underlying 
proprioceptive toxicity. As the degree of transduction of sensory neurons can differ following 
systemic or CNS administration of AAV9 (Schuster et al., 2014), the delivery mode may serve as 
a key modulator of the toxic gain of function I report here. However, sensory deficits were also 




With this in mind, a current clinical trial in milder SMA patients utilizing intrathecal delivery 
(NCT03381729) – an approach directly targeting the CNS which may lead to even higher 
expression of SMN in the particularly susceptible proprioceptive neurons – was recently halted 
due to safety concerns of sensory inflammation in DRGs of non-human primates receiving AAV9-
SMN by spinal injection. Furthermore, as multiple SMN-inducing therapies are now available, 
combinatorial treatment with both gene therapy and splice-modulating antisense oligonucleotides 
is being pursued in patients (Lee et al., 2019), with increased risk of SMN overload. In addition to 
SMA, the overexpression of SMN has been proposed as a modifier of ALS pathology (Rodriguez-
Muela et al., 2017; Turner et al., 2014). These approaches should be more carefully considered 
and the potential for toxicity associated with AAV9-SMN gene therapy deserves careful 
examination in treated patients. Importantly, my findings provide an explanation of the molecular, 
cellular and circuit mechanisms underlying the toxic effects of AAV9-SMN in the motor circuit that 
are likely applicable to other species beyond mice. Moreover, they clearly demonstrate that the 
toxicity of AAV9-SMN is intrinsic to the overexpression of the therapeutic agent (i.e. SMN). 
Collectively, this study characterizes a new deleterious role for SMN when expressed at 
supraphysiological levels which shares common features associated with SMN-deficiency in SMA. 
Mechanistically, these results are accompanied with impairments in snRNP levels and splicing 
dysfunction highlighting the importance of this RNP pathway with regards to synaptic function in 
neuronal health and disease while also raising concerns of potential liabilities of long-term SMN 
overexpression. Here, I assess detrimental effects on the mouse motor circuit, though future 
studies will need to be performed to carefully evaluate potential toxicities in other post-mitotic 
neurons that are highly transduced by AAV9. While it is not known whether the toxicity I observe 
here will be found in SMA patients treated with gene therapy, these results deserve consideration 
of the potential negative consequences associated with long-term overexpression of SMN and 










Figure 5.1. AAV9-SMN rescues behavioral parameters of SMND7 SMA mice. (A-C) Weight 
gain (A), righting time (B), and survival (C) of SMND7 wild-type (n = 17) and SMA mice injected 












Figure 5.2. Long-term AAV9-mediated SMN overexpression induces hindlimb clasping in 
SMND7 SMA and wild-type mice. (A) Example of hindlimb clasping phenotype observed in P190 
AAV9-SMN (5) treated SMND7 SMA mice. (B) Date of onset of hindlimb clasping phenotype in 
AAV9-SMN treated SMND7 SMA mice. Data represent median and interquartile range as the box 
and whiskers show the minimum and maximum values. WT mice do not display hindlimb clasping. 
n = 5. (C) Example of hindlimb clasping phenotype in AAV9-SMN injected C57Bl6J wild-type mice 
at P300 compared to uninjected and AAV9-GFP treated age-matched controls. (D) Date of onset 
of hindlimb clasping phenotype in wild-type mice injected with 2.5x1010vg/g (2.5) (n = 7), 
5x1010vg/g (5) (n = 10), and 1x1011vg/g (10) (n = 10) of AAV-SMN. Uninjected (n = 17) wild-type 
mice or wild type mice treated with 5x1010vg/g (5) of AAV9-GFP (n = 16) and 1.25x1010vg/g (1.25) 
of AAV-SMN (n = 10) do not display hindlimb clasping. Data represent median and interquartile 










Figure 5.3. Long-term AAV9-mediated SMN overexpression induces motor toxicity in wild-
type mice. (A) Weight of uninjected (n = 17), AAV9-GFP (n = 16), AAV9-SMN (1.25) (n = 10), 
AAV9-SMN (2.5) (n = 7), AAV9-SMN (5) (n = 10) and AAV9-SMN (10) (n = 10) injected C57Bl6J 
wild-type mice. Data represent mean and SEM. Statistics were performed with two-way ANOVA 
with Sidak’s multiple comparisons test. (*) p < 0.05; (**) p < 0.01. (B) Survival of uninjected and 
AAV9-injected C57Bl6 mice from the same groups as in (A). (C) Latency to fall on the inverted 
grid test from the same groups as (A) measured weekly and reported as an average per month. 
Data represent mean and SEM. Statistics were performed with two-way ANOVA with Sidak’s 
multiple comparisons test. (*) p < 0.05; (***) p < 0.001; (****) p < 0.0001. (D) Performance of wild-
type mice from the same groups as in (A) on the rotarod assay assessed weekly and reported as 
an average per month. Data represent mean and SEM. Statistics were performed with two-way 










Figure 5.4. AAV9-SMN treated SMA mice never gain ability to perform select motor assays. 
(A) Performance of SMN7 wild-type mice (n = 5) uninjected and SMA mice injected with AAV9-
SMN (5) (n = 5) on the rotarod assay. Animals were assessed weekly and reported as an average 
per month. Data represent mean and SEM. (B) Latency to fall on the inverted grid test from the 
same groups as (A) measured weekly and reported as an average per month. Data represent 
mean and SEM. Statistics were performed with two-way ANOVA with Sidak’s multiple 










Figure 5.5. Long-term AAV9-mediated SMN overexpression impairs sensory-motor 
neurotransmission. (A) Representative EMG recordings from the footpad of P300 C57Bl6 
animals uninjected, or AAV9-GFP (5) and AAV9-SMN (5) treated. Scale bars = 1 ms and 1 mV. 
(B) Quantification of the amplitude of M-response recorded from wild-type mice in the same 
groups as in (A). Data represent median and interquartile range as the box and whiskers show 
the minimum and maximum values. n = 8. Statistics were performed with one-way ANOVA with 
Tukey’s post hoc test. (ns) no significance. (C) Quantification of the amplitude of H-reflex recorded 
from wild-type mice in the same groups as in (A). Data represent median and interquartile range 
as the box and whiskers show the minimum and maximum values. n = 8. Statistics were 
performed with one-way ANOVA with Tukey’s post-hoc test. (*) P < 0.05. (D) Quantification of the 
ratio of the H-reflex and M-response recorded from wild-type mice in the same groups as in (A). 
Data represent median and interquartile range as the box and whiskers show the minimum and 
maximum values. n = 8. Statistics were performed with one-way ANOVA with Tukey’s post hoc 








Figure 5.6. AAV9-SMN induces late-onset deafferentation of motor neurons. (A) ChAT and 
VGluT1 immunostaining of L5 LMC motor neuron somata and dendrites from uninjected, AAV9-
GFP (5) and AAV9-SMN (5) injected wild-type mice at P150. Scalebar = 25 µm. Dendrites scale 
bar = 10 µm (B) ChAT and VGluT1 immunostaining of L5 LMC motor neuron somata and 
dendrites from the same groups as (A) at P300. Scale bar = 25 µm. Dendrites scale bar = 10 µm 
(C) Total number of VGluT1+ synapses on L5 LMC motor neuron somata at P150 and P300 from 
the same groups as in (A). Data represent mean and SEM. n ³ 36 neurons from n = 3 animals 
per group. Statistics were performed with two-way ANOVA with Sidak’s multiple comparisons test. 
(***) P < 0.001; (****) P < 0.0001. (D) Total number of VGluT1+ synapses on L5 LMC motor neuron 
proximal dendrites 0-50 µm from the soma at P150 and P300 from the same groups as in (A). 
Data represent mean and SEM. n ³ 26 dendrites from n = 3 animals per group. Statistics were 












Figure 5.7. AAV9-SMN does not alter C-bouton number. (A) ChAT immunostaining of L5 LMC 
motor neuron somata from uninjected, AAV9-GFP (5) and AAV9-SMN (5) injected wild-type mice 
at P300. Scale bar = 25 µm. (B) Total number of C-boutons on L5 LMC motor neuron somata at 
P150 and P300 from the same groups as in (A). Data represent mean and SEM. n = 3. Statistics 








Figure 5.8. AAV9-SMN leads to degeneration of proprioceptive neurons in wild type mice. 
(A) PV immunostaining of L5 DRG at P300 from uninjected, AAV9-GFP (5) and AAV9-SMN (5) 
injected wild-type mice. Scale bar = 250 µm. (B) Quantification of the total number of 
proprioceptive neurons in L5 DRG from the same groups as (A). Data represent mean and SEM. 













Figure 5.9. AAV9-SMN does not change MN number in wild-type mice. (A) ChAT 
immunostaining of L5 spinal segments at P150 from uninjected, AAV9-GFP (5) and AAV9-SMN 
(5) injected wild-type mice. Scale bar = 100 µm. (B) ChAT immunostaining of L5 spinal segments 
at P300 from the same groups as in (A). Scale bar = 100 µm. (C) Number of L5 LMC motor 
neurons per 75 µm section at P150 and P300 in the same groups as in (A). Data represent mean 
and SEM. n ³ 14 sections per animal from n = 3 animals for each group. Statistics were performed 
with two-way ANOVA with Sidak’s multiple comparisons test. (ns) no significance. (D) Number of 
L5 MMC motor neurons per 75 µm section at P150 and P300 in the same groups as in (A). Data 
represent mean and SEM. n ³ 14 sections per animal from n = 3 animals for each group. Statistics 










Figure 5.10. AAV9-SMN does not change NMJ innervation in wild-type mice. (A) 
Immunostaining of presynaptic (with NF-M and SYP antibodies) and post-synaptic (with BTX) 
terminals of neuromuscular junctions (NMJs) in the EDL muscles at P150 from uninjected, AAV9-
GFP (5) and AAV9-SMN (5) injected wild-type mice. Scale bar = 50 µm. (B) Immunostaining of 
presynaptic and post-synaptic terminals of NMJs in the EDL muscles at P300 from the same 
groups as (A). Scale bar = 25 µm. (C) The percentage of innervated NMJs in the EDL muscle at 
P150 and P300 from the same groups as in (A). Data represent mean and SEM. n = 3. Statistics 







Figure 5.11.  AAV9-SMN leads to the early rescue and late loss of proprioceptive inputs on 
motor neurons of SMA mice. (A) ChAT and VGluT1 immunostaining of L2 spinal segments from 
untreated WT and SMA mice treated with AAV9-GFP (5) or AAV9-SMN (5) at P11 and WT and 
SMA mice treated with AAV9-SMN (5) at P190. Scale bar = 10 µm (B) Total number of VGluT1+ 
synapses on L2 motor neuron somata at P11 and P190 from the same groups as in (A). Data 
represent mean and SEM. n ³ 27 soma from n = 3 animals per group. Statistics were performed 















Figure 5.12. AAV9-SMN does not induce degeneration of proprioceptive neurons in SMA 
mice. (A) PV immunostaining of L2 DRG from WT untreated and AAV9-SMN (5) treated SMA 
mice at P190. Scale bar = 100 µm. (B) Quantification of the total number of proprioceptive neurons 
in L2 DRG from the same groups as (A). Data represent mean and SEM. n = 3. Statistics were 






Figure 5.13.  AAV9-SMN rescues MN loss at early and late timepoints in SMA mice. (A) 
ChAT immunostaining of L2 motor neurons from WT untreated, and AAV9-GFP (5) and AAV9-
SMN (5) treated SMA mice at P11 and WT untreated and AAV9-SMN (5) treated SMA mice at 
P190. Scale bar = 75 µm at P11 and 100 µm at P190. (B) Number of L2 motor neurons per section 
as a percentage relative to WT in the same groups as in (A). Data represent mean and SEM. n ³ 
11 sections from n ³ 3 animals per group. Statistics were performed with one-way ANOVA with 







Figure 5.14.  AAV9-SMN rescues NMJ denervation in SMA mice at early and late timepoints. 
(A) Immunostaining of presynaptic (with NF-M and SYP antibodies) and post-synaptic (with BTX) 
terminals of neuromuscular junctions (NMJs) in the QL muscles from the same groups as in (A). 
Scalebar = 25 µm at P11 and 50 µm at P190. (B) The percentage of innervated NMJs in the QL 
muscle from the same groups as in (A). Data represent mean and SEM. n ³ 3. Statistics were 












Figure 5.15. AAV9 efficiently and stably transduces motor neurons and proprioceptive 
neurons. (A) DAPI, ChAT and GFP immunostaining of L5 spinal cord, DAPI, PV and GFP 
immunostaining of L5 DRGs and DAPI and GFP immunostaining of liver from uninjected and 
AAV9-GFP (5) injected wild-type mice at P11 and P300. Spinal cord scale bar = 250 µm. DRG 
scale bar = 200 µm. Liver scale bar = 100 µm. (B) Percentage of GFP+ L5 LMC motor neurons 
(ChAT+) at P300 in AAV9-GFP (5) injected wild-type mice. Data represent mean and SEM. n = 
3. (C) Percentage of GFP+ L5 MMC motor neurons (ChAT+) at P300 in AAV9-GFP (5) injected 
wild-type mice. n = 3. (D) Percentage of GFP+ proprioceptive neurons (PV+) in the L5 DRG at 














Figure 5.16. AAV9-mediated mRNA expression is maintained in neuronal tissues of wild-
type mice. (A) RT-qPCR analysis of GFP mRNA in the spinal cords, dorsal root ganglia (DRGs) 
and livers of P11 and P300 C57 WT mice injected with AAV9-GFP (5). Data represent mean and 
SEM. n = 3. Statistics were performed with two-way ANOVA with Sidak’s multiple comparisons 
test. (**) P < 0.01. (B) RT-qPCR analysis of full-length human SMN (hSMNFL) mRNA in the spinal 
cords, dorsal root ganglia (DRGs) and livers of P11 and P300 C57 WT mice injected with AAV9-
SMN (5). Data represent mean and SEM. n = 3. Statistics were performed with two-way ANOVA 








Figure 5.17. AAV9-mediated expression is maintained in neuronal tissue of wild-type mice. 
(A) Western blot analysis of spinal cord from C57 WT mice uninjected, or injected at P1 with 
AAV9-GFP (5) or AAV9-SMN (5) at P11 and P300. (B) Western blot analysis of liver from the 










Figure 5.18. AAV9-SMN leads to dramatic overexpression in the spinal cord and DRGs of 
SMND7 mice. (A) RT-qPCR analysis of hSMNFL mRNA levels in spinal cords of SMND7 
uninjected WT mice, or SMA mice injected with AAV9-GFP (5) or AAV9-SMN (5) at P11, and 
uninjected WT mice and SMA mice injected with AAV9-SMN (5) at P190. Data represent mean 
and SEM. n = 3. Statistics were performed with one-way ANOVA with Tukey’s post hoc test. (ns) 
no significance. (B) RT-qPCR analysis of hSMNFL mRNA levels in DRGs of mice from the same 
groups as (A). Data represent mean and SEM. n = 3. Statistics were performed with one-way 
ANOVA with Tukey’s post hoc test. (*) P < 0.05. (C) RT-qPCR analysis of hSMNFL mRNA levels 
in livers of mice from the same groups as (A). Data represent mean and SEM. n = 3. Statistics 









Figure 5.19. AAV9-mediated expression is maintained in neuronal tissue of SMND7 mice. 
(A) Western blot analysis of spinal cord from SMND7 uninjected WT mice, or SMA mice injected 
with AAV9-GFP (5) or AAV9-SMN (5) at P11, and uninjected WT mice and SMA mice injected 









Figure 5.20. AAV9-SMN induces cytoplasmic aggregates in motor neurons. (A) ChAT and 
SMN immunostaining at P11 and P150 of L5 LMC motor neurons from C57Bl6 wild-type mice 
uninjected and injected with AAV9-GFP (5) and AAV9-SMN (5). Scale bar = 10 µm. (B) ChAT 
and SMN immunostaining at P300 of L5 LMC motor neurons from the same groups as in (A). 
Scale bar = 10 µm. (C) Percentage of L5 LMC motor neurons with SMN aggregates at P300 in 








Figure 5.21. AAV9-SMN induces cytoplasmic aggregates in proprioceptive neurons. (A) 
Parvalbumin (PV) and SMN immunostaining at P11 and P150 of L5 DRG proprioceptive neurons 
from C57Bl6 wild-type mice uninjected and injected with AAV9-GFP (5) and AAV9-SMN (5). Scale 
bar = 10 µm. (B) PV and SMN immunostaining at P300 of L5 proprioceptive neurons from the 
same groups as in (A). Scale bar = 10 µm. (C) Percentage of L5 DRG proprioceptive neurons 












Figure 5.22. AAV9-SMN induces cytoplasmic aggregates of SMN in motor circuit neurons 
of SMND7 SMA mice. (A) ChAT and SMN immunostaining at P11 from SMND7 wild-type and 
AAV9-GFP (5) or AAV9-SMN (5) injected SMA mice and at P190 from SMND7 wild-type and 
AAV9-SMN (5) injected SMA mice. Scale bar = 10 µm. (B) PV and SMN immunostaining at P11 
and P190 of L2 proprioceptive neurons from the same groups as in (A). Scale bar = 10 µm. (C) 
Percentage of L2 motor neurons with SMN aggregates at P190 in the same groups as in (A). Data 
represent mean and SEM. n = 3. (D) Percentage of L2 proprioceptive neurons with SMN 










Figure 5.23. AAV9-SMN induces cytoplasmic aggregates of SmB in motor neurons. (A) 
ChAT and SmB immunostaining at P11 of L5 LMC motor neurons from C57Bl6 wild-type mice 
uninjected and injected with AAV9-GFP (5) and AAV9-SMN (5). Scale bar = 10 µm. (B) ChAT 
and SmB immunostaining at P150 of L5 LMC motor neurons from the same groups as in (A). 
Scale bar = 10 µm. (C) ChAT and SmB immunostaining at P300 of L5 LMC motor neurons from 








Figure 5.24. AAV9-SMN induces cytoplasmic aggregates of SmB in proprioceptive neurons. 
(A) PV and SmB immunostaining at P11 of L5 DRG proprioceptive neurons from C57Bl6 wild-
type mice uninjected and injected with AAV9-GFP (5) and AAV9-SMN (5). Scale bar = 10 µm. (B) 
PV and SmB immunostaining at P150 of L5 DRG proprioceptive neurons from the same groups 
as in (A). Scale bar = 10 µm. (C) PV and SmB immunostaining at P300 of L5 DRG proprioceptive 







Figure 5.25. AAV9-SMN induces cytoplasmic aggregates of SMN in motor circuit neurons 
of SMND7 SMA mice. (A) ChAT and SmB immunostaining at P11 and P190 of L2 motor neurons 
from SMND7 wild-type and AAV9-GFP (5) or AAV9-SMN (5) injected SMA mice and at P190 from 
SMND7 wild-type and AAV9-SMN (5) injected SMA mice. Scale bar = 10 µm. (B) PV and SmB 
immunostaining at P11 and P190 of L2 proprioceptive neurons from the same groups as in (A). 




















Figure 5.26. AAV9-SMN induced cytoplasmic aggregates colocalize with SmB. (A) ChAT, 
SmB and SMN immunostaining of an L5 LMC motor neuron in a C57Bl6 wild-type mouse at P150 
injected with AAV9-SMN (5). Scale bar = 5 µm. (B) PV, SmB and SMN immunostaining of an L5 
proprioceptive neuron in a C57Bl6 wild-type mouse at P150 injected with AAV9-SMN (5). Scale 









Figure 5.27. Long-term AAV9-SMN overexpression reduces nuclear snRNP levels in motor 
circuit neurons. (A) Normalized nuclear SmB fluorescence intensity in L5 LMC motor neurons 
from C57Bl6 wild-type mice uninjected and injected with AAV9-GFP (5) and AAV9-SMN (5) at 
P300. Each point represents SmB fluorescent intensity in a single motor neuron, and data were 
collected from n ³ 210 motor neurons from three mice for each group. Mean and SEM are 
represented. Statistics were performed with one-way ANOVA with Tukey’s post hoc test. (****) P 
< 0.0001. (B) Normalized nuclear SmB fluorescence intensity in L5 proprioceptive neurons from 
C57Bl6 mice in the same groups as in (A) at P300. Each point represents SmB fluorescent 
intensity in a single proprioceptive neuron, and data were collected from n ³ 172 proprioceptive 
neurons from three mice for each group. Mean and SEM are represented. Statistics were 









Figure 5.28. SMN aggregates do not colocalize with other markers. (A-J) Immunostaining of 
DAPI, ChAT, SMN, and other markers (as labeled) of L5 LMC motor neurons from C57 mice 












Figure 5.29. AAV9-SMN gene delivery results in splicing alterations in dorsal root 
ganglia. (A) Venn-diagram of the total number of high confidence splicing changes in dorsal 
root ganglia between WT uninjected, AAV9-GFP or AAV9-SMN treated mice at P300 with a 
differential inclusion (dI) greater than ten percent and a false discovery rate (FDR) less than 
0.05. (B) Pie chart of the proportion of each event in the 405 high confidence AAV9-SMN 
dependent splicing changes. Monitored splicing events include cassette exons (CAS), intron 
retention (IRET), alternative 3’ splice sites (ALT 3’), tandem cassette exons (TACA), alternative 












Figure 5.30. AAV9-SMN gene delivery results in alterations of many splicing events in 
dorsal root ganglia. Venn-diagrams of the total number of high confidence splicing changes of 
(A) cassette exons, (B) alternative 3’ splice sites, (C) alternative 5’ splice sites, (D) tandem 
cassette exons, (E) mutually exclusive exons and (F) intron retention events in dorsal root 
ganglia between WT uninjected, AAV9-GFP or AAV9-SMN treated mice at P300 with a 















Figure 5.31. AAV9-SMN induces RNA misprocessing consistent with impairment of the 
spliceosomal machinery. (A) Pie chart displaying the number of high confidence skipped or 
included cassette exons altered by AAV9-SMN in DRGs from wild type mice at P300 with a 
differential inclusion (dI) greater than ten percent and a false discovery rate (FDR) less than 
0.05. (B) Pie chart displaying the number of high confidence skipped or included tandem 
cassette exons (TACA) altered by AAV9-SMN in DRGs from wild type mice at P300 with a 
differential inclusion (dI) greater than ten percent and a false discovery rate (FDR) less than 
0.05. (C) Pie chart displaying the increase or decrease of high confidence intron retention 
events altered by AAV9-SMN in DRGs from wild type mice at P300 with a differential inclusion 










Figure 5.32. AAV9-SMN induces widespread gene expression changes in dorsal root 
ganglia. (A) Volcano plot of gene expression changes in dorsal root ganglia from AAV9-GFP 
injected wild-type mice relative to uninjected at P300. (B) Volcano plot of gene expression 
changes in dorsal root ganglia from AAV9-SMN injected wild-type mice relative to uninjected at 
P300. (C) Volcano plot of gene expression changes in dorsal root ganglia from AAV9-SMN 
injected wild-type mice relative to AAV9-GFP injected at P300. Targets with an adjusted p-value 















Figure 5.33. Gene ontology analysis of SMN-dependent differentially expressed genes.  
(A) Venn diagram of gene expression changes in dorsal root ganglia between WT uninjected, 
and AAV9-GFP and AAV9-SMN injected wild-type mice at P300. Data was filtered based on an 
adjusted p-value < 0.05 and a fold change greater than 2. (B) Pie chart of the 531 AAV9-SMN 
dependent gene expression changes showing direction of fold change. (C) Gene ontology 
analysis of the top 15 most enriched biological pathways associated with the 531 high 











Figure 5.34. AAV9-SMN induces SMA-like transcriptional changes. (A) RNA-seq tracks for 
C1qa reads from the DRGs of wild-type mice either uninjected or injected with AAV9-GFP and 
AAV9-SMN at P300. A representative profile from one biological replicate is shown. (B) RNA-seq 
tracks for C1qb from the same groups as (A). A representative profile from one biological replicate 
is shown. (C) RNA-seq tracks for C1qc from the same groups as (A). A representative profile from 
one biological replicate is shown. (D) RNA-seq tracks for chondrolectin (Chodl) from the same 










Figure 5.35. Features of AAV9-SMN mediated gain of toxic function on the mouse motor 
circuit. AAV9-SMN leads to cytoplasmic aggregation of SMN and sequestration of SmB in motor 
circuit neurons. Long-term overexpression leads to several morphological deficits including a 
reduction in nuclear snRNP levels, motor neuron deafferentation and degeneration of 
proprioceptive neurons. RNA seq analysis also revealed widespread gene expression and 









 Several neurodegenerative diseases share features of RNA dysregulation due to mutations 
in RNA binding proteins or factors involved in RNA processing (Conlon and Manley, 2017; Cooper 
et al., 2009). SMA is one prominent example where a deficit in a ubiquitous protein involved in 
critical RNA pathways leads to selective degeneration and dysfunction of specific neuronal cell 
types (Li et al., 2014; Tisdale and Pellizzoni, 2015). While motor neuron death is the key hallmark 
of SMA, it is increasingly appreciated that SMA pathology is a consequence of multiple deficits 
throughout the motor circuit and beyond (Tisdale and Pellizzoni, 2015). The use of animal models 
has enabled thorough characterization of these defects at the cellular and circuit levels (Tisdale 
and Pellizzoni, 2015; Van Alstyne and Pellizzoni, 2016); however, the molecular mechanisms 
underlying death and dysfunction of motor neurons remain incompletely understood. Elucidation 
of the cellular pathways driving SMA pathogenesis are fundamental for understanding disease 
mechanisms and can uncover SMN-independent therapeutic targets as well as novel factors 
involved in motor circuit function. 
 
Contributions of SMN-dependent RNA pathways to SMA pathology 
 The role of SMN in snRNP assembly is well established (Li et al., 2014), but debate persists 
in the field regarding the contribution of splicing dysfunction and other less defined functions of 
SMN such as axonal mRNA transport to SMA pathology. This is mainly a consequence of the 
seemingly discordant features of impairment in an RNA pathway critical for all cells causing the 
selective vulnerability of motor neurons. In order to assess this, it is fundamental to selectively 
restore implicated RNA pathways – or key downstream effectors – and evaluate their specific 
contribution(s) to SMA pathology in animal models. Additionally, impairment of the same 




 In this dissertation, I used mouse models to establish the direct contribution of select 
splicing targets affected by disruption of SMN’s activity in snRNP assembly to key hallmarks of 
SMA pathology. My work identified Mdm2 and Mdm4 as two downstream genes whose alternative 
splicing is affected by dysfunction of the major (U2-dependent) spliceosomal machinery induced 
by SMN deficiency and underlies motor neuron degeneration (Chapter 2). Similarly, I show that 
Stasimon – a U12 intron containing gene regulated by SMN previously identified for its 
contribution to motor circuit dysfunction in both Drosophila and zebrafish models of SMA (Lotti et 
al., 2012) – plays a role in multiple aspects of motor circuit dysfunction in SMA mice including 
motor neuron degeneration, the loss of proprioceptive synapses and impaired synaptic 
transmission (Chapter 3). In addition to mediating the assembly of spliceosomal snRNPs, SMN 
also plays a critical role in the biogenesis of U7 snRNP which functions in histone 3’end mRNA 
processing (Li et al., 2014). Independent work in the lab has selectively restored the U7 pathway 
in SMA mice and identified an unexpected role in NMJ denervation through dysregulation of the 
synaptic organizer Agrin (Tisdale et al. manuscript in preparation, see also Appendix).  
Elucidation of these molecular mechanisms provides evidence for the direct contribution of 
distinct SMN-regulated RNA pathways (U2-dependent alternative splicing, U12-dependent 
splicing, and U7-mediated histone mRNA processing) to select aspects of motor circuit 
dysfunction in SMA (Figure 6.1). Little overlap is observed in the contribution of these SMN-
dependent RNA pathways to SMA etiology, demonstrating that key disease features of SMA – i.e. 
motor neuron degeneration, NMJ denervation, and proprioceptive synaptic loss – result from the 
convergence of unique molecular pathways occurring in parallel. Furthermore, these studies have 
identified specific effector genes in each pathway that are dysregulated in the context of SMN 
deficiency and play critical roles in SMA pathogenesis. This draws a scenario in which 
dysregulation of particular genes rather than a global collapse in RNA processing selectively 




an amalgamation of select, mechanistically uncoupled RNA misprocessing events that contribute 
to distinct disease features. 
 
Mechanisms of SMA motor neuron death and neuroprotective approaches 
 Motor neuron degeneration is a key characteristic of SMA pathology (Tisdale and Pellizzoni, 
2015; Van Alstyne and Pellizzoni, 2016). This dissertation expands upon our prior knowledge of 
the p53-dependent mechanisms of motor neuron death that involve converging activating 
mechanisms of upregulation and phosphorylation, the latter of which occurs selectively in 
vulnerable SMA motor neurons (Simon et al., 2017). Here, I characterize the upstream 
mechanisms responsible for p53 activation in SMA. I show that dysregulation of Mdm2 and Mdm4 
alternative splicing underlies p53 upregulation, while U12-dependent impairment of Stasimon 
expression triggers N-terminal TAD p53 phosphorylation. These findings provide mechanistic 
insight into the RNA pathways leading to selective degeneration of motor neurons in SMA and 
how they relate to molecularly defined roles of SMN, providing direct evidence for snRNP-
dependent mechanisms of motor neuron death in SMA. While p53 upregulation alone is not 
sufficient to drive motor neuron death and N-terminal phosphorylation is required (Simon et al., 
2017), whether additional modifications are necessary has not yet been established. Future 
studies are needed to determine whether Stasimon-dependent phosphorylation of p53 – in 
combination with p53 upregulation – is sufficient to mediate the degenerative process, or whether 
there further converging mechanisms are at play. Similarly, evaluation of the sufficiency of p38α 
MAPK activation in concert with p53 upregulation to mediate motor neuron death will provide 
insight as to whether additional kinases are required for phosphorylation of p53. Lastly, further 
investigation is also necessary to establish whether the p53-dependent mechanisms of motor 
neuron death that I characterized in the SMND7 model are conserved across other SMA models 




 Elucidation of the molecular mechanisms underlying degenerative processes in SMA has 
the translational potential to uncover new targets for therapeutic approaches. While SMN 
upregulating strategies have proven effective in the clinic, they do not represent a complete cure 
for SMA and further treatments which can be used in combinatorial therapies are sought after 
(Sumner and Crawford, 2018). In characterizing the molecular mechanisms of motor neuron 
death, I found that activation of p38α MAPK underlies N-terminal phosphorylation of p53 in 
vulnerable SMA motor neurons. Accordingly, treatment with MW150 – a specific pharmacological 
inhibitor of p38α  MAPK – is able to rescue the loss of motor neurons in SMA mice. MW150 is 
undergoing clinical development for the treatment of mild cognitive impairment and Alzheimer’s 
related dementia among other indications, and my findings warrant further exploration of 
pharmacological inhibition of p38α MAPK as a candidate neuroprotective approach for 
combinatorial SMA therapy.  
Additionally, having characterized the role of p38α MAPK in the phosphorylation of p53 in 
SMA motor neurons, future studies can profile the downstream targets of p53 that are upregulated 
in SMA following inhibition of either p53 or p38α MAPK. The subset of genes that are 
transcriptionally activated in a phospho-specific manner would represent key candidate effectors 
of motor neuron degeneration. This analysis could reveal not only the non-apoptotic death 
mechanisms occurring in SMA motor neurons but also therapeutically relevant targets to elicit 
neuroprotective effects for disease treatment. 
 
Novel players and pathways regulating motor circuit function 
 Understanding the mechanisms underlying disease etiology in SMA can also uncover novel 
players involved in normal maintenance of the motor system and synaptic function. Stasimon loss 
is associated with altered neurotransmitter release at the NMJ in Drosophila larvae through non 
cell-autonomous motor circuit dysfunction as well as abnormal motor axon outgrowth in zebrafish 




mammalian development; however, the precise abnormalities occurring during embryogenesis 
are unknown. The lethality of Stasimon ablation underlines also the necessity for generation of 
conditional knockout mice to evaluate the temporal and spatial requirement of Stasimon in the 
motor circuit. These models will allow addressing whether Stasimon is also essential when 
depleted postnatally and whether it is particularly important for neuronal functions. As the rescue 
studies in SMA mice suggest a key requirement for Stasimon in the mouse motor circuit, these 
genetic models will also enable the precise assessment of the effects of Stasimon loss in 
proprioceptive or motor neurons and whether this can phenocopy Stasimon-dependent aspects 
of SMA pathology. These avenues of investigation will serve to further evaluate the importance 
of Stasimon as a novel factor required for proper neuronal maintenance and connectivity in 
mammalian models as suggested by our studies to date. 
While Stasimon has been implicated in motor system dysfunction in SMA, its cellular 
functions are still poorly understood. In this dissertation, I found that Stasimon localizes at the 
MAM which mediates key cellular functions that can have broad consequences on ER and 
mitochondrial biology. Initial studies suggest a role in autophagy (Moretti et al., 2018; Morita et 
al., 2018; Shoemaker et al., 2019), consistent with localization at the MAM which has been 
identified as a source for autophagosomal membranes (Hailey et al., 2010; Hamasaki et al., 2013). 
Further investigation is required to assess whether Stasimon impacts the integrity of MAM contact 
sites, and/or has a functional role in other MAM-dependent cellular pathways such as calcium 
buffering, lipid biogenesis, and mitochondrial health among others (Marchi et al., 2014; Wu et al., 
2018). Moreover, the ER has functional contact sites with many other membrane organelles in 
addition to mitochondria, including peroxisomes, the plasma membrane, the Golgi apparatus, and 
endosomes (Wu et al., 2018). Future studies of Stasimon biology should also address the 
potential for a role at other ER membrane contact sites.  
The current understanding of Stasimon function and requirement suggests it sits at an 




specialized neuronal functions in health and disease. MAM dysfunction has been implicated in 
several neurodegenerative disorders including amyotrophic lateral sclerosis/frontotemporal 
dementia (ALS/FTD), Parkinson’s (PD) and Alzheimer’s (AD) disease (Paillusson et al., 2016). 
Garnering a better understanding of the role of Stasimon at ER-mitochondria contact sites can 
therefore provide insight into neurodegenerative pathways that may be conserved across 
diseases. Furthermore, evaluating the importance of Stasimon-dependent MAM regulated cellular 
pathways for neuronal function can lead to key insight into basic neurobiology. 
 
Deleterious role of SMN overexpression and implications for therapies 
 In developing therapies for SMA, the field has focused much attention on developing diverse 
strategies to upregulate SMN expression. However, despite the key importance of proper SMN 
levels – as underlined by the consequences of SMN deficiency in SMA – investigation of the 
effects of excess SMN have been largely ignored based on the premise that they would benign. 
The work in this dissertation identifies an unexpected new aspect of SMN biology through the 
study of gain of toxic mechanisms induced by its overexpression in post-mitotic neurons. These 
findings have especially important clinical implications considering the utilization of AAV9-
mediated gene therapy for SMA patients. While future investigation is required to determine 
whether the long-term neuronal toxicity observed in mouse models are applicable to patients, my 
findings emphasize a deleterious role for supraphysiological levels of SMN that has not received 
much attention as a potential caveat of SMA gene therapy. Interestingly, this toxicity of AAV9-
SMN is associated with impairments in snRNP biogenesis as well as widespread transcriptome 
alterations and splicing changes. Moreover, both a deficiency of SMN that occurs in SMA as well 
as an excess of SMN caused by AAV9-mediated gene delivery share features of motor circuit 
dysfunction that likely occur through snRNP-dependent mechanisms, further underlining the 




 Collectively, this dissertation aimed to establish SMN-dependent RNA mediated 
mechanisms underlying SMA pathology, and in particular the pathways driving motor neuron 
degeneration. Characterization of these pathways has provided further support to the critical 
contribution of snRNP disruption to SMA etiology. It has also identified key effector genes 
dependent on specific SMN-dependent RNA pathways that mediated distinct aspects of SMA 
pathology, mechanistically uncoupling disease processes. These studies have opened exciting 
new avenues of exploration in the characterization of Stasimon biology at the molecular, cellular 
and circuit levels. Furthermore, this work has led to a degree of molecular definition of the SMA 
motor neuron death pathway which has long remained elusive, revealing potential targets for 
development of combinatorial treatments of SMA that might build upon current available 
treatments to maximize therapeutic efficacy. In an effort to provide the best possible care for SMA 
patients, the work described here also has important implications regarding the mechanisms of 
SMN-dependent toxicity resulting from its long-term overexpression – providing new insights into 
SMN biology and SMA therapy with AAV9-SMN. Initial insight into these toxic mechanisms once 
again highlights the importance of snRNP pathways for motor circuit function and uncovers 
parallel themes between the dysregulation of RNA pathways and neuronal dysfunction that can 
















Figure 6.1. Contributions of SMN-dependent RNA pathways to SMA pathology. Investigation 
into SMN-dependent RNA pathways has uncovered contributions of select pathways to distinct 
aspects of SMA pathology. SMN deficiency leads to a reduction in major splicosomal snRNPs 
which leads to increased skipping of key regulatory exons in Mdm2 and Mdm4 driving p53 
upregulation which underlies SMA motor neuron degeneration (Chapter 2). Impairment of the 
minor spliceosomal machinery leads to misprocessing of the U12-intron containing gene 
Stasimon, which plays dual roles in the loss of proprioceptive synapses and p53 phosphorylation 
which occurs through p38α MAPK and drives the selectivity of motor neuron death (Chapter 3). 
Lastly, deficits in U7 snRNP biogenesis lead to the misprocessing of histone mRNAs, which 
reduces Agrin expression and NMJ denervation in SMA (Tisdale et al. manuscript in preparation, 




































DNA constructs  
 For the experiments in Chapter 2, plasmids containing cDNAs for full-length mouse Mdm2 
and Mdm4 were purchased from DharmaconTM (Mdm2 Clone ID: 6415937, Accession: BC050902; 
Mdm4 Clone ID: 3599906, Accession: BC003750). DNA fragments corresponding to the open 
reading frames of GFP and full-length Mdm2 and Mdm4 generated by PCR using these plasmids 
as templates were cloned downstream of the GUSB promoter of vectors harboring AAV2 ITRs for 
the production of self-complementary AAV9. Mdm2 and Mdm4 constructs used for transient 
transfection were generated from the plasmids containing cDNAs described above and cloned 
downstream of the GUSB promoter of the same AAV vector by PCR with primers designed for 
addition a 3x myc tag at the N-terminus. For AAV9-mediated p53 knockdown, a self-
complementary AAV9 vector containing AAV2 ITRs was engineered to harbor a mouse U6 
promoter driving expression of an shRNA targeting the sequence “GTACTCTCCTCCCCTCAAT” 
of mouse p53 in addition to a CMV promoter driving GFP expression in the opposite direction.  
For the experiments in Chapter 3, DNA fragments corresponding to the open reading frames 
of GFP, human SMN (NM_000344), and human STAS (NM_015012) were generated by PCR 
using plasmid templates obtained from OriGene and cloned downstream of the CMV enhancer 
and chicken beta-actin (CB) hybrid promoter in the dsAAV-CB plasmid (a gift from Brian Kaspar) 
harboring AAV2 ITRs for the production of self-complementary AAV9 (Foust et al., 2010). For 
generating stable cell lines with Stasimon knockdown by lentiviral production, complementary 
oligonucleotide templates for an shRNA targeting mouse Stasimon mRNA (5’-
GGAAGACCCGTTGTATACA-3’) were annealed and cloned into pSUPERIOR.puro OligoEngine). 




under the control of a tetracyline-regulated promoter and the puromycin resistance gene driven 
by the PGK promoter were excised from pSUPERIOR.puro and cloned into a modified 
pRRLSIN.cPPT.PGK-GFP.WPRE vector (Addgene plasmid 12252) lacking the PGK-GFP 
cassette as a backbone. Viral stocks pseudotyped with the vesicular stomatitis G protein (VSV-
G) were prepared by transient co-transfection of HEK293T cells using the ViraPower™ Lentiviral 
Packaging Mix (Invitrogen) following manufacturer’s instructions.  
For the experiments in Chapter 4, the open reading frames of human (NM_015012.3) and 
mouse (NM_153525.5) Stasimon were PCR amplified from plasmids purchased from OriGene 
and cloned into the BglII and HindIII sites of pEGFP-C1 (Clontech) to generate N-terminally 
tagged GFP fusions. The plasmid for expression of mCherry-tagged mouse Calnexin was a gift 
from Franck Polleux (Hirabayashi et al., 2017).  
For the experiments in Chapter 5, vectors containing the open reading frames of GFP and 
human SMN cloned downstream of the GUSB promoter of vectors harboring AAV2 ITRs 
generated previously (Passini et al., 2010) were used for AAV9 generation. 
All constructs were verified by DNA sequencing.  
 
Cell lines and treatments 
For all experiments human HEK293 cells and mouse NIH3T3 fibroblasts were grown in 
DMEM with high glucose (Invitrogen) containing 10% of FBS (HyClone), 2 mM glutamine (Gibco), 
and 1% penicillin and streptomycin (Gibco) unless otherwise described below. 
The inducible NIH3T3 cell lines used for experiments in Chapter 2 were described 
previously (Lotti et al., 2012; Ruggiu et al., 2012). Here, NIH3T3 cells were treated with 
doxycycline (100ng/ml) for 5 days (SmnRNAi and SMN/SmnRNAi) or 60 hours (SmBRNAi) prior to 
analysis. 
For transient transfection experiments in Chapter 2, NIH3T3 cells were plated onto glass 




with a 1:3 ratio of DNA:Lipofectamine 2000 (Invitrogen). UV treatment for p53 induction was 
performed 12 hours prior to collection. For UV treatment, media was removed and cells were 
exposed to 10 mJ/cm2 at 254 nm using a Spectrolinker XL-1000 UV Crosslinker (Spectronics 
Corporation). The same media was then returned and cells were allowed to recover for 12 hours 
at 37°C. A total of 72 hours after transfection, cells were fixed on the coverslip for downstream 
analysis. 
For cell culture experiments involving MOs in Chapter 2 and Chapter 3, each MO was 
resuspended in H2O for a stock concentration of 1mM and stored at room temperature. MOs were 
obtained from GeneTools, LLC and the sequences are shown in Table 7.1. MO was added to 
culture media at a final concentration of 10 µM followed by addition of DMSO based Endo-porter 
(GeneTools) at a final concentration of 6 µL/mL. For immunofluorescence experiments, cells were 
plated on glass coverslips in 24 well plates and allowed to adhere prior to addition of MO, then 
incubated for 60 or 72 total hours as described. For RNA analysis of Mdm2 and Mdm4 skipping, 
cells were plated in a 12-well format and collected after 72 hours of MO treatment. For treatment 
with MW150, a final concentration of 8 µM was added to media for 8 hours prior to the addition of 
MOs. 
For experiments in Chapter 4, the NIH3T3-StasRNAi cell line was generated by 
transduction of NIH3T3 cells with pLenti.pur/StasRNAi, followed by antibiotic selection with 5 
μg/ml Puromycin (Sigma) and cloning by limiting dilution as described before (Lotti et al., 2012; 
Ruggiu et al., 2012). For treatments to induce or block autophagy, NIH3T3 cells were plated one 
day prior to addition of compounds. Cells were then cultured for 4 hours in the presence of 100 
nM Bafilomycin A (Alfa Aesar) to block autophagy and/or in DMEM media without glutamine and 
serum for autophagy induction prior to collection. For the induction of p38 MAPK by UV treatment, 
media was removed and cells were exposed to 600 mJ/cm2 at 254 nm using a Spectrolinker XL-




were allowed to recover for 1 hour at 37°C before fixation for immunofluorescence analysis or 
collection for Western blotting. 
For experiments related to analysis of the Stasimon interactome in Chapter 4, HEK293 
cells were transfected using the CalPhos mammalian transfection kit (Clontech) and processed 
72 hours after transfection. For analysis of Stasimon localization, NIH3T3 cells were plated in a 
10cm format one day prior, then transfected with 10 µg of each construct for each plate with a 
1:2:2 DNA:P3000:Lipofectamine 3000 (Invitrogen) ratio. 48 hours post-transfection, cells were 
trypsinized and plated on Zeiss high performance coverslips then fixed for immunofluorescence 
analysis 72 total hours post-transfection. 
 
Immunoprecipitation 
For the immunoprecipitation experiments in Chapter 4, protein extracts were prepared by 
resuspending HEK293 cell pellets in ice-cold lysis buffer (10 mM Tris/Cl pH 7.5; 150 mM NaCl; 
0.5 mM EDTA; 0.5% NP-40) supplemented with protease and phosphatase inhibitors (Roche), 
followed by passing through a 27-gauge syringe five times. Following centrifugation at 4°C for 15 
min at 12,000 g, the protein supernatant was collected, diluted to adjust detergent concentration 
to binding buffer (10 mM Tris/Cl pH 7.5; 150 mM NaCl; 0.5 mM EDTA; 0.1% NP-40), and cleared 
through a 45 µm filter prior to addition to GFP-Trap agarose beads (Chromotek). Incubation was 
carried out at 4°C for 1 h, followed by five washes with 1 ml of ice-cold binding buffer. Proteins 
were eluted in SDS/PAGE sample buffer prior to downstream applications.  
 
Mass spectrometry and bioinformatics 
For analysis in Chapter 4, protein identification by liquid chromatography coupled to tandem 
mass spectrometry (LC MS/MS) was carried out at the Proteomics Shared Resource in the 




immunoprecipitates were separated on 4-12% gradient gels, followed by in-gel digestion with 
trypsin. The resulting peptides were processed using a Dionex Ultimate 3000 Nano liquid 
chromatography system, and electrosprayed into an Orbitrap Fusion Tribrid mass spectrometer 
equipped with an EASY-Spray source (Thermo Scientific). Tandem mass spectra were analyzed 
using the Proteome Discoverer 1.4 software (Thermo Finnigan) to search the human Uniprot 
protein database (September 2014 release). SEQUEST search results from Proteome Discoverer 
were further analyzed by Scaffold (Proteome Software Inc.) with protein and peptide false 
discovery rates set at 1% to generate the protein list and spectral counts shown in Table 4.1. 
Gene ontology analysis was performed using DAVID version 6.7. Functional protein association 
networks were analyzed using STRING version 10.5. 
 
Organelle fractionation 
For fractionation experiments in Chapter 4, purification of mitochondria, ER and MAM was 
performed as previously described (Area-Gomez, 2014; Wieckowski et al., 2009). HEK293 cells 
transfected with GFP and GFP-STAS were homogenized in isolation buffer (250 mM mannitol, 5 
mM HEPES pH 7.4, and 0.5 mM EGTA). The homogenate was centrifuged for 5 min at 600g to 
remove cells debris and nuclei. The supernatant was then centrifuged for 15 min at 10,500g to 
yield the ER/microsomal fraction (supernatant) and the crude mitochondrial fraction (pellet). The 
supernatant was further centrifuged for 1 h at 100,000g to pellet the ER/microsomal fraction. The 
crude mitochondrial fraction was layered on a 30% Percoll gradient, ultracentrifuged for 30 min at 
95,000 g, and the upper (MAM) and lower (mitochondria free of ER) layers were collected. The 
upper layer fraction was then centrifuged at 100,000g for 1 h and the resulting MAM pellet was 
resuspended in isolation buffer. The lower layer fraction was diluted fivefold with isolation buffer 
and washed twice by centrifugation at 6,300g for 10 min, after which pure mitochondria were 
resuspended in isolation buffer. All fractions were quantitated for total protein content using the 





AAV9 production  
 For the experiments in Chapter 2, DNA for production of AAV9 vectors was purified using 
endotoxin free Mega prep kit (Qiagen) according to the manufacturer’s instructions. The 
generation of AAV9 was then performed by Sanofi. The recombinant plasmids were each 
packaged into AAV serotype-9 capsid by triple-plasmid transfection of human HEK293 cells, and 
virions were purified by CsCl gradient centrifugation as previously described (Mueller et al., 2012). 
The resulting vectors were concentrated to final titers of about 2x1013 genome copies/ml using 
Amicon Ultracel centrifugal filter devices with a 30,000 nominal molecular weight limit (Millipore).   
For the experiments in Chapter 3, the corresponding AAV9 vectors packaged into serotype-
9 capsid were custom produced by Vector BioLabs using triple plasmid transfection of HEK293 
cells and purification by two rounds of CsCl gradient centrifugation.  
For the experiments in Chapter 5, GFP and SMN constructs as previously described 
(Passini et al., 2010) were used to generate AAV9 by Sanofi detailed above. 
The titer and purity of each AAV9 preparation were confirmed in-house by qPCR (see Table 
7.1 for primers) and silver staining, respectively. For qPCR analysis of titer, 2 µl of virus was 
added to 48 µl of alkaline digestion buffer (25 mM NaOH, 0.2 mM EDTA) and incubated at 100°C 
for 10 minutes before cooling on ice and addition of 50 µl of neutralization buffer (40 mM Tris-HCl, 
pH 5.0). qPCR was performed using serial dilutions of the virus which were compared relative to 
a standard curve. 
 
Experimental procedures with mice 
All mouse work was performed in accordance with the National Institutes of Health 
Guidelines on the Care and Use of Animals and approved by the IACUC committee of Columbia 




because gender-specific differences were not found. Genotyping for sex determination was 
performed using tail DNA PCR and the primers are listed in Table 7.1. 
The SMND7 mouse line (Smn+/–/SMN2+/+/SMNΔ7+/+) used to generate SMA mice and 
utilized for experiments in Chapter 2, Chapter 3 and Chapter 5 was on a pure FVB background 
and was obtained from Jackson Mice (Jax stock #005025). Genotyping of the Smn knockout allele 
was performed using tail DNA PCR and the primers listed in Table 7.1 as previously described 
(Fletcher et al., 2017). To generate SMA mice that were p53 null used in Chapter 2, the p53 
knockout strain Trp53tm1Tyj (Jax stock #002101) was crossed onto a SMND7 background and 
genotyped using tail DNA PCR and the primers listed in Table 7.1. As described in Chapter 4, 
heterozygous mice harboring the gene trapped Tmem41bGt(OST208407)Lex  knockout allele in a 
129S5/SvEvBrd x FVB/NJ background were obtained from Lexicon Pharmaceuticals and crossed 
with pure FVB mice for over ten generations. Genotyping was carried out with genomic DNA 
isolated from mouse tails or whole embryos by PCR amplification using primers across the 
integration site using a common forward primer and either a reverse primer specific for the wild-
type allele or a reverse primer located in the gene trap cassette for the knockout allele (see Table 
7.1). For experiments in Chapter 5, C57BL6J mice were obtained from the Jackson Laboratory 
(Jax stock #000664).  
All ICV injections in SMA mice were performed at P0 and ICV injections in C57BL6J mice 
were performed at P1. First, mice were anesthetized by 5% isoflurane inhalation with 3% oxygen 
for an initial induction period of one minute then lowered to 2.5% isoflurane for an additional two 
minutes before injection. Injections were performed under a microscope using a 25 µl Hamilton 
syringe with a 32G needle in the right lateral ventricle of the brain at a site located 1 mm lateral 
to the sagittal sinus and 1 mm rostral to the transverse sinus and at a depth of 2 mm. After a 30 




For experiments in Chapters 2 and 3, I delivered ~1x1011 genome copies of the indicated 
AAV9 vectors in a PBS solution containing a final concentration of 0.05% of a vital dye (Fast 
Green, Sigma) by ICV injection. For ICV injections of MOs in Chapter 2, stock solutions of the 
described oligonucleotides at 50 µg/µL in a PBS solution were diluted to the described doses (25-
400 µg) in a final volume of 5µL with the exception of the highest dose which was in a final volume 
of 10 µL. A final concentration of 0.05% of a vital dye (Fast Green, Sigma) was added prior to 
injection. MOs were obtained from GeneTools, LLC and the sequences are shown in Table 7.1. 
For experiments in Chapter 5, a dose response of 1.25x1010vg/g, 2.5x1010vg/g, 5x1010vg/g, and 
1x1011vg/g of AAV9-SMN and 5x1010vg/g of AAV9-GFP were delivered by ICV injection. All ICV 
injections for delivery of AAV9 were performed in a final volume of 5µL with the exception of the 
highest dose of AAV9-SMN in Chapter 5 which was in a final volume of 10 µL. 
For experiments in Chapter 3, IP injections were performed daily using a 10 or 25 µL 
Hamilton syringe with a 32G needle at a volume of 2.5 µL per gram. MW150 dissolved in a saline 
solution was delivered at a final dose of 5 mg/kg. For vehicle treatment, the same volume of a 
saline solution was delivered by IP injection. Injections were performed following daily behavioral 
monitoring. 
For experiments in SMA mice for Chapters 2, 3, and 5, daily measurements of weight, 
righting time and survival were recorded from neonatal mice. To perform the righting time assay, 
pups were placed on their back and the time required to right and stand on four limbs was 
recorded with a cut off time of 60 seconds. This measurement was taken three times per pup 
each day and an average value was recorded as the performance for each animal. Experimental 
SMND7 mice were weighed and monitored for survival every day beginning at P0. 
As described in Chapter 5, motor behavioral assays in adult mice were performed as follows. 
For assessment of hindlimb clasping, mice were suspended by the tail and observed for 60 
seconds for significant clasping of the hindlimbs. Animals were monitored once weekly and the 




inverted grid assay, animals were placed on a metal grid with 1 cm by 1 cm dimensions and slowly 
inverted over a 30 cm tall cylinder then timed until falling. Three trials were performed for each 
animal with a minimum of ten minutes rest between trials and a cut-off time of 180 seconds. Data 
across all trials was averaged for a single value representing the performance of each animal. 
Beginning at three weeks of age, animals were assayed on the inverted grid weekly, and 
performance across each 4 weeks was averaged and reported in monthly time bins. For 
assessment of performance on the rotarod, animals were first trained at a constant speed of 4 
rpm for three trials of 60 seconds each. For data collection the following week, animals were 
placed on the rotarod and the speed was accelerated from 4 rpm to 40 rpm over a period of 300 
seconds. Three trials were performed for each animal with a minimum of 10 minutes between 
each and the times of fall were recorded and averaged for each data point representing the 
performance of one animal. Training was performed at four weeks of age and beginning at five 
weeks of age animals were assayed on the rotarod weekly, and performance across each four 
week period was averaged and reported in monthly time bins. Experimental adult mice used for 
data in Chapter 5 were weighed once per week and monitored for survival daily. Weekly 
measurements of weight were averaged across four week periods and reported in monthly time 
bins. 
For dissection animals were first anesthetized with 5% Avertin. Subsequently, mice were 
sacrificed by decapitation and tissue collection was performed in a dissection chamber under 
continuous oxygenation (95%O2/5%CO2) in the presence of cold (~12°C) artificial cerebrospinal 
fluid (aCSF) containing 128.35mM NaCl, 4mM KCl, 0.58mM NaH2PO4, 21mM NaHCO3, 30mM 
D-Glucose, 1.5mM CaCl2, and 1mM MgSO4. Tissue collected for immunofluorescence analysis 
was submerged in 4% PFA for post-fixation. Muscle tissue collected from neonatal mice was post-
fixed for 1 hour before being moved to PBS, and all other tissues were post-fixed overnight. 




and all other tissues were post-fixed overnight. Tissue collected for RNA and protein analysis was 
flash frozen on dry ice and stored at -80°C. 
For the embryo analysis described in Chapter 5, pregnant females were first euthanized 
CO2 asphyxiation. An incision was made to open the peritonium and expose the body cavity. The 
uterus was then removed and placed in cold PBS where each embryo was separated, cleaned of 




Recordings of the monosynaptic reflex for experiments in Chapter 2 and 3 were performed 
as previously described (Simon et al., 2017). The intact ex vivo spinal cord preparation was 
perfused continuously with oxygenated (95%O2/5%CO2) aCSF (~10ml/min). The dorsal root and 
ventral root of the L2 (Chapter 2) or L1 (Chapter 3) segment were placed into suction electrodes 
for stimulation or recording respectively. The extracellular recorded potentials were recorded (DC 
- 3kHz, Cyberamp, Molecular Devices) in response to a brief (0.2ms) stimulation (A365, current 
stimulus isolator, WPI, Sarasota, FL) of the corresponding dorsal root. The stimulus threshold 
was defined as the current at which the minimal evoked response was recorded in three out of 
five trials. Recordings were fed to an A/D interface (Digidata 1440A, Molecular Devices) and 
acquired with Clampex (v10.2, Molecular Devices) at a sampling rate of 10kHz. Data were 
analyzed off-line using Clampfit (v10.2, Molecular Devices). Measurements were taken from 
averaged traces of five trials elicited at 0.1Hz. The temperature of the physiological solution 
ranged between 21-25°C. Synaptic depression experiments were performed and analyzed for all 
experimental groups at P11. The dorsal root was stimulated at 10Hz for five stimuli and the 
resulting monosynaptic component of the amplitude recorded and analyzed off-line. The 





For experiments in Chapters 2 and 3, the function of the neuromuscular junctions of the 
QL muscle at P11 was assessed ex vivo as previously described (Fletcher et al., 2017). After the 
removal of the spinal cord, the remaining vertebral column with the ventral root L1-L3 in continuity 
to the QL was transferred to the recording chamber into aCSF. The ventral root L2 was placed 
into a suction electrode to stimulate the motor neuron axons. Visual twitching of the QL after 
stimulation of the ventral root L2 ensured proper stimulation of the muscle. Subsequently, to 
measure the compound muscle action potential (CMAP), a concentric bipolar electrode was 
inserted in the QL between the insertion point of ventral roots L1 and L2. The stimulus threshold 
was defined as the current at which the minimal evoked response was recorded in three out of 
five trials. The nerve was stimulated at 1, 2, 5 and 10X threshold to ensure a supramaximal 
stimulation of the muscle. The maximum CMAP amplitude (baseline-to-peak) was determined as 
the average from five measurements. 
 For measurements of the H-reflex, EMG recordings were performed under isoflurane 
anesthesia (2% vaporized in O2 at a 2 liters per minute flow rate). A pair of needle electrodes was 
inserted in the thigh for sciatic nerve stimulation and another pair of electrodes was inserted in 
the hind paw for interosseous muscles electromyogram recording. A constant-current stimulator 
was used to deliver short pulses (0.1ms in duration) at increasing intensities of low-frequency 
(0.1Hz to 10Hz). The stimulation intensity was ranged from sub-threshold levels for the induction 
of Compound Muscle Action Potentials to twice this intensity (sufficient to elicit maximal M-waves 
amplitude). The maximal amplitude reached throughout the stimulation intensity range for the H-
reflex was acquired and stored for analysis. Body temperature was monitored and maintained at 
38°C with a heating pad throughout the entire recording session and the mouse was euthanized 
immediately thereafter with an intraperitoneal injection of tribromoethanol (300 mg/kg) followed 






Motor neuron isolation by LCM 
The LCM of motor neurons for experiments in Chapter 2 was carried out essentially as 
previously described (Lotti et al., 2012). In order to retrogradely label motor neurons, the IL and 
QL muscles of P2 WT and SMA mice were exposed, and ~1 µl of cholera toxin B subunit (CTb) 
conjugated to Alexa 488 was delivered by intramuscular injection using a finely pulled glass 
microelectrode. At P6, the spinal cord was dissected, and the L1 through L3 segments were 
embedded in OCT and flash frozen using liquid nitrogen. Segments were sectioned longitudinally 
at a thickness of 14µm and mounted on PEN-Membrane Slides 2.0 (Zeiss) then stored at -80°C 
until LCM. Frozen slides immediately submerged in fresh 100% ethanol for 15 seconds to fix prior 
to laser capture microdissection. Following air-drying for 30 seconds to allow remaining ethanol 
to evaporate, individual motor neurons were microdissected using a DM6000B microscope 
equipped with a LMD6000 laser capture unit (Leica). Each slide was processed for a maximum 
of 30 minutes and cells were collected into a tube containing lysis buffer to preserve RNA quality. 
Approximately 200 motor neurons were collected bilaterally from L1-L3 spinal segments of one 
or more mice for each sample group and biological replicate.  
 
RNA and protein analysis 
For RNA analysis in Chapters 2, 3, 4 and 5, purification of total RNA from mouse tissue 
(except DRGs and LCM motor neurons) and NIH3T3 cells was carried out using TRIzol reagent 
(Invitrogen). Each cell pellet was resuspended in 1 mL of TRIzol the passed through a 25G needle. 
For tissue samples 0.5 mL of TRIzol was added and a manual pestle was used to homogenize 
the tissue. Another 0.5 mL of TRIzol was then added and the sample was passed through a 21G 
needle followed by a 25G needle. 200 µl of chloroform was added to each sample and then 
vigorously vortexed. After a 3 minute incubation at room temperature, samples were centrifuged 




isopropanol, vortexed and incubated at room temperature for 10 minutes. Samples were then 
centrifuged for 10 minutes at 12,000 g to pellet precipitated RNA. Following two washes with 70% 
ethanol and 5 minute centrifugations at 7,600 g, pellets were allowed to air-dry for 10 minutes at 
room temperature. Pellets were then resuspended in nuclease free H2O and treated with RNAse-
free DNaseI (Ambion). A final phenol/chloroform extraction was performed and RNA was ethanol 
precipitated with glycogen at -80°C. Prior to running an RT reaction, samples were centrifuged 
for 30 minutes at 16,100g then washed once with 70% ethanol. After air-drying and resuspension 
in nuclease free H2O the concentration was measured with a Nanodrop (ThermoFisher). For each 
RT reaction 1 µg of RNA was used. cDNA was generated using RevertAid RT Reverse 
Transcription Kit (ThermoFisher) with equal amounts of random hexamer and oligo dT primers.  
For RNA analysis by RT-qPCR and RNA seq from DRGs in Chapter 5, total RNA was 
isolated using RNAqueous®-Micro Kit (Ambion) including DNaseI treatment. For RT-qPCR 
analysis, cDNA was generated using RevertAid RT Reverse Transcription Kit (ThermoFisher) 
with equal amounts of random hexamer and oligo dT primers. For each RT reaction 200 ng of 
RNA was used.  
For experiments in Chapter 2, total RNA was purified from LCM motor neurons using the 
Absolutely RNA Nanoprep Kit (Agilent). RNA quality and quantity was assessed using the 2100 
Bioanalyzer (Agilent) to ensure a RIN value greater than 7. Amplified cDNA was prepared from 
total RNA using the Ovation PicoSL WTA System V2 Kit (Nugen) and purified with the MinElute 
Reaction Cleanup Kit (Qiagen).  
For experiments in Chapter 2, RT-PCRs were first performed at increasing cycle numbers 
to ensure analysis was performed within the linear range of amplification using AmpliTaq Gold 
DNA Polymerase (Thermo Fisher). The identity of all the RT-PCR products was confirmed by 
DNA sequencing. Quantification of RT-PCR bands was performed with ImageJ. For all RT-qPCR 




reaction was run with 2.0 µl of a 100 µl RT reaction in a final volume of 25 µl. The primers used 
for RT-PCR and RT-qPCR experiments are listed in Table 7.1. 
For protein extract preparation for Western blot analysis from NIH3T3 cells, samples were 
resuspended in 2X SDS PAGE sample buffer and vigorously mixed. Two cycles of a 10 minute 
sonication in a water bath, and 5 minutes heating at 95°C were followed by passing through a 
27G needle. For protein extracts from mouse tissue, 2X sample buffer was added based on mass 
of the tissue at a concentration of 100 µg/µl for liver and 200 µg/µl for spinal cord. Tissue was 
homogenized first using a manual pestle, then the Microson Ultrasonic Cell Disruptor XL (Misonix). 
Sonication was performed at a setting of 2.5 for 10 seconds, followed by 30 seconds on ice and 
repeated three times. Samples were then heated at 95°C for 5 minutes then passed through a 
27G needle before quantification. Protein samples in sample buffer were quantified using the 
compatible RC DCTM protein assay (BioRad). Protein extracts were run on 12% polyacrylamide 
gels and transferred to nitrocellulose membranes for probing. Membranes were blocked for 1 hour 
in 5% milk in PBS/0.1% Tween or in 5% BSA in PBS/0.1% Tween for probing with phospho-
specific antibodies. Primary antibodies were diluted in PBS/0.1% Tween and incubated for 2 
hours at room temperature. Following three 10 minute washes, membranes were incubated in 
secondary antibodies diluted in PBS/0.1% Tween for 1 hour. After probing with secondary 
antibodies membranes were subject to three 10 minute washes before developing with 
SuperSignalÒ West Pico Chemiluminescent Substrate. The antibodies and dilutions used 
Western blot are listed in Tables 7.2 and 7.3.  
 
RNA sequencing and analysis 
Total RNA was isolated from lumbar DRGs using RNAqueous®-Micro Kit (Ambion) 
followed by DNaseI treatment as detailed above. RNA quality and quantity was assessed using 




independent replicates per experimental group were deep-sequenced with the HiSeq 4000 
platform, yielding about 80 million 2x100 paired-end reads per sample. All RNA-Seq data were 
mapped to the reference mouse genome (mm10) and a database of exon junctions using OLego 
(v1.1.5) (Wu et al., 2013). As described previously (Yan et al., 2015), the Quantas pipeline 
(http://zhanglab.c2b2.columbia.edu/index.php/Quantas) was used to quantify alternative splicing 
(AS) and perform differential splicing analysis, requiring read coverage ≥ 20 reads and false 
discovery rate (FDR) ≤ 0.05 (FDR was estimated by the Benjamini-Hochberg procedure) 
(Benjamini, Yoav ; Hochberg, 1995). The edgeR method included in the Quantas pipeline was 
used to perform differential expression analysis between WT, AAV-GFP, and AAV-SMN. All the 
biological replicates were combined for quantification. To identify exons with differential splicing 
in two compared conditions, statistical significance of splicing changes was evaluated using both 
exonic and junction reads that support each of the two splice isoforms. In the two compared 
conditions, an AS event was determined to be differentially spliced if the event had sufficient read 
coverage (coverage ≥ 20), proportional change of exon inclusion |∆I| ≥ 0.1, and FDR ≤ 0.05. 
Similarly, statistical significance of differentially expressed genes within two compared conditions 
was called by requiring FDR < 0.05, fold change > 2, and RPKM greater than median in either 
condition. Gene ontology analysis was performed using DAVID version 6.8. 
  
Immunofluorescence and immunohistochemistry analysis 
For immunofluorescence analysis, NIH3T3 fibroblasts plated on coverslips were fixed in 
4% PFA for 15 minutes then permeabilized with 0.5% Triton-X 100 in PBS for 10 minutes at room 
temperature. Samples were blocked in 3% BSA/0.05% sodium azide in PBS for 1 hour, and 
incubated with primary antibodies in blocking buffer for 2 hours. Following three 5 minutes washes, 
coverslips were incubated with secondary antibodies (Jackson ImmunoResearch) and DAPI 




ProLongTM Gold Antifade Mountant (Thermo Fisher). Coverslips were allowed to cure overnight 
at room temperature before being sealed. 
For spinal cord analysis, specific lumbar segments were identified by the relative thickness 
and location of the ventral roots. Prior to sectioning, the specific segment of interest was cut from 
the spinal cord and the dura mater and roots were thoroughly removed. Similarly, DRGs were 
also identified by the ventral roots. Spinal cord segments, DRGs, or liver used for 
immunohistochemical analysis were embedded in 5% agar in PBS. Blocks were then cut to size 
and sectioned at 75 µm with a VT1000 S vibratome (Leica) at a speed of 4 and a frequency of 7. 
No more than five sections were placed in each well of a 12 well plate and stained as free-floating 
sections. First, blocking was performed in 10% donkey serum in 0.01M PBS/0.4% Triton-X for 1.5 
hours. For the staining of DRGs in Chapter 5 that were performed with mouse primary antibodies, 
an additional blocking step with 40 µg/ml of Anti-mouse IgG Fab Fragment (Jackson) in 0.01M 
PBS/0.4% Triton-X for two hours was performed after normal blocking with donkey serum. After 
blocking, sections were then incubated with primary antibodies at a volume of 700 µl overnight at 
room temperature. Six washing steps of 10 minutes each with 0.01M PBS/0.4% Triton-X were 
done prior to incubation with secondary antibodies (Jackson ImmunoResearch) at a volume of 
750 µl diluted in 0.01M PBS for 3 hours at room temperature. Another six washing steps with 
0.01M PBS were performed before sections were mounted on slides with 30% glycerol/PBS. For 
co-staining of SMN and SmB described in Chapter 5, the protocol above was followed first staining 
with ChAT for spinal cord sections and PV for DRG sections. After the last washing step following 
incubation with secondary antibodies, SMN primary antibody was added to the section and the 
protocol was repeated using an isotype specific secondary antibody. The protocol was repeated 
once again for SmB using an isotype specific secondary antibody before mounting on slides as 
described above. For co-staining of PV and mouse primary antibodies in DRGs shown in Chapter 
5, DRG sections were stained sequentially in the manner described above, first with PV, then with 




For NMJ analysis of skeletal muscle (QL or EDL), tissue was first cryoprotected in 10% 
sucrose for 1 hour, 20% sucrose for 2 hours, and 30% sucrose overnight. The next day, muscles 
were embedded in OCT, and flash frozen on dry ice before storing at -80°C. Before sectioning, 
blocks were equilibrated at -20°C for 30 minutes. 30µm cryosections were cut and adhered to 
Superfrost Plus slides and stored at -80°C. Upon staining, slides were brought to room 
temperature and a hydrophobic barrier was drawn around the sections with a PAP pen. PBS was 
added on top of sections for 10 minutes to dissolve remaining OCT. Sections were then blocked 
with 5% donkey serum in TBS/0.2% Triton-X for 1 hour at room temperature prior to staining. 700 
µl primary antibody in blocking buffer was added to the top of sections and incubated overnight 
at 4°C. The next day, sections were washed three times for 10 minutes in TBS/0.2% Triton-X, 
then incubated with secondary antibodies in TBS/0.2% Triton-X for 1 hour at room temperature, 
followed by three washing steps of 5 minutes each. Slides were mounted with Fluoromount-G® 
(SouthernBiotech) and allowed to cure overnight at room temperature. 
The antibodies and dilutions used for immunohistochemistry and immunofluorescence 
experiments are listed in Table 7.2.  
 
Confocal microscopy and quantification 
All imaging of immunofluorescence and immunohistochemistry experiments were 
acquired using a Leica SP5 confocal microscope and analyzed off-line using the Leica LASAX 
software from z-stack images.  
For motor neuron number quantification in P11 neonatal mice for Chapters 2 and 3, entire 
segments of the L1, L2 or L5 spinal cord were sectioned and scanned using a 20X objective at 3 
µm steps in the z-axis. The number of motor neurons of one hemi cord from each section was 
quantified and 11 sections were added to obtain the total number of motor neurons for that 




a minimum of 14 sections were sectioned, scanned and quantified as detailed in the figure 
legends and each biological replicate is reported as an average value of all sections. For motor 
neuron quantification of P11 neonatal mice in Chapter 5, 11 sections for each spinal segment 
were quantified and each biological replicate is reported as an average value of all sections. In 
Chapter 5 motor neuron number in the SMNΔ7 mice was normalized to the average number of 
all wild-type replicates for each age of analysis. 
For quantification of proprioceptive synapses images were acquired using a 40X objective 
at 0.3 µm steps in the z-axis. Gamma motor neurons which do not receive VGluT+ inputs were 
excluded from the analysis. The number of the total proprioceptive inputs on single motor neurons 
were quantified from scans that spanned the entire soma and data is reported as an average of 
all neurons that were counted from multiple biological replicates. For analysis of proprioceptive 
inputs on motor neuron dendrites in Chapter 5, the number of VGluT1+ synapses on the proximal 
50 µm of dendrites were counted and divided by the length to determine the synaptic density. 
For the quantification of MNJ denervation, images were obtained using a 20X objective at 
2 µm steps in the z-axis. Scans were set through visualization of bungarotoxin – a marker of the 
post-synaptic terminus – in order to remain unbiased. A minimum of ~200 NMJs from each 
biological replicate of neonatal mice or ~100 NMJs from adult mice were quantified per animal 
and data is reported as an average percent for multiple biological replicates. 
For SmB intensity analysis in Chapters 2 and 5, images were acquired using a 40X 
objective (for L2) or 20X objective (for L5 and DRG) at identical settings for WT and SMA or WT 
and AAV-injected samples which were collected and processed in parallel. Scans were collected 
at 3 µm steps and analysis was performed using LASAX software by measuring the peak intensity 
per unit area of the nuclear region of motor neurons and proprioceptive neurons. The data for 
each individual neuron is represented with multiple biological replicates being pooled together for 




For the quantification of p53 and p-p53 positivity in cell culture experiments in Chapter 3 
scans were performed using a 40X objective with a 2 µm step using identical settings for all 
treatment groups which were processed in parallel. Positivity was scored as a significant nuclear 
signal relative to background. For quantification of in vivo experiments in Chapters 2 and 3, scans 
were performed using a 20X objective with a 3 µm step using identical settings for all treatment 
groups which were processed in parallel. Positivity was again scored as a significant nuclear 
signal relative to background. 
 
Structured illumination microscopy (SIM) 
Cells plated on high-performance coverslips (Zeiss) were imaged on a Nikon Ti Eclipse 
inverted microscope with a SIM illuminator and iXon Ultra 897 camera (Andor) using an apo TIRF 
100X oil immersion objective. Image reconstruction was performed with NIS-Elements software 
(Nikon). Reconstruction parameters were set as follows. Illumination modulation contrast of 2 for 
all channels. High-resolution noise suppression of 0.33, 0.29, and 0.10 for 561, 488, and 405 




Results are expressed as mean + standard error of the mean (SEM) from at least three 
independent experiments and biological replicates unless otherwise indicated. For statistical 
analysis, differences between two groups were analyzed by two-tailed unpaired Student's t-test 
and differences among three or more groups were analyzed by one-way followed by Tukey’s post 
hoc test or two-way ANOVA with Sidak’s multiple comparisons test as appropriate. Statistical 
analyses used are described in detail in the figure legends. GraphPad Prism 5 or GraphPad Prism 
8 was used for all statistical analyses and P values are indicated as follows: (*) P < 0.05; (**) P < 




Table 7.1 Primers and Oligonucleotides used in this study. 
 
RT-qPCR primers for analysis of mRNA expression 
Gene Name Forward Sequence (5’ to 3’) Reverse Sequence (5’ to 3’) 
mouse Mdm2 total TGGAGTCCCGAGTTTCTCTG GATGTGCCAGAGTCTTGCTG 
mouse Mdm4 total GTTCAGCATCTGACAGTGC CACCTGCTGCATGCAAAATC 
mouse Mdm2 E3 incl CAAGCACCTCACAGATTCCAGC GTAAGTGTCGTTTTGCGCTCC 
mouse Mdm4 E7 incl CTCAGACTCTCGCTCTCGCAC TCAGTTCTTTTTCTGGGATTGG 
mouse p53 GCCAAGTCTGTTATGTGCAC GACTTCTTGTAGATGGCCATG 
mouse Cdkn1a GACATTCAGAGCCACAGGCACC GAGCGCATCGCAATCACGGCGC 
mouse Perp1 CAGAGCCTCATGGAGTACGC GAGAATGAAGCAGATGCACAGG 
mouse Ccng1 CAGTTCTTTGGCTTTGACAC CTTTCCTCTTCAGTCGCTTT 
mouse Gtse1 TGACAAAGAGAACGTGGACTCAC GAGGTGGGAGGCTTAGGTTC 
mouse Ptprv GGAGCGCTCATTTTGTCTTC TGAGGCTAAGGCGGTAAGAA 
mouse Pmaip CACCTGAGTTCGCAGCTCAAC CATCTGCGCCAGAACCACAG 
mouse Fas GCTTGCTGGCTCACAGTTAAG CAGCAAAATGGGCCTCCTTG 
mouse Plk2 CGTACAGGTGCATAAGGGAAG GGACAGCATGCTAGCTATCAAG 
mouse Crip2 CACGATGGCCAGCCCTACTGC CGGGTCCTTGTCGTAGATATAG 
mouse Sesn1 GCCTTCTGAAAGCAGAGGAGC GTAGTGTGTGAGCAGAACCAC 
mouse Mmp2 CACCACGTGACAAGCCCACAG GCCTCATACACAGCGTCAATC 
mouse Aldh4aI GTGGAAGCCCAGTGACACTGC CCGTCGGCTGGCACAAACTG 
mouse c-Fos CATCCTTACGGACTCCCCACC CTTCTGCCGATGCTCTGCGCTC 
mouse Pten CTGCAGAGTTGCACAGTATC GCTGCAACATGATTGTCATC 
mouse Stas GAACGAAAAGCCTTGTGCAGAAGC  TTCACCCTCTCTTCCTCACTAAGCTG  
mouse Stas Aber TGACGCCAAGGCTCTAGGAAAA CCAAGTCCGGAGCATTGTACATAAAAGG 
mouse H1c pre GAGCCACCACTCCCACTTAAG GGATCGAGTCCCTTGCAAC 
mouse Chodl CCTACCTTTACCAGTGGAATGACG TGGGTCTCTTCAGGTTGGTTTG 
mouse Smn TGCTCCGTGGACCTCATTTCTT TGGCTTTCCTGGTCCTAATCCTGA 
mouse SmB ATCGGGACCTTCAAAGCCTTTGAC GAAGCAACACCAGACCAAGGACT 
mouse Gapdh AATGTGTCCGTCGTGGATCTGA GATGCCTGCTTCACCACCTTCT 
human SMN2FL CACCACCTCCCATATGTCCAGATT GAATGTGAGCACCTTCCTTCTTT 
human STAS AGCAGAGACCACCAGAAGGAAA GCTGCAGATAAGAAAATGGACACCAAT 
GFP CGTCTATATCATGGCCGACAAGCA TTGTGGCGGATCTTGAAGTTCACC 
RT-PCR primers for analysis of Mdm2 and Mdm4 alternative splicing 
Gene Name Forward Sequence (5’ to 3’) Reverse Sequence (5’ to 3’) 
mouse Mdm2 E2-5 GATCACCGCGCTTCTCCTGC CAATGTGCTGCTGCTTCTCG 
mouse Mdm2 E2-6/7 GATCACCGCGCTTCTCCTGC GATGTGCCAGAGTCTTGCTG 
mouse Mdm2 E6/7-12 CAGCAAGACTCTGGCACATC GTGTGATGGAAGGGGAGGATTC 
mouse Mdm4 E5-8 TGTGGTGGAGATCTTTTGGG TCAGTTCTTTTTCTGGGATTGG 
mouse Mdm4 E1-E5 CAGCTAGGAGGGGGAGCGACTC GCTCTGACATCCAAGTAGATCTCC 




qPCR primers for AAV titration 
Gene Name Forward Sequence (5’ to 3’) Reverse Sequence (5’ to 3’) 
GUSB CACCTCCCGCGCTTTTCTTAGC CGGGCCATGCTTCCCGGTCCC 
AAV-5‘ GTTGCCTTTACTTCTAGGCCTGTACG TCGGCCCTTAAAACCGGTGGAT 
AAV-3’ CCTTCTAGTTGCCAGCCATCTGTT AGTGGCACCTTCCAGGGTCAA 
Antisense morpholino oligonucleotides 




PCR primers for mouse genotyping 
Gene Name Forward Sequence (5’ to 3’) Reverse Sequence (5’ to 3’) 
SmnWT GATGATTCTGACATTTGGGATG TGGCTTATCTGGAGTTTCACAA 
SmnKO GATGATTCTGACATTTGGGATG GAGTAACAACCCGTCGGATTC 
p53WT AGGCTTAGAGGTGCAAGCTG TGGATGGTGGTATACTCAGAGC 
p53KO CAGCCTCTGTTCCACATACACT TGGATGGTGGTATACTCAGAGC 
SmnRes  ACGCGTACCGTTCGTATAGC  TGAGCACCTTCCTTCTTTTTG  
StasWT ACCAAATAGACCGGTTCGTTATCC AAAAGGACGCGCAACTACAACTACC 
StasKO  ACCAAATAGACCGGTTCGTTATCC ATAAACCCTCTTGCAGTTGCATC 
PVWT  GGATGCTTGCCGAAGATAAGAGTG CGAGGGCCATAGAGGATGG 
PVCRE  GGATGCTTGCCGAAGATAAGAGTG GCGGAATTCTTAATTAATCAGCG 
ChATWT  GTTTGCAGAAGCGGTGGG GGCCACTTAGATAGATAATGAGGGGCTC 
ChATCRE  TCGCCTTCTTGACGAGTTCTTCTG GGCCACTTAGATAGATAATGAGGGGCTC 





Table 7.2 Antibodies used in this study. 
 
The antibodies used in this work are as follows. The dilutions are indicated for Western blot (WB) 
and immunofluorescence (IF), and immunohistochemistry (IHC). 
 
Primary Antibodies 
Name Source Cat # Host Application Dilution 
SMN (clone 8) BD Transd Lab 610646 Mouse WB, IHC 
1:10,000, 
1:100 
Tubulin (DM1A) Sigma T9026 Mouse WB 1:10,000 
p53 Leica Novocastra NCL-p53-CM5p Rabbit IHC 1:1,000 
p53 Cell Signaling 2524 Mouse WB,  IF 
1:1,000, 
1:200 
p-p53S15 Cell Signaling 9284 (Lots: 12,15) Rabbit IF,  IHC 
1:500, 
1:200 
SmB Carissimi et al., 2006 N/A Mouse WB,  IF, IHC 
1:10,  
1:2 
GFP Aves GFP-1020 Chicken IF, IHC 1:500 
VGluT1 Covance (custom made) N/A 
Guinea 
pig IHC 1:5,000 
Synaptophysin Synaptic Systems 101-004 Guinea pig IHC 1:500 
Neurofilament Millipore AB1987 Rabbit IHC 1:1000 
ChAT Millipore AB144P Goat IHC 1:100 
Bungarotoxin Invitrogen T1175 N/A IHC 1:500 
p62 MBL PM045 Rabbit WB,  IF, IHC 
1:1,000, 
1:500 
LC3B Novus NB600-1384 Rabbit WB 1:4,000 
p38 MAPK Cell Signalling 8690 Rabbit WB 1:1000 
p-p38 MAPK Cell Signalling 4511 Rabbit WB 1:1000 
COPA (H-3) Santa Cruz sc-398099 Mouse WB 1:1000 
COPB (D-10) Santa Cruz sc-393615 Mouse WB 1:1000 
VDAC1 Abcam ab34726 Rabbit WB 1:2000 
ERLIN2 Cell Signaling 2959 Rabbit WB 1:1000 
GFP Sigma G1544 Rabbit WB 1:5000 
SDHA Abcam ab14715 Mouse WB 1:1000 
dsRed Takara 632496 Rabbit IF 1:250 
OXPHOS Abcam ab110413 Mouse IF 1:250 
Parvalbumin Covance custom made Chicken IF 1:10,000 
Parvalbumin Swant PV25 Rabbit IHC 1:1000 











GW182 Bethyl 330A-1 Rabbit IHC 1:200 
FUS Bethyl A300-A393 Rabbit IF 1:1,000 
HuR Santa Cruz sc-5261 Rabbit IF  
KSRP Bethyl 021A-1 Rabbit IF 1:100 
hnRNPA1 (4B10) Santa Cruz sc-32301 Mouse IHC 1:100 
Crm1 BD 611832 Mouse IHC 1:200 
Ran BD 610340 Mouse IHC 1:200 
TIA-1 Santa Cruz sc-1751 Goat IHC 1:200 
ubiquitin Santa Cruz sc-6085 Goat IHC 1:100 
Actin  Proteintech 66009 Mouse WB 1:10,000 
Gapdh Millipore MAB374 Mouse WB 1:5,000 
Name Source Cat # Host Application Dilution 
DAPI Molecular probes D3571 N/A IF, IHC  1:1,000 
488 Anti-rabbit Jackson 711-545-152 Donkey IHC 1:250 
488 Anti-goat Jackson 705-545-147 Donkey IHC 1:250 
Cy3 Anti-rabbit Jackson 711-165-152 Donkey IHC 1:250 
Cy3 Anti-mouse Jackson 715-165-150 Donkey IHC 1:250 
Cy3 Anti-goat Jackson 705-165-147 Donkey IHC 1:250 
Cy5 Anti-goat Jackson 705-175-147 Donkey IHC 1:250 
Cy5 Anti-guinea pig Jackson 706-175-148 Donkey IHC 1:250 
488 Anti-chicken Jackson 703-545-155 Donkey IF 1:400 
405 Anti-mouse Jackson 715-475-150 Donkey IF 1:400 
HRP Anti-mouse  Jackson 115-035-044 Goat WB 1:10,000 
HRP Anti-rabbit Jackson 111-035-003 Goat WB 1:5000 
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Appendix. Other Scientific Contributions 
 
  
In addition to the work presented in this dissertation, I have contributed to several other 
projects described in this section. 
 
Advances in modeling and treating spinal muscular atrophy 
 
Meaghan Van Alstyne and Livio Pellizzoni 
 
Current Opinion in Neurology, 2016, 29(5):549-56 
 
 Spinal muscular atrophy (SMA) is an inherited childhood neurodegenerative disorder 
caused by ubiquitous deficiency of the survival motor neuron (SMN) protein - the hallmarks of 
which are the selective loss of motor neurons and skeletal muscle atrophy. Phenotypic 
characterization of mouse models of the disease, combined with analysis of SMN restoration or 
depletion in a spatially and temporally controlled manner, has yielded key insights into the normal 
requirement of SMN and SMA pathophysiology. Increasing evidence indicates a higher demand 
for SMN during neuromuscular development and extends the pathogenic effects of SMN 
deficiency beyond motor neurons to include additional cells both within and outside the nervous 
system. These findings have been paralleled by preclinical development of powerful approaches 
for increasing SMN expression through gene therapy or splicing modulation that are now in 
human trials. Here, we highlight recent progress in the understanding of SMA pathology and in 




Converging Mechanisms of p53 Activation Drive Motor Neuron Degeneration 
in Spinal Muscular Atrophy 
 
Christian M. Simon*, Ya Dai*, Meaghan Van Alstyne, Charalampia Koutsioumpa, John G. 
Pagiazitis, Joshua I. Chalif, Xiaojian Wang, Joseph E. Rabinowitz, Christopher E. Henderson, 






Cell Reports, 2017, 21(13):3767-3780 
 
The hallmark of spinal muscular atrophy (SMA), an inherited disease caused by ubiquitous 
deficiency in the SMN protein, is the selective degeneration of subsets of spinal motor neurons. 
Here, we show that cell-autonomous activation of p53 occurs in vulnerable but not resistant motor 
neurons of SMA mice at pre-symptomatic stages. Moreover, pharmacological or genetic inhibition 
of p53 prevents motor neuron death, demonstrating that induction of p53 signaling 
drives neurodegeneration. At late disease stages, however, nuclear accumulation of p53 extends 
to resistant motor neurons and spinal interneurons but is not associated with cell death. 
Importantly, we identify phosphorylation of serine 18 as a specific post-translational 
modification of p53 that exclusively marks vulnerable SMA motor neurons and provide evidence 
that amino-terminal phosphorylation of p53 is required for the neurodegenerative process. Our 
findings indicate that distinct events induced by SMN deficiency converge on p53 to trigger 




Minor snRNA gene delivery in SMA mice links U12 splicing dysfunction to 
the loss of proprioceptive sensory synapses on motor neurons 
 
Erkan Y. Osman*, Pei-Fen Yen*, Meaghan Van Alstyne, Francesco Lotti, Zhihua Feng, Karen 






Submitted for publication 
 
Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder caused by reduced 
expression of the survival motor neuron (SMN) protein. SMN has key functions in multiple RNA 
pathways, including the biogenesis of small nuclear ribonucleoproteins (snRNPs) that are 
essential components of both major (U2-dependent) and minor (U12-dependent) spliceosomes. 
Here we investigated the specific contribution of U12 splicing dysfunction to SMA pathology 
through selective restoration of this RNA pathway in mouse models of varying phenotypic severity. 
We show that viral-mediated delivery of minor snRNA genes specifically improves U12 splicing 
defects induced by SMN deficiency both in cultured mammalian cells and in the spinal cord of 
SMA mice without increasing SMN expression.  This approach resulted in a moderate but 
significant amelioration of several parameters of the disease phenotype in SMA mice, including 
survival, weight gain and motor function. Importantly, minor snRNA gene delivery induced a 
robust rescue of the severe loss of proprioceptive sensory synapses on SMA motor neurons, 
which is an early pathogenic signature of motor dysfunction in mouse models. Taken together, 
these findings establish the direct contribution of U12 splicing dysfunction to synaptic 





SMN Regulates Neuromuscular Junction Integrity Through U7 snRNP 
 




Spinal muscular atrophy (SMA) is a motor neuron disease caused by deficiency in the SMN 
protein that controls the biogenesis of several essential RNPs, however the contribution of 
individual SMN-dependent RNPs to motor circuit dysfunction in SMA remain unknown. To 
disentangle the SMN-dependent RNP pathways whose disruption functionally contributes to 
disease phenotypes, we investigated the contribution of the U7 snRNP pathway, which controls 
histone mRNA 3’ end processing, to SMA by selective restoration of this RNP under conditions 
of SMN deficiency. We show that overexpression of LSm10 and LSm11—two U7 snRNP-specific 
proteins—can increase U7 snRNP levels both in cellular and animal models of SMN deficiency 
leading to restored histone mRNA 3’ end processing. Postnatal restoration of U7 snRNP 
biogenesis in SMA mice lead to significant amelioration of neuromuscular junction pathology yet 
provided no benefit to other features of the disease such as sensory-motor synaptic defects or 
motor neuron survival. Overall, these findings establish a significant contribution of U7 snRNP 
dysfunction to SMA phenotypes in a mouse model, and suggest a basis for SMA disease that is 





FUS is not required for snRNP assembly and SMN localization to nuclear 
bodies 
 
Beatriz Blanco-Redondo, Meaghan Van Alstyne, Eileen Workman, Darrick Li, Martin Jacko, Neil 




Amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are fatal 
neurological disorders that involve the selective degeneration of spinal motor neurons. SMA is a 
monogenic disorder caused by ubiquitous deficiency in the SMN protein. ALS is predominantly a 
sporadic disorder, but several gene mutations have been linked to familial cases. Genetic and 
molecular studies have shown that FUS depletion or ALS-linked FUS mutations disrupt the normal 
localization of SMN to nuclear bodies. Furthermore, FUS has been shown to associate with SMN 
as well as spliceosomal snRNPs whose biogenesis is SMN-dependent. However, the normal 
requirement of FUS for snRNP biogenesis and the contribution of SMN dysfunction to FUS-ALS 
pathology remain unknown. To investigate whether FUS and SMN are functionally linked, we 
studied the effects of FUS depletion on the localization and function of SMN using a 
comprehensive set of molecular, biochemical and immunohistochemical approaches in mouse 
models. Here we demonstrate that while FUS and SMN do interact, FUS is not required for the 
activity of SMN in snRNP assembly and that FUS ablation neither affects snRNP biogenesis nor 
SMN localization to nuclear bodies in motor neurons in vivo. These findings argue against 
disruption of SMN-mediated snRNP biogenesis through FUS loss-of-function as a potential 
mechanism for ALS pathogenesis. 
 
